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Hereditary non-polyposis colon cancer syndrome (HNPCC) is associated with an 
increased risk of developing several types of cancer and is the most common cause 
of hereditary ovarian cancer after BRCA1 and BRCA2 mutations. HNPCC results 
from a germline mutation in one of the DNA mismatch repair (MMR) genes: MLH1, 
MSH2, PMS1, PMS2, MSH6, MSH3 and MLH3. While there has been extensive 
investigation of MMR deficiency in colorectal cancer, MMR in ovarian cancer is 
relatively under-investigated. The goal of this project was to study MMR deficiency 
in ovarian cancer at both the clinical and molecular level. The first aim was to 
examine the frequency of MMR loss in a large patient cohort and investigate the 
clinical consequences of MMR deficiency. The second aim was to describe the 
molecular characteristics of MMR deficiency in ovarian cancer cell lines and 
establish an in vitro cell line model of MMR deficiency in ovarian cancer. The third 
aim was to identify synthetic lethal strategies for the treatment of ovarian cancer to 
maximise cytotoxicity in a MMR-deficient background. 
In order to characterise the clinical consequences of MMR deficiency, a large patient 
cohort was studied with regard to MMR status. Three tissue microarrays consisting 
of 581 ovarian tumours were constructed, and expression of the four most frequently 
lost MMR proteins: MLH1, MSH2, PMS2 and MSH6 were detected by 
immunohistochemistry. Afterwards, MMR status and histology subtypes were 
analysed in combination with the associated clinical data. The overall incidence of 
MMR deficiency (loss of any MMR protein) was 15.7%, with PMS2 being the most 
frequently lost protein (9.7%). In addition, MMR deficiency tended to appear in a 
grouped fashion: MLH1 with PMS2; MSH2 with MSH6.  Patients with non-serous 
subtypes of ovarian cancer, clear cell or mucinous especially, had higher incidence of 
MMR deficiency compared to patients with serous ovarian cancer. Overall MMR 
deficient patients were more likely to be diagnosed at early stages compared with 
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MMR proficient patients, and this is probably due to the association between MMR 
deficiency and non-serous histology. However, platinum-based treatment for patients 
with MMR deficiency gives no advantage over those without MMR deficiency. 
Therefore better treatments for this subgroup of patients may be needed. 
The features of MMR deficiency in ovarian cancer were also characterized at the 
molecular level. After quantifying mRNA and protein expression of MMR genes in 
19 ovarian cell lines, three cell lines (SKOV3, TOV21G and IGROV1) were found to 
have a defect in MLH1 expression at both the mRNA and protein level. Interestingly, 
the three cell lines also carried a defect in PMS2 expression at the protein level but 
not at the mRNA level, which is consistent with our clinical data demonstrating that 
MLH1 protein and PMS2 protein are paired in loss. In addition, across the 19 cell 
lines, MLH1 and PMS2 showed positive correlation at both the mRNA level (R=0.53, 
p=0.02) and protein level (R=0.72, p=0.0006). In order to study co-expression of 
MLH1 and PMS2, a plasmid encoding the cDNA for MLH1 was transfected into the 
three MLH1 deficient cell lines; and conversely siRNA targeting MLH1 was 
transfected into the MMR proficient cell line A2780 and expression of MLH1 
protein and PMS2 protein was quantified. The results showed that re-introduction of 
MLH1 into MLH1 deficient cells resulted in increased expression of PMS2 protein, 
while knocking down MLH1 in MMR proficient cells leads to decreased PMS2 
protein expression. This indicates that MLH1 may play a crucial role in regulating 
PMS2 protein expression. As the three MLH1 and PMS2 protein deficient cell lines 
all express PMS2 mRNA, the regulation of PMS2 expression by MLH1 is likely to 
be at the translational or post-translational level. However, the expression of PMS2 
protein was not increased in the absence of MLH1, even when the proteasomal and 
lysosomal protein degradation pathways were blocked (as seen with SKOV3 cells), 
suggesting decreased PMS2 protein expression is not due to rapid degradation in the 
absence of MLH1. Therefore MLH1 may play a role in regulating the synthesis of 
PMS2 protein at the translational level, rather than preventing the degradation of 
PMS2. Thus, to investigate the mechanism by which PMS2 protein levels are 
regulated by MLH1, future work should focus on translational regulation of PMS2. 
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In order to identify synthetic lethal strategies to target MMR deficiency in ovarian 
cancer, an isogenic cell line model of MMR deficiency was established by stable 
transfection of a plasmid for MLH1 and its corresponding empty vector into SKOV3 
cells. The MLH1+ cell line SAC-1 and MLH1- cell line SN-5 were selected for drug 
screening based on their phenotype and growth rate. The AlamarBlue assay, with z’ 
above 0.5, was chosen for drug screening and a kinase inhibitor library containing 
362 drugs of known target was screened. Two drugs with similar structures that 
targeted PLK1 showed greater growth inhibition of SN-5 compared with SAC-1. 
When the two cell lines were treated with another PLK1 inhibitor, BI2536, with 
different structure, a 2-fold difference in growth inhibition between SAC-1 and SN-5 
was also observed, suggesting PLK1 is a potential synthetic lethal target for MLH1 
deficiency in ovarian cancer.  
Together these data demonstrate that clinically, MMR deficiency is associated with 
non-serous subtypes of ovarian cancer and specific MMR proteins are paired in loss. 
While current standard therapy offers no selective benefit to ovarian cancer patients 
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1.1 Ovarian cancer epidemiology 
Epithelial ovarian cancer is the leading cause of gynaecological cancer death in the 
developed world, with a lifetime risk of 1-2% [1-3]. The most common histological 
subtype is high grade serous (approximately 70%); other subtypes include 
endometrioid (approximately 10%), clear cell (5-10%), low grade serous (3-5%), 
mucinous (3%), and undifferentiated (1%) [4-9]. Due to a lack of effective screening 
methods and the absence of early symptoms, ovarian cancers tend to present at a late 
stage with poor prognosis and low survival rate [3]. Over 60% of patients are 
diagnosed at advanced stage with metastatic disease, and the five year survival rate is 
20-30% [3]. In contrast, for patients with stage I ovarian cancer, the long-term 
survival rate can reach as high as 90% [3, 10]. 
According to clinical behaviour and the molecular genetic abnormalities, Shih and 
Kurmanwe [11] proposed a classification that divided ovarian cancers into type I and 
type II tumours. Type I tumours include low-grade serous, mucinous, endometrioid 
and clear cell subtypes. These kinds of tumours tend to be low-grade and arise from 
borderline tumours. In addition, type I tumours evolve relatively slowly. These kinds 
of tumours are also characterized by frequent mutations in KRAS, BRAF, PTEN, 
ERBB2, PIK3CA, CTNNB1, ARID1A, and PPP2R1A with microsatellite instability 
[11, 12]. In contrast, type II tumours evolve rapidly, and arise directly from the 
surface epithelium or inclusion cysts. Type II tumours are composed of high-grade 
serous, carcinosarcomas, and undifferentiated subtypes. These kinds of tumours 
frequently carry mutations in TP53, BRCA1, and BRCA2. 
One of the most significant risk factor for ovarian cancer is family history which 
depends on the number of first and second degree relatives with ovarian or breast 
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cancer and their age at diagnosis [2, 13, 14]. Hereditary ovarian cancer is estimated 
to account for 10% to 20% of all ovarian cancers [15-17]. Genetic mutations in 
BRCA1 and BRCA2 which are the cause of hereditary breast and ovarian cancer 
(HBOC) are associated with an 11% to 40% risk of developing ovarian cancer [13], 
and account for 65-85% of all inherited cases [18-20]. Hereditary nonpolyposis 
colorectal cancer (HNPCC), which is caused by mutations in genes that are 
responsible for DNA mismatch repair (MMR), is the next most common cause of 
hereditary ovarian cancer, and accounts for 10% to 15% of all cases of hereditary 
ovarian cancer [18, 21]. Besides HBOC and HNPCC, there are other types of 
autosomal dominant cancer syndromes which are not mainly associated with causing 
ovarian cancer. Examples include Li–Fraumeni syndrome (mutation in TP53), 
Familial adenomatous polyposis (mutation in APC), and Nevoid basal cell carcinoma 
syndrome (mutation in PTCH). 
Many studies have investigated MMR deficiency in colorectal cancer, leading to 
defined clinical guidelines for detecting HNPCC kindred, identification of unique 
clinical and pathological features of these tumours and a greater understanding of the 
molecular pathogenesis of colorectal cancer. However, MMR deficiency in ovarian 
cancer is relatively under-investigated. The goal of this project is to study MMR 
deficiency in ovarian cancer at both the clinical and molecular level. 
1.2 The Mismatch Repair System 
The MMR system plays an important role in maintaining genomic stability. It 
recognizes and corrects biosynthetic errors that arise during DNA replication [22-25] 
as well as mispaired bases that are generated during recombination or caused by 
oxidative DNA damage [26-28]. MMR therefore reduces DNA errors 100-1000 fold, 
and prevents them from becoming fixed mutations during cellular proliferation. 
MMR has been extensively studied in E. coli, and human MMR proteins have been 
discovered based on their homology to E. coli proteins [24, 29]. Seven proteins 
including three MutS-homologs (MSH2, MSH3 and MSH6), and four MutL 




DNA mismatch repair consists of three steps: initiation, excision and resynthesis 
(Figure 1.1) [32]. MMR is initiated once MutS recognizes mismatched DNA and 
binds to it. The MutS homodimer is formed by either MSH2/MSH6 (the MutSα 
complex) or MSH2/MSH3 (the MutSβ complex). The MutSα complex recognizes 
single base mismatches and short insertion-deletion loops in the DNA, while the 
MutSβ complex recognizes larger loops [33, 34]. Subsequently, MutLα (formed by 
MLH1 and PMS2) is recruited and it mediates the process from mismatch 
recognition by MutS to activation of downstream activities [35]. The endonuclease 
function in the PMS2 subunit is then activated by the mismatch and MutS complex 
and directs strand excision in a proliferating cell nuclear antigen (PCNA)-, 
replication factor C (RFC)-, and ATP-dependent process [36-38]. RFC loads PCNA 
onto the DNA helix and PCNA plays an important role in both excision and DNA 
repair synthesis [39-42]. Replication protein A (RPA) and Exonuclease 1 (Exo1) are 
also involved in the excision process, and Exo1 has been reported to function in both 
3′and 5′-directed repair events [23, 35, 43]. PMS1 and MLH3 also dimerize with 
MLH1, but their role in DNA repair is less well understood [29]. High-fidelity 










Figure 1.1 The mismatch repair pathway. The MutS complexes (MSH2/MSH6 or 
MSH2/MSH3) recognize mismatches in the DNA and the MutLα complex (MLH1/PMS2) is 
recruited. PCNA is loaded onto the DNA strand by RFC. Endonuclease function in the 
PMS2 subunit is then activated and the protein-protein and protein-DNA interactions are 
ATP-dependent. RPA and Exo1 are also involved in excision. Resynthesis is completed by 




1.3 MMR deficiency and cancer development 
1.3.1 MMR deficiency leads to Microsatellite instability 
Defects of these MMR genes result in microsatellite instability (MSI) [44]. MSI is 
characterized by accelerated accumulation of single nucleotide mutations and altered 
length of microsatellite sequences [45]. Microsatellites, also known as short tandem 
repeats (STRs) and simple sequence repeats (SSRs) are short, repetitive sequences of 
DNA between one and six base pairs in length distributed throughout the genome 
[46]. The length of these repeats varies between individuals, but is constant within 
the cells of an individual, unless they have microsatellite instability. When MMR 
fails, DNA replication infidelity across these tandem repeats coupled with MMR 
deficiency results in the accumulation of mutations. 
MSI can significantly affect cellular behaviour and is associated with multi-step 
tumourigenesis, as instability at coding microsatellites in cancer-related genes can 
cause frameshift mutations and functional inactivation of corresponding proteins [47]. 
To date a number of genes involved in DNA repair, apoptosis, signal transduction, 
transcriptional regulation and immune surveillance have been found mutated in 
cancers exhibiting MSI (Figure 1.2) [47-55]. Mutated genes that provide selective 
growth advantage to cells lacking MMR function are considered as the driving force 
during MSI tumourigenesis and are termed Real Common Target genes [47]. 
As a hallmark feature of HNPCC-associated cancers, MSI has been found in 90% of 
colorectal tumours from individuals with Lynch syndrome, and in 10% to 15% of 
sporadic colorectal tumours [56]. It also occurs in 75% of endometrial and up to 100% 
of ovarian cancers in patients from HNPCC families [56]. 
According to the uniform criteria developed by the National Cancer Institute (NCI), a 
panel of five independent genomic sites is recommended for microsatellite status 
analysis in colorectal cancer, including two mononucleotide repeats (Bat25 and 
Bat26) and three dinucleotide repeats (D2S123, D5S346, and D17S250). Tumours 
are termed high-frequency MSI (MSI-H) if two or more of the five loci exhibit 
variations in microsatellite sequence length (e.g. Insertion/deletion mutations). If 
only one of the microsatellite sequences shows instability, the tumour is termed low 
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frequency MSI (MSI-L). The tumour is classified as microsatellite stable (MSS), if 
no mutation has occurred in any of the five markers [45]. 
1.3.2 MMR deficiency promotes telomerase-independent cell proliferation  
Maintenance of telomere length by reactivation of telomerase is crucial for cancer 
cells to achieve an unlimited number of cell divisions [57, 58]. Telomerase activity 
has been detected in 85-95% of human tumours but not in adjacent normal tissues 
[59, 60]. However some cancer cells have a telomerase-independent telomere 
maintenance mechanism known as alternative lengthening of telomeres (ALT) which 
is achieved through homologous recombination [61, 62]. One way in which MMR 
maintains genome stability is by preventing homologous recombination at telomeres 
[63]. Loss of MSH2, MLH1 and PMS1 has been reported to promote cell 
proliferation in telomerase-deficient yeast [64]. Bechter et al [65] reported that MMR 
deficient human colon cancer cells exhibit telomere lengthening via an ALT-like 
mechanism when activity of telomerase is inhibited. Lack of telomerase activity has 
also been reported in human ovarian and gastric tumours which exhibit MSI-H [66, 
67]. These findings indicate that loss of MMR function and hence enhanced 
homologous recombination contributes to cell immortalization and leads to 
tumourigenesis.  
 
1.3.3 MMR deficiency can also be caused by promoter hypermethylation 
As shown in Figure 1.2, MMR dysfunction can be caused by both genetic and 
epigenetic mechanisms. In Lynch syndrome, MMR deficiency is a result of germline 
mutation of one of the 7 MMR genes, with MLH1 accounting for most cases. 
Somatic inactivation of the remaining wild-type allele can be caused by loss of 
heterozygosity, somatic mutation or promoter methylation which act as second hits 
in hereditary cancers according to the ‘two-hit’ hypothesis [68]. Hypermethylation of 
the CpG promoter region of MLH1 has been observed in many cases of hereditary 
CRC showing MSI and has also been found in sporadic tumours showing MSI-H, 






Figure  1.2 Genetic and epigenetic pathways leading to MSI-H and resulting in 
tumourigenesis. MMR deficiency can be caused genetically and epigenetically and results 
in MSI-H which then leads to increased accumulation of somatic mutations in a number of 






1.4 Incidence of MMR deficiency in ovarian cancer 
Women with HNPCC have approximately a 12-15% lifetime risk of developing 
ovarian cancer [71, 72]. HNPCC related ovarian cancers in general occur at a 
younger age, with a median age at diagnosis of 41-49 years, compared to  60-65 
years for sporadic ovarian cancer [19, 73-76]. Pal et al [75] reported that clearly 
pathogenic germline MLH1, MSH2 and MSH6  mutations occurred in only 9/1893 
(0.5%) unselected ovarian cancer patients (with the majority harbouring MSH6 
mutations), although a further 28 patients (1.5%) had unique predicted pathogenic 
missense variants. Murphy and Wentzensen [77] conducted a systematic review to 
analyze the frequency of MSI, loss of MMR gene expression by 
immunohistochemical (IHC), and MLH1 promoter hypermethylation in ovarian 
cancers. Studies between 1993 and 2009 were included. They reported that the 
pooled proportion of MSI detection was 0.10 (1234 cases in 22 studies); the pooled 
proportion of MLH1 or MSH2 staining loss was 0.06 (474 cases in three studies); 
and the pooled proportion of MLH1 methylation was 0.10 (672 cases in seven 
studies). 
After the NCI recommended 5 standard markers for detecting MSI in 1997, 28 
studies have reported the frequency of MSI in a number of ovarian cancer series, 
with a wide range from 0% to 86.4% (Table 1.1). Selection criteria, choice of MSI 
markers and small sample size are the main causes of the large variation of MSI 
frequency for most studies. Shilpa et al [78] is the first study of a defective MMR 
system in ovarian cancer for the Indian population. They used the five standard 
markers recommended by NCI and reported MSI frequency of 86.4% (MSI-H: 68.2% 
and MSI-L: 18.2%). This study also reported 75% MSI (MSI-H: 50% and MSI-L: 
25%) in benign tumours. These authors considered that ethnically diverse population 
and racial background of the patients enrolled in the study is one of the factors 
responsible for the high MSI frequency and that MSI may not be the unique feature 
of malignant tumour. For the rest of these studies, most of them used a different 
number of markers (two to 69), and did not include all five standard markers. 12 
studies included all five recommended markers, and only five studies [69, 79-82] 
used the exact NCI markers to detect MSI. Among the five studies, one was 
restricted to clear cell cancer only [79].  Three studies [69, 80, 81] (which were 
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unselected on the basis of histology) reported an MSI frequency between 5-13%; and 
the largest study so far (with sample size of 834) [82] reported MSI-H frequency of 
14.9%. 15 studies (Table 1.2) investigated MSI status in different histotypes, and the 
summarized results suggest that non-serous types have higher MSI frequency than 
serous ovarian cancers. Watanabe et al [83] also reported that cases with MSS in 
primary resected tumours exhibited MSI in the residual tumours after cisplatin-based 




















Reference Year No. of 
markers 
 
NCI markers used 
(5 in total) 
Sample 
size 
MSI Proportion  
of MSI 
[84] 1998 8 BAT26 12 2 17% 
[85] 1998 69 D2S123, D5S346 31 0 0 
[86] 1999 6 D5S346 20 4 20% 
[87] 2000 4 D2S123, BAT26 26 1 4% 
[88] 2000 9 D2S123, BAT26 33 1 3% 
[89] 
(serous32;mucinous 29) 
2000 5 D2S123 61 15 25% 
[90] 2001 5 D2S123, BAT26 43 3 7% 
[91] 2001 6 BAT25, BAT26, D2S123, 
D5S346, D17S250 
116 37 32% 
[92] 2001 3 BAT25, BAT26 14 4 29% 
[69] 2001 5 BAT25, BAT26, D2S123, 
D5S346, D17S250 
42 2 5% 
[93] 
(Endometrioid only) 
2001 2 BAT25, BAT26 26 5 19% 
 [94] 2001 13 BAT25, BAT26, D2S123, 
D5S346, D17S250 
109 39 36% 
 [83] 2001 10 BAT25, BAT26, D2S123, 
D5S346 
24 9 38% 
 [95] 2003 6 BAT25, BAT26, D2S123, 
D5S316, D17S250 
107 32 30% 
 [79] 
(clear cell only) 
2004 5 BAT25, BAT26, D2S123, 
D5S316, D17S250 
42 9 21% 
 [80] 2004 5 BAT25, BAT26, D2S123, 
D5S316, D17S250 
39 5 13% 
[96] 2004 7 BAT25, BAT26, D2S123, 
D5S316, D17S250 
66 20 30% 
 [97] 
(endometrioid only) 
2004 4 BAT25, BAT26,D5S346, 
D17S250 
74 24 32% 
 [98] 
(serous53,nonserous 22) 
2004 11 BAT25, BAT26, D2S123, 
D5S346, D17S250 
75 11 15% 
 [99] 
(clear cell only) 
2005 16 BAT25, BAT26, D2S123, 
D5S346, D17S250 
24 9 38% 
 [30] 2006 3 BAT25, BAT26, D2S123 75 0 0 
 [100] 2008 16 D17S250 171 4 2% 
 [101] 2008 8 BAT25, D2S123, D5S346 51 10 20% 
[102] 2008 12 BAT26, D2S123 64 1 2% 
 [103] 2008 14 BAT25, BAT26, D2S123, 
D5S346, D17S250 
26 4 15% 
 [81] 2008 5 BAT25, BAT26, D2S123, 
D5S346, D17S250 
52 5 10% 
[78] 2014 5 BAT25, BAT26, D2S123, 
D5S346, D17S250 
88 76 86.4% 





















[87] 2000 1/16 0/3 0/2 0/1 0/4 
 [89] 2000 4/32   11/29  
[92] 2001 0/8  1/1 2/2 0/2 
[93] 2001   5/26   
[94] 2001 28/70     
[83] 2001 5/17 1/2 2/3 1/1 0/1 
[95] 2003 23/87 1/4 7/22 2/9  
 [79] 2004 9/42     
[96] 2004 17/24 4/7 11/21 6/11  
 [97] 2004   24/74   
[98] 2004 16/53 1/3 4/14 0/5  
 [99] 2005  9/24    
[30] 2006 0/36 0/3 0/13 0/10 0/3 
 [102] 2008 1/41 0/3 0/6 0/4 0/6 
[103] 2008 2/8  1/8 1/10  










Table 1.2 MSI status by histologic subtypes. 
 
After 1997, 14 studies used immunohistochemistry staining (IHC) to investigate 
expression of MMR proteins in ovarian cancers (Table 1.3). At least one of the six 
MMR proteins (MLH1, MSH2, MSH6, PMS2, MSH3 and PMS1) was tested in these 
studies. The 14 studies had sample sizes from 24 to 834 and reported the frequency 
of MMR deficiency (loss of any protein) to range from 2% to 29%. 10 of these 
studies reported histologic subtypes of samples with MMR protein loss (Table 1.4). 
Pal et al  [75] reported that endometrioid and clear cell histological subtypes account 
for the majority of ovarian cancer cases with germline MMR gene mutations.  
Consistent with the results of MSI frequency studies, non-serous histologies have a 
higher frequency of MMR protein deficiency than serous cancers. Copppola et al 
[104] also reported that the overall frequency of MMR protein loss in full section 
slides was lower compared to TMA slides, which suggest that it is important to 
consider specimen type when performing IHC in ovarian samples.  
To date, nine studies have investigated MSI status in tumours lacking MMR protein 
expression (Table 1.3). Results from six studies show that the vast majority of 
tumours deficient in an MMR protein are MSI-H.  Three studies [19, 99, 105] 
12 
 
reported that all MMR deficient tumours possessed a MSI-high phenotype. Liu et al 
[97] reported that of 11 out of 74 tumours lacking a MMR protein, one case was 
MSS, one case MSI-L and the rest were MSI-H.  Cai et al [79] and Domanska et al 
[74] also reported two out of six and one out of six MMR deficient tumours were 
MSS respectively.  In addition, Liu et al [97] and Cai et al [79] reported six out of 15 
and two out of six MSI-H tumours did not lack expression of MMR proteins 
respectively. Moreover, Geisler et al [95] reported 21 MSI-H tumours, with MLH1 
mRNA absent in 10 cases. The remaining 11 MSI-H tumours did not lack expression 
of any of the six MMR genes.  Helleman et al [30] reported that all seven tumours 
with MLH1 hyper-methylation had an MSS phenotype and none of the 75 tumours 
showed MMR inactivation.  Shilpa et al [78] also reported that loss of MMR protein 
expression was not significantly correlated with either promoter methylation or the 
MSI phenotype. Very recently, Lee et al reported that 67.6% (564 out of 834 cases) 
MSI and IHC results in epithelial ovarian cancers were concordant: 41 cases 
exhibited MSI-H with loss of MMR protein expression; the 523 MSS cases all 
expressed tested MMR proteins. Of the 270 discordant cases, 83 were MSI-H 
without MMR protein loss and 187 were MSS with MMR deficiency.  Watanabe et 
al [83] is the only study that compared MSI status and MMR protein expression 
before and after cisplatin-based chemotherapy and found that 73.3% of cases 
changed from MSS to MSI-H and also lost MLH1 protein expression after treatment. 
These studies suggest that MMR protein loss in ovarian cancer is associated with 
MSI-H. However, MMR deficient tumours do not always exhibit MSI phenotype; 
and tumours with MSI phenotype do not always carrying defects in MMR. These 
findings may be explained by heterogeneity of ovarian tumours. At the histological 
level, ovarian cancer comprises distinct histological subtypes which are associated 
with distinct tissues of origin [106]. At the molecular level, these histological 
phenotypes have distinct complex genetic fingerprints [107]. In addition, these 
pathways that causing MMR deficiency and/or MSI may function independently and 
are not mutually exclusive in promoting tumourigenesis  [78].  Furthermore, besides 
known MMR proteins, there are other causes of MSI-H. It has been reported that 
tumours from Exonuclease 1(EXO1) families may exhibit variable levels of MSI but 
EXO1 is not an HNPCC gene [44]. Moreover, as some MMR deficient tumours are 
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MSS, there might be compensatory mechanisms that maintain genome stability.  
Further large scale studies are required to explore this area.  
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Reference Year Tested MMR proteins Method Sample size Loss of  any 
MMR 
Proportion MSI status 
(MSI-H/MSI-L) 





IHC 74 11 15% 9/1 
 [19] 
2006 












[105] 2006 MLH1, MSH2 IHC 322 7 2% 7/0 
 [74] 
2007 
MLH1, MSH2, MSH6, 
PMS2 
IHC 98 6 6% 5/- 
[108] 2008 MSH6 IHC 310 34 11% - 
[81] 
2008 
MLH1, MSH2, MSH6, 
PMS2 
IHC 52 4 8% - 
 [79] 
(clear cell only) 2004 
MLH1, MSH2 IHC 
42 6 14% 4/0 
 [99] 
(clear cell only) 
2005 
MLH1, MSH2, MSH6, 
MSH3 
IHC 
24 6 25% 6/0 




MLH1, MSH2, MSH6, 
PMS2 
IHC 






487 62 12.7%  
[78] 2014 MLH1, MSH2, PMS2 IHC 64 18 28.1% 0/0 
[82] 2014 MLH1, MSH2, MSH6 IHC 834 228 27.3% 41 (MSHI-H) 
Table 1.3 Proportion of MMR deficiency in ovarian cancer cases and MSI status of MMR deficient case.
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Mixed type MMR 
loss/total 
[110] 2001 3/26   1/9  1/8 
[79] 2004  4/42     
 [80] 2004  1/18  3/22  1/15 
 [97] 2004   12/74    
[99] 2005  6/24     
 [19] 2006 0/84 1/22 0/15 1/5  1/1 
[105] 2006 0/168 2/16 1/34 0/7 0/8 3/73 
 [111] 2007  0/7 3/15    
 [108] 2008 20/230 7/16 4/34 2/6 0/8  
[109] 2012   7/71    
 [104] 2012 24/178 6/17 12/52 7/18   

















1.5 Response to chemotherapy and survival of ovarian cancers with MMR 
deficiency 
 
To date, numerous studies have investigated survival in colorectal cancers (CRCs) 
with MMR deficiency. After reviewing 32 eligible studies which stratified survival 
in CRC patients by MSI status, Popat et al [112] confirmed that MSI-H is associated 
with better survival. Radman and Wagner [113] suggested that the genetic instability 
related to microsatellite instability may lead to compromised cancer progression and 
therefore result in improved survival. However, the role of MSI-H as a marker for 
predicting benefit from 5-fluorouracil (5-FU) chemotherapy in colorectal cancer is 
unclear. Compared with CRCs, survival and treatment response in MMR defective 
ovarian cancers are very under-investigated.  
A small number of studies have investigated the survival of women with ovarian 
cancer due to MMR defects, and the results are inconclusive.  Crijnen et al [73] 
compared survival in stage matched HNPCC associated ovarian cancer and sporadic 
ovarian cancer, and found that there was no significant difference between the two 
groups, with cumulative 5 year survival rates being 64.2% and 58.1% respectively. 
In contrast, Scartozzi et al [114] suggested that loss of MLH1 correlated with 
improved survival in advanced ovarian cancer after comparing 19 patients with an 
MLH1 defect (median survival: 55 months) and 15 patients with functional MLH1 
(median survival: 12 months). On the other hand, Grindedal et al [115] investigated 
144 women with HNPCC associated ovarian cancers, and reported that 10 year 
survival was as high as 80%. Among the 144 patients, 18.5% were diagnosed at stage 
3 or 4, and five year survival of these patients was 59% which is also significantly 
higher than that of general population.  A probable explanation for this finding is that 
because HNPCC-associated ovarian cancers are most likely to be non-high grade 
serous, these tumours are more likely to present with early stage disease (compared 
to matched sporadic tumours) and therefore are more likely to be curable by surgery 
alone. 
Currently, the gold standard treatment of ovarian cancer consists of debulking 
surgery and platinum-taxane combination chemotherapy [2, 8]. However, 
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approximately 20-30% of patients never achieve a clinical response and have 
progressive disease during treatment [2].  
There are studies suggesting that loss of MMR proteins is associated with drug 
resistance in ovarian cancer. Strathdee et al and Zeller et al [116, 117] reported that 
methylation of the MLH1 promoter plays an important role in causing cisplatin-
resistance in ovarian cancer in vitro. Ercoli et al [118] investigated MSH2 protein 
expression level in 20 epithelial ovarian cancers, and reported that non-responding 
patients had significantly lower MSH2 levels compared to those of patients who 
achieved either complete or partial response to cisplatin-based chemotherapy. This 
study also found that the amount of MSH2 was significantly lower in stage IV 
patients than that in stage III patients. Subsequently, Marcelis et al [119] reported 
high level chemotherapy resistance in two women from an HNPCC family with 
germline mutations in MSH2. On the other hand, Samimi et al [120] found that 
expression of both MLH1 and MSH2 reduced significantly after platinum-based 
chemotherapy. However, lower expression of MLH1 did not indicate lack of 
sensitivity to platinum-based therapy and there was no association between MSH2 
expression and response. Taken together, studies on treatment response in ovarian 
cancers with MMR deficiency have produced inconclusive results. There are several 
possible explanations for this. First of all, different methods were used to determine 
MMR status, including protein expression analysis, mRNA expression analysis, 
promoter hypermethylation assays and microsatellite instability testing. Secondly, 
when comparing the MMR deficient group to the MMR proficient group, varying 
numbers (from 1 to 5) of MMR genes were considered.  In addition, many studies are 
limited by small sample size. Moreover, strategies of sampling are also different. 
Therefore further large scale studies using uniform criteria and stage, treatment, and 
histological subtype are needed to investigate survival and response to chemotherapy. 
Specifically, the one clear signal that is coming through these studies is that MMR 
deficiency is much more frequent in non-serous ovarian cancers. Therefore more 
meaningful results may be obtained by performing further studies within an 





1.6 Synthetic lethality – targeting MMR deficiency 
 
In recent years, synthetic lethality has been investigated extensively as an approach 
to develop new targeted cancer therapeutics. Synthetic lethality is based on the 
premise that loss of function of two or more genes or pathways (in tumour cells of a 
patient) leads to cell death, whereas inactivation of one of these genes or pathways 
(within non tumour cells of the patient) does not [121].  This strategy can lead to a 
high therapeutic index. The classic example is BRCA1 or BRCA2 germline defects 
and Poly (ADP-ribose) polymerase (PARP) inhibition. BRCA1 and BRCA2 are 
required for DNA double-strand break repair by homologous recombination, while 
PARP is needed for the repair of DNA single-strand breaks [122, 123]. Compared 
with cells which are wild type for BRCA1 or BRCA2, BRCA1/2 deficient cells are 
1000 times more sensitive to PARP inhibitors  [124, 125]. This is because PARP 
inhibition prevents the repair of single-strand DNA breaks, which are converted to 
double-strand breaks on replication that cannot be repaired in BRCA1/2 deficient 
cells.  [124, 125]. Previously investigations of MMR related synthetic lethality has 
identified Dihydrofolate reductase (DHFR), DNA polymerase β (POLβ) and DNA 
polymerase γ (POLγ) , as well as PTEN-induced putative kinase 1 (PINK1) as 
synthetically lethal to certain MMR defects by causing accumulation of oxidative 
DNA damage [126-128]. They also reported that inhibition of DHFR is selective for 
MSH2; MSH2 deficiency is also synthetically lethal with inhibition of POLβ, while 
MLH1 deficiency is synthetically lethal with POLγ; inactivation of PINK1 is 
synthetically lethal with defects of MLH1, MSH2 or MSH6.  Currently, 
Methotrexate, a DHFR inhibitor, is under clinical trial to treat advanced bowel 
cancers with MSH2 deficiency [128]. So far, synthetic lethality has not been 
investigated in MMR defective ovarian cancers. Whether these newly identified 
targets also apply to ovarian cancer is unknown. Future studies are required to test 
the above synthetic lethal strategies and looking for new targets to treat MMR 
deficient ovarian cancer. 
1.7 Summary and aims of the project  
 
Women with HNPCC have an increased lifetime risk of developing ovarian cancer.  
In addition to germline mutation, MMR deficiency can also be caused by epigenetic 
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mechanisms. Based on studies on MMR deficiency in colorectal cancer, various 
methods such as testing MSI status, MMR promoter hypermethylation, MMR protein 
expression and MMR mRNA expression have been developed to help identify 
defects in MMR.  However, only a limited number of studies have investigated 
MMR deficiency in ovarian cancer. Early age of onset and non-serous histological 
subtypes has been found associated with MMR deficiency. However, other important 
factors such as impact of MMR deficiency on response to chemotherapy and survival 
within a histotype-specific context remain unclear. In addition, further studies are 
required to test synthetic lethal strategies identified in the colorectal cancer setting in 
ovarian cancer as well as to identify new targets to achieve the goal of targeted 
therapies for this subset of patients. 
 
The hypothesis of this project is that HNPCC-deficient ovarian cancer is a distinct 
subgroup with different chemosensitivity and underlying biology. The first aim of 
this project was to examine the frequency of MMR loss in a large patient cohort and 
investigate the clinical consequences of MMR deficiency. The second aim was to 
describe the molecular characteristics of MMR deficiency in ovarian cancer cell lines 
and establish an in vitro cell line model of MMR deficiency in ovarian cancer. The 
third aim was to identify synthetic lethal strategies for the treatment of ovarian 











Materials and Methods 
 
2.1 Materials 
2.1.1 General materials                                         
Automatic pipettes……………………………………………………. Gilson, France 
Cell culture flasks (T25, T75)……………………………..Greiner bio-one, Germany 
Cell culture plates………………………………………….Greiner bio-one, Germany 
Cryovials (1.2ml) ………………………………………….Greiner bio-one, Germany       
Eppendorfs (0.2ml, 0.5ml, 1ml, 2ml)…………… …………………….....Starlab, UK 
Centrifuge tubes (15ml, 50ml)……………………………. Greiner bio-one, Germany 
Universals (30ml)………………………………………….Greiner bio-one, Germany 
Pipette tips (10µl, 20 µl, 200 µl, 1000µl)…………………………………Starlab, UK 
Pipette filter tips (10µl, 20 µl, 200 µl, 1000µl)………………………..…. Starlab, UK 
Sterile Striplettes (5ml, 10ml, 25ml, 50ml)………………………………Costar, USA 
0.1-10µl Round Gel-Loading Tip…………………………………...…… Starlab, UK 
Trichloroacetic acid……………………………………..……… Sigma-Aldrich, USA                                                              
Tween 20…………………………………………………….…. Acros organics, USA 
Sodium Chloride…………………………………………...……Sigma-Aldrich, USA                                                     
Tris……………………………………………………..………. Sigma-Aldrich, USA                                                     
Ethylene glycol tetraacetic acid (EGTA)………………………. Sigma-Aldrich, USA                                                     
Triton-×100…………………………………………….………. Sigma-Aldrich, USA                                                     
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Ethanol…………………………………………………………. Fisher Scientific, UK 
Methanol……………………………………………………….. Fisher Scientific, UK 
Acetic acid……………………………………………………….Sigma-Aldrich, USA                                                   
 
2.1.2 Tissue culture reagents 
RPMI-1640 Medium………………………………………………….. Invitrogen, UK 
Fetal Bovine serum…………………………………………………….Invitrogen, UK 
Fungizone……………………………………………………………...Invitrogen, UK 
Penicillin-streptomycine………………………………………………….Sigma, USA                                                          
Cell freezing medium-DMSO Serum Free………………………….……Sigma, USA                                                     
Trypsin-EDTA solution (10×)… ………………………………………...Sigma, USA                                                     
 
2.1.3 Reagents used in protein extraction 
Complete Protease inhibitor Tablet………………………Roche Diagnostics Ltd (UK) 
Phosphatase Inhibitor Cocktail 2……………………………….. Sigma-Aldrich, USA 
Phosphatase Inhibitor Cocktail 3…………………………….…. Sigma-Aldrich, USA 
Aprotinin from bovine lung…………………………..…………Sigma-Aldrich, USA 
 
2.1.4 Materials and reagents used in PCR 
QIAamp DNA Mini Kit (50) ……………………………………….Qiagen, Inc. USA 
Absolutely RNA miRNA Kit…………………………….Agilent Technologies, USA 
Ambion® TURBO DNA-free™ Kit…………………………………..Invitrogen, UK 
SuperScript® VILO™ cDNA Synthesis Kit…………………………..Invitrogen, UK 
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Platinum® Taq DNA polymerase……………………………………..Invitrogen, UK 
PCR Nucleotide Mix…………………………………………...………Promega, USA 
QuantiTect SYBR Green PCR Kit…………………….……………Qiagen, Inc. USA 
 
2.1.5  Reagents used in Agarose Electrophoresis
Agarose……………………………………………………Bioline Reagents Ltd, UK 
SafeView  Nucleic Acid Stain……………………..………NBS Biologicals Ltd, UK 
Tris-Borate-EDTA buffer (TBE buffer)……………………Bioline Reagents Ltd, UK 
TrackIt™ 50 bp DNA Ladder…………………………………………Invitrogen, UK 
1KB DNA ladder……………………………………………….New England Biolabs 
Blue/Orange 6× Loading Dye…………………………………….……Promega, USA 
 
2.1.6  Materials and reagents used in protein detection 
Micro BCA
TM
  Protein assay kit……………….………Thermo Scientific Pierce, UK 
NuPAGE® LDS Sample Buffer (4X)…………………………………Invitrogen, UK 
NuPAGE® Sample Reducing Agent (10X)………………..…………Invitrogen, UK  
 NuPAGE® Novex 4-12% Bis-Tris Gel………………………………Invitrogen, UK 
NuPAGE® MOPS SDS Running Buffer  
(for Bis-Tris Gels only) (20X)…………………..……………………..Invitrogen, UK           
NuPAGE® Transfer Buffer (20X)…………………………………….Invitrogen, UK 
NuPAGE® Antioxidant………………………………………..………Invitrogen, UK 
Precision Plus Protein Dual Color Standards………....Bio-Rad Laboratories Ltd (UK) 
MagicMark™ XP Western Protein Standard……………………… …Invitrogen, UK 
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Immobilon-P transfer membrane……………………………...…….Millipore, Ireland 
Immobilon-FL transfer membrane………………………….………Millipore, Ireland 
Licor-Odyssey Blocking Buffer……………………………LI-COR Biosciences, UK                                                             
Phosphate Buffered Saline with Tween 20 (PBST-20X)…New England Biolabs (UK)  
XCell SureLock™ Electrophoresis System…………………...……. Invitrogen, USA 




2.1.7 Materials and reagents used in cloning 
Agar powder……………………………………………………..Sigma-Aldrich, USA 
SOC Medium…………………………………………………..………Invitrogen, UK 
DH5α competent cells…………………………………………………Invitrogen, UK 
QIAGEN Plasmid Mini, Midi, and Maxi Kits………………..…….Qiagen, Inc. USA 
QIAquick® Gel Extraction kit………………………………...……Qiagen, Inc. USA 
Resection enzymes………………………………….....New England Biolabs (UK) Lt   
Alkaline Phosphatase (CIP)……………………….…..New England Biolabs (UK) Lt 
 
2.1.8 Materials and reagents used in Transfection 
Opti-MEM Reduced Serum Medium…………………………...……..Invitrogen, UK  
Lipofectamine®2000 Transfection Reagent…………………………..Invitrogen, UK 
TurboFectin
TM
 8.0 Transfection Reagent……………………….………Origene, USA 
Lipofectamine® RNAiMAX Transfection Reagent…………..………Invitrogen, UK 
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SR30005-RNAse free siRNA duplex re-suspension buffer………….....Origene, USA 
pCMV6-XL5-MLH1 plasmid…………………………………….…….Origene, USA 
pCMV6-AC-MLH1 plasmid……………………………………………Origene, USA 
pCMV6-Neo plasmid……………………………………………...……Origene, USA 
 
2.1.9 Materials and reagents used in studying cell proliferation and viability
MTT…………………………………………………………..Molecular Probes, USA 
AlamarBlue……………………………………………..……………Invitrogen, USA 
Matrix microplates, clear, 96 well, V bottom……….…..Thermo Scientific, Denmark 
DMSO, 3ml per bottle……………………………………….. Life technologies, USA 
Nunc black optical buttom 96 well plates……………………Thermo Scientific, USA 
Cisplatin injection solution 50mg/50ml……………….... Teva Pharmaceuticals, USA 
Etoposide…………………………………………………………………Sigma, USA
Daunorubicin Hydrochloride……………………….……….. LKT laborotories, USA 
Doxorubicin Hydrochloride……………………..…..……………………Sigma, USA 
5-Fluorouracil……………………………………………………..……..Sigma, USA 
Oxaliplatin………………………………..………………………………Sigma, USA 
Methotrexate hydrate…………………………………………...………..Abcam, USA 
GSK kinase inhibitor library……………………………………..………….GSK, UK 
BI 2536………………………………………………………….……… Selleck, USA 
 
2.1.10  Materials and reagents used in immunocytochemistry 
Paraformaldehyde 16% w/v…………………………………………Alfa Aesar, USA 
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Vectashield mounting medium for fluorescence, H-1000…..Vector Laboratories, UK 
Albumin from bovine serum……………………...……………. Sigma-Aldrich, USA 
Triton-×100……………………………………………..……… Sigma-Aldrich, USA 
Microscope slides, 76×26mm………………………………… Thermo scientific, UK 
Nail polish, clear…………………………………………..….……….L'Oréal, France   
DAPI…………………………………………………………….Sigma-Aldrich, USA 












Mouse Cell signalling 
Mouse anti-MSH2 1:1000 (WB) Mouse Invitrogen 
PMS2 (B-3): sc-25315 1:1000 (WB) Mouse 
BD Transduction 
Laboratories 
Purified Mouse Anti-MSH6 1:2000 (WB) Mouse 
BD Transduction 
Laboratories 
Mouse Anti-Human MSH3 1:1000 (WB) Mouse 
BD Transduction 
Laboratories 
Anti-beta Tubulin antibody  1:6000 (WB) Rabbit Abcam 
Anti-beta Tubulin antibody  1:1000 (WB) Mouse Sigma-Aldrich 
Anti-PLK1 antibody  
[36-298] 
1:1000 (WB) Mouse Abcam 
Phospho-Histone  H2A.X 
(Ser139)   
1:1000 (WB) Rabbit Cell signaling 
Table 2.1  List of primary antibodies used in western blot (WB) and 
immunocytochemistry (ICC) 
 




donkey anti–mouse IgG 1:500 (ICC) Mouse Life Technologies 
Licor Anti-mouse 800 1:10000 (WB) Mouse Licor Odyssey 
Licor Anti-Rabbit 680 1:10000 (WB) Rabbit Licor Odyssey 
Licor Anti-mouse 680 1:10000 (WB) Mouse Licor Odyssey 
Licor Anti-Rabbit 800 1:10000 (WB) Rabbit Licor Odyssey 






Cell line Species Cell type 
OVCAR-3 Human ovarian adenocarcinoma (epithelial) 
OVCAR-4 Human ovarian adenocarcinoma (epithelial) 
OVCAR-5 Human ovarian adenocarcinoma (epithelial) 
PEA1 Human ovarian adenocarcinoma (epithelial) 
PEA2 Human ovarian adenocarcinoma (epithelial) 
PEO-1 Human ovarian adenocarcinoma (epithelial) 
PEO-4 Human ovarian adenocarcinoma (epithelial) 
PEO-16 Human ovarian adenocarcinoma (epithelial) 
PEO-14 Human ovarian adenocarcinoma (epithelial) 
PEO-23 Human ovarian adenocarcinoma (epithelial) 
IGROV-1 Human ovarian adenocarcinoma (epithelial) 
CAOV-3 Human ovarian adenocarcinoma (epithelial) 
41M Human ovarian cystadenocarcinoma (epithelial) 
TOV21G Human ovarian  clear cell carcinoma ((epithelial)) 
A2780 Human ovarian carcinoma (epithelial) 
59M Human ovarian carcinoma (epithelial) 
SKOV-3 Human ovarian adenocarcinoma (epithelial) 
OAW-42 Human ovarian cystadenocarcinoma (epithelial) 
HOSE11 Human Ovary (epithelial) 
HOSE12 Human Ovary (epithelial) 








start primer sequence 
product 
size 
MLH1 v1-4 forward 1980 gagtggctggacagaggaag 225 
MLH1 v1-4 reverse 2204 tcttcgtcccaattcacctc 225 
MSH2 forward 2471 tgtcacagcactaccactg 218 
MSH2 reverse 2689 agcacttctttgctgctggt 218 
MSH6 forward 3628 tacgtccctgctgaagtgtg 164 
MSH6 reverse 3790 tccacaagcaccagagaatg 164 
PMS1v1-3 forward 2680 cctcgtcttacagcgaatgg 219 
PMS1v1-3 reverse 2898 acgcactgcttctccctcta 219 
PMS2 forward 2446 gatcttcatgctgagcgaca 199 
PMS2 reverse 2644 gtgtctcatggttggccttc 199 
MLH3 v1-2 forward 4261 tgccactgactgtccagaag 166 
MLH3 v1-2 reverse 4428 gctaacggcagcatagaagg 166 
MSH3 forward 2461 caaggtcgctaagcaaggag 193 
MSH3 reverse 2960 ctttccacccatgtttggtc 193 
TBP forward 1083 aggttagaaggccttgtgctc 240 
TBP reverse 1323 gggaggcaagggtacatgag 240 
HPRT1 forward 362 tgctgacctgctggattaca 248 
HPRT1 reverse 620 cctgaccaaggaaagcaaag 248 
Table 2.4 List of primers 




























SR30004 - Origene 
MLH1 SR302909A GCCATAGAAACAGTGTATGCAGCCT Origene 
MLH1 SR302909B AGCATCAAACCAAGTTATACCTTCT Origene 
MLH1 SR302909C GCAGTACATATCTGAGGAGTCGACC Origene 
PLK1 A-003290-29 UGUGGGACUCCUAAUUACA Dharmacon 




2.2.1 Cell culture  
2.2.1.1 Aseptic techniques  
Sterile working is vitally important in cell culture, which can prevent contamination 
from bacteria, fungi and mycoplasma and cross contamination with other cell lines. 
Lab coat and sterile gloves were worn. All materials specifically used for cell culture 
were autoclaved. Solutions including cell culture media and PBS, and plastic 
materials such as cell culture flasks and stripettes were purchased sterilised. Other 
solutions such as drug vehicles were sterilised via 0.2μM syringe filters or 
autoclaving. Before and after cell culture work, Class II laminar flow biological 
safety cabinet was sanitized with 70% (v/v) ethanol. Materials such as racks, media 
bottles, pipette boxes used in the cabinet were sprayed with 70% (v/v) ethanol before 
entering the cabinet. In addition, waste products of cell culture were discarded into 
waste bottle (containing decontaminating solution) or clear bags which were then 
autoclaved. 
 
2.2.1.2 Recovery of cells from liquid nitrogen 
RPMI-1640 medium (with 10% FBS and 1% penicillin/streptomycin) was warmed to 
37°C in water bath. 6ml of the medium was added into a T25cm
2
 flask, and 5ml of 
the medium was added into a universal. The cryovial was taken from liquid nitrogen, 
then warm medium was added to the cryovial to defrost cells. Cells were transferred 
to the universal containing 5ml medium. After centrifuging, the cell pellet was re-
suspended in 1ml medium, and then transferred into the T25cm
2
 flask. Cells were 
transferred to T75cm
2
 flask once they were confluent.  
 
2.2.1.3 Cryopreservation of cells  
Cell freezing medium-DMSO Serum Free (sigma) was defrosted and kept on ice. 
Three cryovials were prepared labelled with cell line, growth medium, date and 
initials. Cells were taken from the incubator, and then detached using the 
trypsin/versene method. The cell suspension was centrifuged, and the supernatant 
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was discarded. The cell pellet was re-suspended in 3 ml of cold cell freezing medium. 
1 ml of the cell suspension was added to each cryovial. The 3 cryovials were placed 
in -80℃, and then moved to liquid nitrogen after one or two days.  
  
2.2.1.4 Passaging of cells 
Cells were passaged routinely once they had reached confluence to ensure they grew 
optimally. Medium in the flask was removed, followed by adding 10ml of PBS to 
wash the flask. After discarding the PBS, 2ml of trypsin/versene solution (1:3) was 
added into the flask, followed by incubation for 5 minutes in a 
37°C and 5% CO2 incubator. Once the cells were detached, 10ml of medium was 
added to the flask, followed by transferring the cell suspension to a universal to 
centrifuge (5 minutes at 2500 gav). The supernatant was discarded and cell pellet 
was re-suspended in 4ml to 8ml medium. 1ml cell suspension was transferred into a 
new flask which was pre-filled with 10ml medium. The flask was labelled and placed 
in 37°C and 5% CO2 incubator. 
 
2.2.2 Reverse transcription polymerase chain reaction (RT-PCR) 
RT-PCR is a technique where RNA is reverse transcribed to complementary DNA 
(cDNA) by reverse transcriptase and the resulting cDNA is then amplified by PCR.  
  
2.2.2.1 Total RNA extraction from cell lines 
Cells were washed with PBS and RNA was extracted using the Absolutely RNA 
miRNA Kit (Agilent Technologies) according to the manufacturer’s protocol. 
 
2.2.2.2 Remove genomic DNA from RNA preparations 
Residual genomic DNA in each RNA sample was removed using Ambion® TURBO 




2.2.2.3 Determination of RNA concentration 
Concentrations of RNA samples were measured by the NanoDrop
TM
 ND-1000 
spectrophotometer (Thermo Scientific).  1 µl of sample was pipetted onto the 
machine and RNA concentration was measured at 260nm. The ratio of 260nm and 
280nm was used to assess the RNA sample’s purity. Samples with a ratio of around 
2.0 were considered sufficiently pure.  Concentrations were given in ng/µl. 
 
2.2.2.4 cDNA synthesis  
Complementary DNA was synthesised using SuperScript® VILO™ cDNA Synthesis 
Kit (Invitrogen) according to the manufacturer’s protocol. For each sample, 1 µg of 
RNA was used. RNA sample was prepared as follows: 
Reagent Volume (µl) 
5X VILO™ Reaction Mix* 4 
The 10X SuperScript® Enzyme Mix* 2 
RNA (1µg) X 
DEPC-treated water to 20 
*5X VILO™ Reaction Mix contains random primers, MgCl2, and dNTPs.The 10X 
SuperScript® Enzyme Mix contains SuperScript® III Reverse Transcriptase, RNaseOUT™ 
Recombinant Ribonuclease Inhibitor and a proprietary helper protein. 
Samples were then placed on the PCR machine (MJ Research DNA Engine) and the 
program was set as follows: 25°C for 10 minutes, 42°C for 60 minutes and 85°C for 
5 minutes.  cDNA samples were stored at -20°C until use.  
 
2.2.2.5 Agarose gel electrophoresis 
Agarose gel electrophoresis is a commonly used method for visualizing PCR 
products, which can separate DNA fragments by their sizes and allow visualisation 
under UV light. This technique is based on the fact that the DNA molecule is 
negatively charged in an environment with neutral pH due to its phosphate backbone. 
Therefore, DNA molecules will move toward to the anode once an electrical current 
is provided. As smaller molecules move faster through the gel than the larger 
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molecules do, DNA fragments with different length form distinct bands on the gel.  
DNA is stained with a fluorescent dye in order to be visualized on an Ultraviolet 
Transilluminator. The DNA ladder, a set of DNA fragments with known size, is used 
as a standard to measure the sizes of unknown DNA molecules. The procedure is 
described as follows: 
Step 1. Preparation of a gel 
1g of agarose was dissolved in 90ml of deionized water, followed by adding 10ml of 
10× Tris-Borate-EDTA buffer (TBE buffer) to the solution. After adding 10µl of 
SafeView Nucleic Acid Stain (NBS Biologicals Ltd) the solution was poured into a gel 
cast to make a gel.  
Step 2. Loading the gel 
The loading buffer was made by adding 50ml of TBE buffer to 450ml of deionized 
water. 5 µl of Blue/Orange 6× Loading Dye (Promega) was added to 25 µl of each 
sample. The loading buffer was poured into the electrophoresis apparatus/tank. The 
gel cast was placed in the tank. 6 µl of TrackIt™ 50 bp DNA Ladder (Invitrogen) 
was loaded into the first well, 12 µl of each sample was loaded from the second well. 
Step 3. Running the gel 
The gel was run at 100 volts until the blue dye approached the bottom of the gel. 
Step 4. Visualizing the gel 
The gel was taken out from the gel cast and placed into the UV light box of the 
Ultraviolet Transilluminator (Biomaging systems). Bands were visualized under UV 
light and photos were taken. 
 
2.2.2.6 Quantitative Real Time PCR (QRT-PCR) 
QRT-PCR is a technique used to amplify and quantify a targeted DNA fragment. 
This method is based on detecting fluorescence produced by fluorescent reporter 
molecules that bind to double stranded DNA which increases in concentration as the 
reaction proceeds.  Fluorescent reporter molecules include dyes which bind to 
double-stranded DNA (such as SYBR® Green) and sequence specific probes.  
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QuantiTect SYBR Green PCR Kit (QIAGEN) was used and the double delta Ct 
(∆∆Ct) method [129] was used to analyse the relative expression level of genes. For 
each gene, three runs were performed and samples were prepared in triplicate for 
each run. The mean Ct value was used for the final analysis. All 7 MMR genes were 
normalized against two housekeeping genes-TBP and HPRT1. Standard curves are 
shown in Appendix 1. Preparation of a sample (total volume 15 µl) is shown as 
follows: 
Reagent Volume (µl) 
2x QuantiTect SYBR Green PCR Master Mix* 7.5 
Forward primer 0.18 
Reverse primer 0.18 
cDNA or DNA 4 
Deionized water 3.14 
*2x QuantiTect SYBR Green PCR Master Mix contains HotStarTaq® DNA Polymerase, QuantiTect 
SYBR Green PCR Buffer, dNTP mix, including dUTP,  SYBR Green I, ROX™ passive reference dye 
and 5 mM MgCl. 
Samples were run in Rotor-Gene 3000 (Corbett Research) QRT-PCR machine. The 
cycling programme was set as follows: 
Step Temperature Time 
Hold 1 95 °C 15 minutes 
Cycling×40 
95°C 15 seconds 
57°C 20 seconds 
72°C 20 seconds 
Hold 2 72°C 5 minutes 
 
2.2.3 Western blot 
Western blot, also known as protein immunoblot, is an analytical technique used to 
detect specific proteins in given samples. Gel electrophoresis is used to separate 
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proteins and the proteins are then transferred to a membrane where target proteins 
can be detected by specific antibodies.     
 
2.2.3.1 Preparation of protein lysates 
Protein was extracted from cells growing in T 75cm
2
 flasks. Medium was discarded, 
and cells were washed with ice cold PBS. One complete protease inhibitor tablet 
(Roche), 100µl of phosphatase inhibitor cocktail 2 (Sigma),  100µl of phosphatase 
inhibitor cocktail 3 (Sigma), 50µl of aprotinin and 100µl of Triton-×100 were added 
to the ice cold pre-prepared 10ml protein lysis buffer (50mM Tris, pH 7.5; 5mM 
EGTA pH 8.5; 150mM Nacl). 200µl of the lysis buffer was added into the flask. 
Cells were scraped to detach from the flask and suspended in lysis buffer and the 
suspension was left on ice for 15 minutes. Cell suspension was transferred to a 1.5 ml 
tube, followed by centrifuging at 13,000 for 30 minutes at 4°C. The supernatant was 
transferred into a new tube and stored at -80°C.  
 
2.2.3.2 Determination of protein concentration 
The bicinchoninic acid assay (BCA assay) was used to determine the total 
concentration of protein. The BCA assay is based on the mechanism that in highly 
alkaline environment the peptide bonds of protein reduce Cu
2+
 ions from the cupric 
sulfate to Cu
+
 and the amount of Cu
2+
 decreased is proportional to the amount of 
protein in the solution. Then the chelation of two molecules of BCA with each Cu
+
 
forms a purple-coloured reaction product which exhibits a strong absorbance at 562 
nm.  The concentration of protein in each sample is determined by measuring the 
absorbance and comparing with bovine serum albumin (BSA) standard curve. 
Micro BCA
TM
  Protein assay kit (Thermo Scientific) was used. Albumin Standard 
Ampules are 2mg/ml. Reagent A contains containing sodium carbonate, sodium 
bicarbonate and sodium tartrate in 0.2 N NaOH. Reagent B contains bicinchoninic 




Preparation of BSA standard curve 
Final protein  
concentration (µg/ml) 
Solution 1 
50µl of lysis buffer + 50µl BSA stock 
(2mg/ml) 
20 
Solution 2 50µl of lysis buffer + 50µl of solution 1 10 
Solution 3 50µl of lysis buffer + 50µl of solution 2 5 
Solution 4 50µl of lysis buffer + 50µl of solution 3 2.5 
Solution 5 40µl of lysis buffer + 10µl of solution 4 0.5 
Blank Lysis buffer only 0 
 
 
Preparation of reagent mix:  
Reagent Percentage of Volume 
Reagent A 50 
Reagent B 48 
Reagent C 2 
 
Standard and unknown samples were prepared in duplicate. 20µl of standard, 1ml of 
dH2O and 1 ml of reagent mix were added into corresponding tubes (standard curve). 
5µl of unknown sample, 1ml of dH2O and 1ml of reagent mix were added into 
corresponding tubes. All tubes were sealed with parafilm and placed in 60°C water 
bath for 1 hour to facilitate the reaction. Absorbance of each solution was then 
measured at 562nm. A BSA standard curve (shown below) was plotted and protein 






2.2.3.3 SDS-PAGE gel electrophoresis 
SDS-PAGE stands for Sodium dodecyl sulfate (SDS) polyacrylamide gel 
electrophoresis (PAGE), which is a technique used for separating proteins according 
to their size. SDS, an anionic detergent can destroy the complex structure of proteins, 
reducing proteins to their linearized primary structure. In addition, binding of SDS to 
polypeptide chains coats them with evenly distributed negative charges per unit mass. 
The negative charged polypeptide chains are strongly attracted toward an anode in an 
electric field, which results in a fractionation by their size during electrophoresis. 
The XCell SureLock™ Mini-Cell Electrophoresis System (Invitrogen) was used 
according to manufacturer’s protocol. For each sample 10-20 µg of protein is used. 
Samples were prepared as shown below: 
Reagent Volume (µl) 
Sample X 
NuPAGE® LDS Sample Buffer (4X) 4 
NuPAGE® Sample Reducing Agent 
(10X) 
1.6 
Deionized Water to 10.4 
Total Volume 16 
Samples were heated at 70 °C heating block for 10 minutes 
 
y = 0.0411x + 0.1559 
















Protein concentration (µg/ml) 
BSA standard curve 
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Preparation of 1 X SDS Running buffer: 
Reagent Volume (ml) 
NuPAGE® MOPS SDS Running Buffer 
(20X)          
50 
Deionized water 950 
 
Once the XCell SureLock™ Mini-Cell apparatus was assembled, the central chamber 
was filled with 200ml of the 1 X SDS Running buffer, and the outer chamber was 
filled with 600ml of the 1 X SDS Running buffer. 500 µl of NuPAGE® Antioxidant 
was then added to the central chamber. After all samples were loaded, the gel was 
run at 200 V for 50 minutes. 
Preparation of Transfer buffer: 
Reagent Volume (ml) 
NuPAGE® Transfer Buffer (20X)  50 
100% methanol  100 
10% SDS 10 
Deionized water 840 
 
Four filter papers and four sponges were soaked in the transfer buffer. An 
Immobilon-FL transfer membrane was soaked in 100% methanol. Two sponges, two 
pieces of filter paper, the transfer membrane, the gel, another two pieces of filter 
paper and two sponges were placed on the transfer cell followed by assembling into 
the apparatus. The central chamber was filled with the transfer buffer and the outer 
chamber was filled with water. The tank was run at 100 V for 70 minutes.  
 
2.2.3.4 Western blotting 
After transfer, the membrane was blocked in 50% Li-Cor Odyssey Blocking Buffer 
(diluted in PBS) for one hour at room temperature. After that, primary antibodies 
were added to the blocking buffer and incubated with the membrane overnight at 4°C 




Li-Cor Odyssey Blocking Buffer 5 ml 
PBS 5 ml 
Tween-20 10 µl 
primary antibody (mouse) x µl 
Primary antibody (Rabbit) x  µl 
 
The next day, the membrane was taken out from the cold room, followed by washing 
3 times with PBS/Tween-20(0.1%) for 5 minutes each. The membrane was then 
incubated with secondary antibodies in dark for 45 minutes. Preparation of solution 
with secondary antibodies is shown as below: 
Reagent Volume 
Li-Cor Odyssey Blocking Buffer 5 ml 
PBS 5 ml 
10% SDS 20 µl 
Tween-20 20 µl 
Secondary antibody (mouse) 1 µl 
Secondary antibody (Rabbit) 1  µl 
 
After that, the membrane was washed 4 times with PBS/Tween-20 (0.1%) for 5 
minutes each. Then the membrane was washed with PBS for 1 minute to remove 
residual Tween-20. Afterwards, the membrane was placed on a piece of filter paper, 
then wrapped with tissue and left in dark to dry. The dried membrane was scanned 




2.2.4   Cloning 
2.2.4.1 Plasmid Construction 
Plasmid vector pPyCAGASIZ was modified and prepared by Professor David 
Melton. The vector was then digested by Not1 enzyme and dephosphorylated with 
Alkaline Phosphatase (CIP). The insert fragment, MLH1 cDNA was released from 
pCMV6-XL5-MLH1 (ORIGENE) plasmid using Not1 which does not cut the MLH1 
cDNA. DNA of the vector and the insert were visualized by Agarose gel 
electrophoresis and purified from the gel by using QIAquick Gel Extraction kit 
(QIAGEN) according to manufacturer’s instructions. The fragments of insert and 
vector were ligated by using T4 ligase. After plasmid DNA amplification, the 
orientation of the insert was checked by digestion using restriction enzymes Bsrg1 
which cuts the vector and Bgl2 that cuts MLH1 fragment at a site close to its 5’ end.  
 
 
Maps of pCMV6-XL5-MLH1 and pPyCAGASIZ-MLH1 
 







Digestion mixture Volume added (µl) 
Enzyme(s) 1 
10×Reaction buffer 3 
10× BSA buffer 3 
DNA 3 (variable) 
dH2O 20 (variable) 
Total volume 30 
 
Ligation mixture (insert only ) Volume added (µl) 
T4 ligase 0.5 
Ligation buffer 0.5 
MLH1 DNA fragment 3 
dH2O 1 






Ligation mixture (vector only ) Volume added (µl) 
T4 ligase 0.5 
Ligation buffer 0.5 
Vector DNA 3 
dH2O 1 
Total volume 5 
 
Ligation mixture (vector+insert ) Volume added (µl) 
T4 ligase 0.5 
Ligation buffer 0.5 
MLH1 DNA fragment 3 (variable) 
Vector DNA  1(variable) 
Total volume 5 
 
2.2.4.2 Plasmid DNA amplification 
Plasmid DNA or DNA ligation mixture was transformed to into DH5α competent 
cells (Invitrogen) according to manufacturer’s instructions. 10-100µl of transformant 
was spread onto L-agar plates containing ampicillin (100µg/ml). Plates were then 
incubated at 37°C overnight upside down. Single colonies were picked up and grown 
in LB selection medium containing ampicillin (100µg/ml). Afterwards, Plasmid 
DNA was purified using QIAGEN plasmid purification kit according to 
manufacturer’s instructions. Purified plasmid DNA was stored at -20°C.  
 
2.2.5 Transient transfection of cells  
2.2.5.1 Overexpression 
Cell lines SKOV3, IGROV1 and TOV21G were transfected with pCMV6-AC-
MLH1 plasmid or empty vector control pCMV6-Neo (both ORIGENE) using 
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TurboFectin8.0 (Origene) or Lipofectamine2000 (Invitrogen) transfection reagent 
according to the manufacturer’s instructions. For IGROV1 and TOV21G cells, 
plasmid pPyCAGASIZ-MLH1 and its empty vector were also used. Cells were 
seeded in 6cm dishes and transfection was conducted when cells were 70-80% 
confluent. 2 µg DNA and 6 µl of transfection reagent were diluted in 250 µl of Opti-
MEM Reduced Serum Medium  respectively. After 5 minutes incubation of 
transfection reagent and Reduced Serum Medium at room temperature, the diluted 
DNA was mixed with the transfection reagent thoroughly, followed by incubation at 
room temperature for 20 minutes to form cationic liposome-DNA complexes. Then 
the mixture was added dropwise to cells. 
2.2.5.2 Knockdown 
SKOV3 clones and A2780 cells were transfected with siRNAs that target PLK1 or 
MLH1 using Lipofectamine® RNAiMAX Transfection Reagent according to the 
manufacturer’s instructions. Cells were seeded in 6 well plates and transfection was 
conducted when cells were 30-50% confluent. A certain amount of siRNA and 9 µl 
of transfection reagent were diluted in 150 µl of Opti-MEN Reduced Serum Medium 
separately. Then the diluted siRNA was mixed with the transfection reagent 
thoroughly, followed by incubation at room temperature for 5-10 minutes. Then the 
mixture was added dropwise to cells. After optimization experiments (concentrations 
tested: 5nM, 10nM, 20nM and 50nM) of these siRNAs, 5nM of siRNAs targeting 


















2.2.6 Establish stable cell lines 
2.2.6.1 Determine the optimal concentration of drug for selection 
Cells were seeded in a 12 well plate and each well contained 1ml of medium. G418 
solution (50mg/ml, Sigma) was used as selection antibiotic.  Selection medium was 
changed every 3 days. The lowest concentration of drug that begins to give massive 
cell death in 1 week and kills all cells in two weeks was chosen. For SKOV3 and 
IGROV1, 500µg/ml was used while 700µg/ml was chosen for selection of TOV21G.  






















Layout of the kill curve plate 
 
Volume of 50mg/ml stock solution added 
(µl) 















2.2.6.2 Transfection of cells 
Cells were seeded in 10 cm dishes and transfected using the method described in the 





Cells were split at 1:10, 1:20 and 1:50 dilution into fresh growth medium containing 
selective antibiotics with concentration determined before. Selection medium was 
changed every 2-3 days. Cells which did not take or had lost the plasmid with the 
neomycin resistance cassette were killed and were discarded during medium 
changing. After 2 weeks, cells that continued to grow in selection medium had 
presumably retained the plasmid which stably integrated into the genome of these 
cells. Their colonies appeared in the bottom of the dish. Well isolated colonies were 
picked up and grown in 24 well plates containing selection medium. Afterwards, 
cells were transferred to 6 well plates and finally to T75 flasks when they reached 
confluence. Expression of MLH1 protein in picked clones was checked by western 
blot and immunocytochemistry.  
 
2.2.7 Immunocytochemistry  
Immunocytochemistry (ICC) is a technique which uses antibodies that target specific 
peptides or proteins in the cells. Bound primary antibodies can be detected by using 
different methods such as fluorescent secondary antibodies. The result shows 
whether or not the cells express the specific antigen and its location in a cell.  
Cells were grown on 19mm glass coverslips, and fixed with 4% of paraformaldehyde 
for 15 minutes. Afterwards cells were washed 3 times with PBS for 5 minutes each. 
Cells were then blocked in blocking buffer (1.1% BSA, 0.2% Triton in PBS) for one 
hour, followed by incubating with MLH1 primary antibody (1:300 dilution in 
blocking buffer) overnight at 4°C. After that cells were washed 3 times with PBS for 
5 minutes, following incubating with DAPI (1:2000 dilution in blocking buffer) and 
fluorescent secondary antibody (AlexaFluor 488 Donkey anti-mouse IgG, 1:500 
dilution in blocking buffer) for one hour at room temperature in dark. Cells were then 
rinsed 3 times with PBS for 5 minutes each. Afterwards coverslips and microscope 
slides were mounted using Vectashield mounting medium. Photos were taken using 




2.2.8 Methods used in studying cell proliferation and viability 
2.2.8.1 IncuCyte ZOOM Live Cell Imaging 
IncuCyte ZOOM comprises a microscope gantry that resides in the cell incubator, 
and a networked external controller hard drive that gathers and processes image data 
[130]. This system was used to quantify the proliferation rate of SKOV3 clones. 
Cells were plated in 96 well Nunc black optical bottom plates (in triplicate) with a 
seeding density of 500 cells per well. Cells were grown for 96 hours, and images of 
each well were taken every three hours by the IncuCyte ZOOM microscope. Cell 
confluence at different time points was then measured by the IncuCyte ZOOM 
software. Afterwards, proliferation rate of each cell line was quantified.  
 
2.2.8.2 MTT cytotoxicity assay  
The MTT assay is a colorimetric assay that was first designed by Mosmann in 1983 
[131] and then modified by Denizot and Lang in 1986 [132]. This assay is based on 
the fact that the conversion of 3-[4,5-Dimethylthiazol-2-yl]-2,5-disphenyl-
tetrazolium bromide (MTT) to MTT-formazan, blue water insoluble crystals, by the 
mitochondrial enzyme, succinate dehydrogenase, only takes place in living cells and 
the amount of formazan produced is proportional to the number of viable cells 
present. Therefore, the MTT assay is a reliable method to measure cytotoxicity. 
This assay was carried out on 96 well sterile cell culture plates. 
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B W PC         VC W 
C W PC         VC W 
D W PC         VC W 
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Layout of MTT plate 
W= 200 μl of sterile water  
PC= cells and positive control drug in media (final volume: 100 μl) 
VC= cells and vehicle control in media (final volume: 100 μl) 




Cells were seeded in a 96 well plate at a seeding density of 2000 cells/well. As 
illustrated in the figure above, 200 μl of sterile water was added into the outside 
wells of the plate. 95 μl of cell suspension was added to the rest of wells. The plate 
was then incubated at 37 °C for 24 hours. After that 5 μl of prepared drug solution or 
vehicle control was added to corresponding wells. After 3 days incubation, 20 μl of 
MTT solution (5g/ml) was added to each well, followed by further incubation of 3-4 
hours to allow development of formazan crystals. After that, 50 μl of DMSO was 
added to each well and the plate was incubated in 37 °C for 5 minutes for colour 
generation. Then the plate was read at wavelength of 570nm.  
 
2.2.8.3 Alamar Blue Cell Viability Assay 
The alamarBlue® Assay is designed to measure proliferation of various cell lines, 
bacteria and fungi [133]. This assay incorporates a fluorometric/colorimetric growth 
indicator based on detection of metabolic activity. It has an oxidation-reduction 
(REDOX) indicator that exhibits both fluorescence and colorimetric change relating 
to cellular metabolic reduction. In addition, AlamarBlue is non-toxic to cells and 
therefore less likely to interfere with normal metabolism.  
SKOV3 clones were seeded in a 96 well plate at a seeding density of 1000 cells/well. 
The layout of plate and treatment of cells were the same as that of MTT assay 
described above. After 3 days incubation, 10 μl of AlamarBlue solution was added to 
each well, followed by further incubation of 2-3 hours at 37 °C. After that the 
fluorescence is monitored at 530-560nm excitation wavelength and 590nm emission 
wavelength. 
 
2.2.8.4 Determination of cell growth parameters 
In this study the following parameters were determined: GI50: 50% growth inhibition 
- The dose that inhibits 50% of cell growth; TGI: Total growth inhibition – the dose 
that causes a cytostatic effect; LC50: 50% lethal concentration - The dose that kills 50% 
of the members of a tested population after specified test duration. 
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The formula used to determine the above parameters emphasizes the correction for 
the cell count at time zero. This is recommended by the National Cancer Institute 
(NCI) (http://dtp.nci.nih.gov/docs/compare/compare_methodology.html) [134].  
(T-T0)/(C-T0)*100 for concentrations for which T>/=T0 
(T-T0)/T0*100 for concentrations for which T<T0. 
Where growth at time zero = T0, vehicle control growth (at termination time) =C, 
and the test growth in the presence of drug (at termination time) =T.  
Thus, GI50 is the concentration of test drug where 100*(T-T0)/(C-T0) =50. 
 
2.2.9 Statistical analysis  
Statistical analysis in this project was performed by using GraphPad Prism6. 
Fisher's exact test was used to analyse 2x2 contingency table.  
Mann-Whitney U test was used to analyse two groups of unpaired variables when 
assumptions for the independent t-test are not satisfied: 1. Data do not follow normal 
distribution. 2.  There are unequal variances across groups. 3. Data with outliers.  
Log-rank test was used to analyse survival distributions.  
Pearson Correlation analysis was used to measure of the linear correlation 
(dependence) between two groups of variables.  
One-way ANOVA analysis was used to compare means of three or more groups of 
variables when there was only one independent variable.  
Two-way ANOVA analysis was used to compare means of three or more groups of 






Clinical consequences of MMR deficiency in 
epithelial ovarian cancer 
 
 
 3.1 Introduction 
As discussed previously, women with HNPCC have an increased lifetime risk of 
developing ovarian cancer and a proportion (2-29%) of unselected ovarian cancers 
have been reported to exhibit defects in MMR protein expression. In addition, 
compared with MMR deficiency in colorectal cancer, MMR in ovarian cancer is 
relatively under-investigated. The following questions need to be addressed:   What 
is the overall incidence (unselected histology) and specific incidence (based on each 
histology subtype) of MMR deficiency in ovarian cancer? What is the treatment 
response and survival with the MMR+/- background in patients receiving current 
standard therapy? In order to characterise the clinical consequences, a large patient 
cohort was studied with regard to MMR status.  
In the first instance, three tissue microarrays (TMA) consisting of 581 ovarian 
tumours were constructed in the pathology department. Then the MMR status was 
characterised by using immunohistochemistry (IHC) for detection of expression of 
the most frequently lost proteins in HNPCC: MLH1, MSH2, PMS2 and MSH6. The 
other three MMR proteins were not tested because suitable antibodies were not 
available. The IHC results were then scored and histological subtype of each tumour 
was reviewed by expert gynaecological pathologists using corresponding H&E 
(haematoxylin and eosin) stained slides. Afterwards, the results of MMR status and 
histology subtypes were analysed in combination with the associated clinical data. Of 
the 581 tumours, 538 had defined MMR status combined with reviewed histology. 
Clinical consequences of MMR deficiency in ovarian cancer were characterized. 
However, as matched blood samples were not available, it was not possible to 
determine MMR germline mutation status in these patients. Therefore, detected 
MMR deficient patients had either sporadic ovarian cancers with somatic 
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inactivation of MMR or hereditary ovarian cancer caused by germline mutation of 
MMR genes.   
 
3.2 Analysis of histological subtypes of ovarian tumours and testing of MMR 
status 
Collection and processing of patient samples  
Formalin fixed paraffin embedded (FFPE) ovarian tumour samples were retrieved 
from different hospitals in South East Scotland. Sections were cut from these FFPE 
blocks, followed by H&E staining. Afterwards, 581 cases were used to construct 
TMA slides in triplicate. The criteria of selection of TMA samples are shown in 
Table 3.1.    
The collection and processing were performed by technicians in the pathology 
department of Western General Hospital.  TMA sample selection was performed by 
Dr Caroline Michie.  
Inclusion 
criteria 
Histologically confirmed primary ovarian, peritoneal or fallopian tube cancer 
Pathological specimen available as both an H&E stained slide and FFPE block 
(1984-2006) for analysis 
International Federation of Gynaecology and Obstetrics (FIGO) stage IC – IV 
Patients must have received first line platinum-based chemotherapy or platinum-
taxane at standard doses following cytoreductive surgery. 




Borderline malignancy or another subtypes of ovarian neoplasm;  small cell, 
granulosa cell, mixed mesodermal tumours, squamous cell, neuroendocrine, 
carcinoid, choriocarcinoma, transitional cell, germ cell or a mixed cell 
population including any of the above. 
Prior radiotherapy or chemotherapy for ovarian cancer 
Inadequate or lost to follow up 
Interval cytoreductive surgery following neo-adjuvant chemotherapy 
Table 3.1 Selection criteria for ovarian TMA samples.  (Information adapted from Dr 
Caroline Michie.) 
 
IHC staining and scoring 
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IHC staining was performed on the TMA slides in triplicate to detect expression of 
MLH1, MSH2, PMS2 and MSH6. Two scores were used to determine MMR status: 
either MMR deficiency (lack of staining) or MMR proficiency (tumour core with 
dark brown staining). For each tumour (in triplicate), if absence of staining was seen 
at least twice, the tumour was considered MMR deficient.  
IHC staining was performed by technicians in the pathology department of Western 
General Hospital; Blinded independent scoring was performed by two individuals 
following training by members of the pathology department at the University of 
Edinburgh. 
 
Combination of MMR status and histology types with clinical data 
Histological subtypes of the tumours on the TMA were independently assessed by 
two pathologists (Professors Alistair Williams and Glenn McCluggage) using H&E 
stained tumour sections. Afterwards, the results were combined with stages, 
treatment response and survival to characterise the clinical consequences of MMR 
deficiency in ovarian cancer. 
 
Summary of excluded cases 
As shown in Table 3.2, of the total of 581 tumours in the TMA, 25 of them were not 
reviewed by pathologists due to problems retrieving corresponding tumour samples; 
eight cases appear in the clinical database twice; therefore they could not be included 
for further analysis. Other exclusions were suggested by pathologists after histology 
review: 10 cases were considered as metastatic tumours which were not original 
ovarian cancers; one case was considered as borderline tumour, and no tumour was 
seen on the H&E stained slide in another case. The remaining 536 cases were 





 Number of cases % of total 
Total cases 581  
Included cases 536 92.3 
Excluded cases 45 7.7 
Not original ovarian tumour 10 1.7 
Borderline 1 0.2 
Duplication in dataset 8 1.4 
No tumour on slide 1 0.2 
Histology not reviewed 25 4.3 
Table 3.2 Summary of included and excluded cases.  
 
Table 3.3 summarises the histological subtypes of ovarian tumours. Among the 536 
tumours, 18 are of serous/undifferentiated subtype. After consulting pathologists 
Professors Alistair Williams and Glenn McCluggage, the 18 cases were grouped with 
high grade serous subtype for the purposes of further analysis (Table 3.4).   
In total, out of 536 patients, 394 (73.5%) were of high grade serous subtype. This 
was consistent with epidemiology data of ovarian cancer demonstrating that high 
grade serous subtype accounts for about 70% of all epithelial ovarian cancers [135]. 
For the MMR deficient cases, non-serous subtypes accounted for just over a half: 43 
out of 84 (51.2%). There was a higher incidence of MMR deficiency in patients with 
clear cell (42.5%) or mucinous (45.5%) ovarian cancers (Table 3.4). However, for 
the most common subtype, high grade serous, only 9.9% had apparent MMR 
deficiency. In addition, there was a significant difference in the incidence of MMR 
deficiency between high grade serous subtype and each non-serous subtype of 
ovarian cancer (high grade serous vs endometrioid, p=0.0001; high grade serous vs 








Histology Subtypes Number of 
patients 
High grade serous 376 






Clear cell 40 
Mucinous  11 
undifferentiated 3 
Total 536 







patients in each 
subtype 




Number of  
MMR+ 
patients  
Number of  
MMR- patients 







serous subtype  


































3 - - 
Mixed 1 
(0.2%) 
1 - - 
Total 536 452 84  
 
Table 3.4 Analysis of histology subtypes of ovarian cancer with regard to MMR status. 
Fisher’s exact test was performed to compare the proportion of MMR- patients between high 




3.3 Analysis of stage of ovarian cancer at diagnosis with regard to histological 
subtype and MMR status 
For the 536 tumours, 517 had information on stage at diagnosis recorded in the 
database. Table 3.5 and Table 3.6 indicate stage of ovarian cancer with regard to 
MMR status and histological subtype respectively. Overall, out of the 517 patients, 
391 (75.6%) were diagnosed at advanced stage (Table 3.5). Compared with MMR 
proficient ovarian cancers (91 out of 434, 20.9%) a much larger proportion of MMR 
deficient ovarian cancers (35 out of 83, 42.2%) were diagnosed at early stages, and 
the difference was statistically significant (stage I: p=0.0092; stage II:  p=0.0167) 
(Table 3.5). Table 3.6 shows that overall there is noticeable difference in stage at 
diagnosis (from stage I to III) between high grade serous subtype and each non-
serous subtype. In addition, for MMR proficient patients, the difference in stage at 
diagnosis (from stage I to III) between high grade serous subtype and non-serous 
subtypes was also obvious (Table 3.6). For MMR deficient patients, there is 
noticeable difference in stage at diagnosis (from stage I to III)   between high grade 
serous subtype and clear cell subtype. This indicates that early stage of diagnosis is 
associated with non-serous histology. MMR deficiency is more likely to occur in 
non-serous ovarian cancers and therefore also linked with early stage of diagnosis.   
As shown in Table 3.6, the most deadly subtype of ovarian cancer, high grade serous, 
overall had 88.1% (334 out of 379) of patients diagnosed at advanced stages. In 
addition, for this subtype, 10.8% (37 out of 342) of MMR proficient patients were 
diagnosed at stage I or II, whereas 21.6% (8 out of 37) of MMR deficient patients 
were diagnosed at early stages. Low grade serous ovarian cancer also had a high 
percentage (81.8%) of patients diagnosed at advanced stages but this subtype had 
only 2 MMR deficient patients, and both were diagnosed at stage III.  
On the other hand, for non-serous subtypes, endometrioid (41 out of 74, 55.4%), 
mucinous (7 out of 11, 63.6%), and clear cell (28 out of 38, 73.7%), over half of the 
cases were diagnosed at early stages (Table 3.6). In addition, for these three non-
serous subtypes, both MMR proficient and deficient groups had over half of patients 
diagnosed at early stages. Within the clear cell subtype, a higher proportion of MMR 
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deficient patients (82.4%, 14 out of 17) were diagnosed in early stages compared 
with MMR proficient patients (66.7%, 14 out of 21). However, within endometrioid 
(MMR+: 57.4%, 31 out of 54; MMR-: 50%, 10 out of 20) and mucinous subtypes 
(MMR+:66.7%, 4 out of 6; MMR-: 40%, 2 out of 5), a higher percentage of MMR 
proficient patients were diagnosed at early stages.  
The results indicate that both high grade serous and low grade serous subtypes are 
associated with advanced stage of diagnosis, whereas non-serous subtypes are 
associated with early stage of diagnosis. Overall MMR deficient patients are more 
likely to be diagnosed at early stages compared with MMR proficient patients, and 
this is probably due to the association between MMR deficiency and non-serous 
histology. Since the sample size in non-serous and low grade serous subtypes was 
small, larger scale studies are needed to make a firm conclusion linking stage of 





(% of total) 
Number of  
MMR+ 
patients (% 
of total ) 
Number of 
MMR- 
patients  (% 
of total) 
Statistical difference 
between  MMR+ and 
MMR-patients 
I 63 (12.2%) 45 (10.4%) 18 (21.7%) p=0.0092 
II 63 (12.2%) 46 (10.6%) 17 (20.5%) p=0.0167 
III 305 (58.9%) 269 (61.9%) 36 (43.4%) p=0.0022 
IV 86 (16.6%) 74 (17.1%) 12 (14.5%) P=0.6320 
Total 517 434 83 - 
Table 3.5  Stage of ovarian cancer with regard to MMR status. Fisher’s exact test was 
































































































































































































































































0 -  
Total 379 342 37 11 9 2 74 54 20 11 6 5 38 21 17 3 1 








3.4 Analysis of treatment response of ovarian cancer with regard to MMR 
status 
532 out of the 536 cases had treatment response recorded in the clinical database. 
Patients all had platinum-based standard treatment. Table 3.7 summarises treatment 
response of these patients. The following criteria are used to determine different 
treatment responses. 1. Complete response: no features to suggest residual or 
recurrent disease. 2. Partial response: at least 50% reduction of disease. 3. No change 
or stable disease:  less than 50% reduction of disease or no greater than 25% increase 
in disease.4. Progressive disease: any sign of new disease areas, or 25% increase in 
disease. 5. Not evaluable: when it is impossible to accurately fulfil the above criteria 
from scan information, or no scan was done at the end of therapy.  
After consulting data manager Mrs Tzyvia Rye, “PR Recist” was grouped with 
“Partial Response” for data analysis, whereas “Not Evaluable” cases and “Not 
Applicable” cases were excluded. Professor Charlie Gourley also suggested 
exclusion of the “Clinical Deterioration” case. In total 213 cases were included in 
analysis regarding MMR status (Table 3.8) and histology subtypes (Table 3.9). Table 
3.7 shows that overall 142 (66.6%) patients had complete or partial response, while 
24 (11.3%) patients did not respond to the treatment and 47 (22.1%) patients had 
progressive disease.  
There was no significant difference in treatment response (Fisher’s exact test, 
p=0.2219) between patients with and without MMR deficiency: 68.5% (124 out of 
181) MMR proficient patients had complete or partial response; 56.2% (18 out of 32) 
MMR deficient patients had complete response or partial response (Table 3.8). Out 
of the 213 cases, 175 were of high grade serous subtype, and 125 (71.5%) patients 
had complete or partial response (Table 3.9). For other subtypes of ovarian cancers, 
their sample size was too low (low grade serous: 1 case; endometrioid: 20 cases; 










with  MMR 
deficiency 
NOT EVALUABLE 284 241 43 
COMPLETE RESPONSE 61 52 9 
PARTIAL RESPONSE 78 69 9 
NO CHANGE 24 20 4 
PROGRESSIVE DISEASE 47 37 10 
NOT APPLICABLE 34  26 8 
CLINICAL DETERIORATION 1 1 - 
PR RECIST 3 3 - 
Total 532 449 83 





Treatment response Number of patients Patients without MMR deficiency Patients with MMR deficiency 
COMPLETE RESPONSE 61 (28.6%) 52 (28.7%) 9 (28.1%) 
PARTIAL RESPONSE 81 (38.0%) 72 (39.8%) 9 (28.1%) 
NO CHANGE 24 (11.3%) 20 (11.1%) 4 (12.5%) 
PROGRESSIVE DISEASE 47 (22.1%) 37 (20.4%) 10 (31.3%) 
Total 213  181 32 





Number of patients High grade serous Low grade serous Endometrioid Clear cell Mucinous 
COMPLETE 
RESPONSE 
61 (28.6%) 50 (28.6%) - 7  3  1 
PARTIAL 
RESPONSE 
81 (38.0%) 75 (42.9%) - 3  1  2 
NO CHANGE 24 (11.3%) 18 (10.3%) - 5  1  - 
PROGRESSIVE 
DISEASE 
47(22.1%) 32 (17.3%) 1 5  8  1 
Total 213 175 1 20 13 4 




3.5 Analysis of age at diagnosis with regard to MMR status in ovarian cancer 
As shown in figure 3.1A and B, for both the 452 MMR+ patients and the 84 MMR- 
patients, over 70% were diagnosed between 50 to 70 years of age. For the MMR+ 
patients, the median age at diagnosis is 60; the 25% percentile age and the 75% 
percentile age are 53 and 68 respectively.  For the MMR- patients, the median age at 
diagnosis is 59; the 25% percentile age and the 75% percentile age are 51 and 64 
respectively. There is no significant difference in age at diagnosis between patients 
with or without MMR deficiency (3.1C). Since HNPCC related ovarian cancers in 
general occur at a younger age, with a median age at diagnosis of 41-49 years [19, 
73-76], the vast majority of MMR- patients in this study were unlikely from HNPCC 
families. Their ovarian cancers were very likely to arise sporadically, instead of 
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Figure 3.1 Analysis of age at diagnosis in unselected ovarian cancers with regard to 
MMR status. (A) Distribution of age at diagnosis of MMR+ patients. (B) Distribution of 
age at diagnosis of MMR- patients. (C) Compare age at diagnosis between patients with or 
without MMR deficiency. Mann-Whitney U test was performed by using GraphPad Prism 6. 
MMR+: 60 (53, 68); MMR-: 59 (51.25, 64); P=0.0837. There is no significant difference in 
age at diagnosis between patients with or without MMR deficiency.     
 
3.6 Analysis of patient survival with regard to histological subtypes and MMR 
status in ovarian cancer 
For the 536 patients 535 had overall survival (OS) information recorded, 512 had 
progression free survival (PFS) information recorded. The remaining cases that lack 
information of survival were not included in analysis.  
Figure 3.2 shows that there was a significant difference in both overall survival 
(Logrank test, p<0.0001) and progression free survival (Logrank test, p<0.0001) in 
patients with different types of ovarian cancers.  The difference of survival between 
high grade serous subtype and non-serous subtypes was stage dependent as over 80% 
of high grade serous and low grade serous ovarian cancers were diagnosed at 
advanced stages, while over 50% of the three non-serous ovarian cancers were 
diagnosed at early stages. The results are consistent with published data [8, 136] that 




has the lowest survival compared with other subtypes of ovarian cancers (Figure 3.1, 
Table 3.10). Figure 3.3 (A B) and Table 3.11 show that patients with type II ovarian 
cancers had significant worse overall survival (Log-rank test, p=0.0001) and 
progression free survival (Log-rank test, p<0.0001) compared with patients classified 
as type I ovarian cancers. There was noticeable difference (Log-rank test, p=0.0523) 
in PFS between the two groups when comparing cases diagnosed at early stages 
(Figure 3.3 C). This is consistent with the fact that type II ovarian cancers’ clinical 
behaviour is more aggressive than that of type I ovarian cancers [12]. However, for 
those patients diagnosed at early stages, there was no significant difference in OS 
between the two groups (Figure 3.3 D). Also, no difference in PFS and OS was 
observed between the two groups when comparing patients diagnosed at advanced 
stages (Figure 3.3 E F). These results indicate that the significant difference in PFS 
and OS observed in figure 3.3 (A B) was probably due to the fact that much larger 
proportion of type II ovarian cancers were diagnosed at advanced stages (Table 3.6).  
Figure 3.4 (A B) and table 3.12 show that there was no significant difference in 
survival between ovarian cancer patients with or without MMR deficiency under 
current standard treatment in spite of the fact that a larger proportion of MMR 
deficient cases were diagnosed at earlier stages (MMR+: about 18%; MMR-: about 
40%).  However, as shown in figure 3.4 (C D), for cases diagnosed at early stages, 
MMR+ patients had slightly better survival compared with MMR- patients (PFS: 
Log-rank test, p=0.1803; OS: Log-rank test, p=0.1040). This suggests that at early 
stages MMR+ tumours may be slightly more sensitive to current therapy.  
As the vast majority of the patients were of high grade serous subtype (and therefore 
dominated the analysis) it is important to compare survival regarding MMR status in 
each specific subtype. Figure 3.5 and Table 3.13 show that there was no significant 
difference in survival between patients with or without MMR deficiency in high 
grade serous, endometrioid and clear cell subtypes. Survival curves of low grade 
serous (for OS, MMR+: n=9; MMR-: n=2; for PFS, MMR+:n=7; MMR-:n=2) or 
mucinous subtype (for OS, MMR+:n=6; MMR-:n=5; for PFS, MMR+:n=5; MMR-
:n=5) were not made because sample sizes for these two subtypes were too small. For 
the three subtypes, although a larger proportion of MMR- patients were diagnosed at 
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early stages, these patients did not have significantly better survival over MMR+ 
patients (Figure 3.5, Table 3.13).This suggests that platinum-based treatment for 
patients with MMR deficiency gives no advantage over those without MMR 
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Figure 3.2 Analysis of survival in unselected ovarian cancers with regard to histology subtypes. (A) Progression free survival. Log-rank test, 
p<0.0001. (B) Overall survival. Log-rank test, p<0.0001. There is significant difference in both overall survival and progression free 
survival between patients with different subtypes of ovarian cancers.   
Histology subtype PFS OS 
Number of cases 
HGS LGS Endo Muci Clear HGS LGS Endo Muci Clear 
380 9 72 10 37 393 11 76 11 40 
Median survival  (Month) 14 Undefined 47 99.5 30 31 54 74 30 44 
Table 3.10  Summary of median survival of patients with different histology subtypes of ovarian cancer. Progression free survival 
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Figure 3.3 Analysis of survival in unselected ovarian cancers with regard to Type I and Type II classification. (A) Progression free survival.  Log-
rank test, p<0.0001. (B) Overall survival. Log-rank test, p=0.0001. (C) Progression free survival of cases diagnosed at early stages. (D) Overall survival 
of cases diagnosed at early stages. (E) Progression free survival of cases diagnosed at advanced stages. (F) Overall survival of cases diagnosed at 
advanced stages. Overall, there is significant difference in both overall survival and progression free survival between patients with Type I and Type II  
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Total number  
of cases 
127 373 73 44 54 329 136 385 78 47 58 338 
Median survival 
(Month) 
39 14 Undefined 74 12 13 57 31 123 96 21 29 
Table 3.11  Summary of median survival of patients with regard to Type I and Type II classification. Progression free survival (PFS). Overall 
survival (OS) .  
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Figure 3.4 Analysis of survival in unselected ovarian cancers with regard to MMR status. (A) Progression free survival. (B) Overall survival. (C) 
Progression free survival for cases that diagnosed at early stages. Log-rank test, p=0.1803. (D) Overall survival for cases that diagnosed at early stages. 
Log-rank test, p=0.1040. There is no significant difference in survival between patients with or without MMR deficiency but there is noticeable 
difference in overall survival between the two groups of patients that diagnosed at early stages. 











Total number of cases 431 79 85 32 451 84 90 36 
Median survival (Month) 16 15 167 77 34 38 140 79 
Table 3.12  Summary of median survival of patients with and without MMR deficiency. Progression free survival (PFS). Overall survival (OS).  
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Figure 3.5 Analysis of survival in different subtypes of ovarian cancer with regard to MMR status. (A, B) Progression free survival and Overall 
survival of high grade serous ovarian cancers. (C, D) Progression free survival and Overall survival of endometrioid ovarian cancers. (E, F) Progression 
free survival and Overall survival of clear cell ovarian cancers. There is no significant difference between patients with and without MMR deficiency in 
each subtype of ovarian cancer.  
 
Table 3.13  Summary of median survival of patients with three different histology subtypes of ovarian cancer with regard to MMR status. 






High grade serous Endometrioid Clear cell High grade serous Endometrioid Clear cell 
MMR+ MMR- MMR+ MMR- MMR+ MMR- MMR+ MMR- MMR+ MMR- MMR+ MMR- 
Total number 
 of cases 
341 39 53 19 22 15 354 39 55 21 23 17 
Median survival 
(Month) 
14 13 47 21 30 19 30 38 65 74 45 44 
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3.7 Incidence of specific MMR protein loss in ovarian cancer 
Out of the 536 patients 84 had MMR protein loss, and the overall incidence of MMR 
deficiency was 15.7% (Table 3.14). For the four tested MMR proteins, the most 
frequently lost protein was PMS2 (9.7%), followed by MSH6 (8.2%), MSH2 (5.2%) 
and MLH1 (2.0%) (Table 3.14). In addition, many patients lost more than one MMR 
protein; the 84 patients had 135 MMR protein losses in total (Table 3.14).  
Table 3.15 shows that the pattern of MMR protein loss in ovarian tumours tends to 
appear in a grouped fashion. For the 11 MLH1 losses, only one case lost MLH1 
alone, the other 10 cases are accompanied by PMS2 protein loss (4 cases had defects 
of MLH1 and PMS2, 2 cases had defects of MLH1, MSH6 and PMS2; 4 cases had 
deficiency in all four MMR proteins); while for the 28 cases of MSH2 protein losses, 
six cases lost MSH2 alone, the other 20 cases are companied by MSH6 protein loss 
(9 cases had deficiency of MSH2 and MSH6; 9 cases lost MSH2, MSH6 and PMS2, 
four cases lost all four MMR proteins). However, loss of PMS2 protein or MSH6 
protein is unlikely to result in loss of other MMR proteins because losing PMS2 
protein or MSH6 protein alone accounts for 34.5% and 19.0% respectively in the 84 
MMR deficient cases.  
For the 4 cases that had deficiency in all four MMR proteins, one case was high 
grade serous and diagnosed at stage III. Three cases were of non-serous subtypes and 
diagnosed at early stages (mucinous, stage I; mucinous, stage II; endometrioid, stage 
I). Surprisingly, although diagnosed at early stages, all three cases had much shorter 
progress free survival and overall survival (PFS: 12 months, 5 months, 14 months; 
OS: 14months, 6 months, 34 months) compared with median survival of MMR- and 
MMR+ groups diagnosed at early stages (showing in table 3.12: median PFS: 77 
months for MMR-, 167 months for MMR+; median OS: 79 months for MMR-, 140 
months for MMR+).  This suggests that at early stages MMR deficiency is associated 



























MLH1 11 2.0% 
536 84 15.7% 
MSH2 28 5.2% 
PMS2 52 9.7% 
MSH6 44 8.2% 
Total 135 -    
Table 3.14 MMR protein loss in all ovarian tumours.  
 
Loss of MMR protein Number of patients 
MLH1 only 1 (1.2%) 
MSH2 only 6 (7.1%) 
PMS2 only 29 (34.5%) 
MSH6 only 16 (19.0%) 
MLH1, PMS2 4 (4.8%) 
MSH2, MSH6 9 (10.7%) 
MSH6, PMS2 4 (4.8%) 
MLH1,MSH6 PMS2 2 (2.4%) 
MSH2,MSH6 PMS2 9 (10.7%) 
MSH1,MSH2 MSH6 ,PMS2 4 (4.8%) 
Total 84 
Table 3.15 MMR protein loss in MMR deficient tumours.  
 
3.8 Discussion and conclusion 
In order to characterise the clinical consequence of MMR deficiency in ovarian 
cancer, MMR status and histology subtypes of 536 tumours were determined and the 
data was combined with clinical records. Overall and consistent with published data, 
high grade serous was the most common subtype and accounted for approximately 
70% of all epithelial ovarian cancers. However, in the background of MMR 
deficiency, non-serous subtypes account for about 50% of all cases; and there was a 
significant difference in incidence of MMR deficiency between the high grade serous 
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subtype and non-serous subtypes (p<0.01).  In addition, clear cell and mucinous 
subtypes were particularly associated with higher incidence of MMR deficiency, 
with 42.5% and 45.5% carrying MMR defect respectively (Table 3.4).  
Table 3.5 shows that 75.5% of these patients were diagnosed at stage III or IV, which 
is consistent with published data that over 60% patients are diagnosed with advanced 
stage disease [3]. Non-serous subtypes are associated with early stage of diagnosis, 
with over a half of patients diagnosed at stage I or II, whereas serous subtypes are 
associated with advanced stage of diagnosis, with over 80% of patients diagnosed at  
stage III or IV. Overall, compared with MMR proficient patients, MMR deficient 
patients were more likely to be diagnosed at early stages. For the high grade serous 
subtype, the percentage of patients diagnosed at early stages in the MMR deficient 
group was twice that of patients in the MMR proficient group. For non-serous 
subtypes, as the sample size was small, larger scale studies based on specific subtype 
are needed to draw firm conclusions regarding MMR status and stage of diagnosis.  
The results of treatment response (Table 3.8) show that MMR deficient patients did 
not have an advantage using current treatment, with 56.2% having a complete or 
partial response compared with 68.5% of MMR proficient patients who had complete 
or partial response. Treatment response between each subtype of ovarian cancers is 
not comparable as sample sizes of non-serous subtypes were too low.  
Patients with high grade serous ovarian cancers had significantly lower survival 
compared with patients with other subtypes of ovarian cancer (Figure 3.2, Table 
3.10), and this is in line with the fact that a much larger proportion (88.1%) of high 
grade serous ovarian cancers were diagnosed at advanced stages than non-serous 
subtypes (<50%) of ovarian cancer . Many patients diagnosed at early stages could 
be cured by surgery alone, whereas patients diagnosed at advanced stages had much 
worse prognosis. However, for low grade serous ovarian cancers, although over 80% 
were diagnosed at stage III or IV this subtype showed better survival (Figure 3.2, 
Table 3.10). Plaxe [136] explained that low grade serous ovarian cancers have 
unique clinical and biological features and have better survival, particularly at 
advanced stages (stage Ⅰ: p=0.0003; advanced stages: p<10-5, log rank test), than 
that of high grade serous ovarian cancers. In addition, as expected, overall patients 
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with type I ovarian cancers had significant better survival than patients with type II 
ovarian cancers (Figure 3.3, Table 3.11), which is consistent with the fact that type II 
ovarian cancers are more aggressive than type I ovarian cancers and tend to appear at 
advanced stages.  
Survival between patients with and without MMR deficiency was compared based on 
both unselected histology and specific histology subtypes; and no significant 
difference was seen between MMR proficient and MMR deficient groups, despite of 
larger proportion of MMR deficient patients  were diagnosed at early stages.  
Surprisingly, for patients diagnosed at early stages, the MMR- group had slightly 
worse survival compared with the MMR+ group (Figure 3.4 C D; Table 3.12). In 
addition, there were 4 patients had deficiency in all 4 MMR proteins (Table 3.15) 
and three of them were of non-serous subtypes. Although all three cases were 
diagnosed at early stages, they all had very short survival (PFS: 5 to 14 months; OS 6 
to 34 months). This indicates that at early stages MMR deficiency is associated with 
worse prognosis and that current treatment cannot give advantage to MMR deficient 
patients and better treatments are needed for these patients. 
Table 3.14 shows that the incidence of MMR deficiency in unselected ovarian 
cancers was 15.7%, with PMS2 protein being the most frequently lost protein (9.7%). 
The vast majority of this MMR deficiency is believed to have arisen sporadically 
because 1. HNPCC related ovarian cancers in general occur at a younger age, with a 
median age at diagnosis of 41-49 years [19, 73-76]; whereas in this study patients 
(with or without MMR deficiency) were all diagnosed at much older ages (Figure 
3.1C:  median age of MMR+ group, 60; median age of MMR- group, 59) . In 
addition, the incidence of germline mutation of MMR genes in ovarian cancer is very 
low. Pat et al [75] reported  that fewer than 1% of women were found harbouring 
germline mutation in HNPCC genes, after testing MLH1, MSH2 and MSH6 in 1893 
ovarian cancer patients. However, the incidence may increase slightly if PMS2 gene 
was studied.  
Table 3.15 shows that MMR deficiency in ovarian cancer tended to appear in a 
grouped fashion, with MLH1 loss combining with PMS2 loss, MSH2 loss combining 
with MSH6 loss. Similarly, MMR deficiency is also observed in 15-20% of sporadic 
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colorectal cancers, and that MLH1-PMS2 and MSH2-MSH6 also exhibit paired loss 
[137, 138].  
Out of the 84 MMR deficient cases, 52 (61.9%) had a PMS2 defect; either losing 
PMS2 alone or combined with MLH1 protein loss. This high frequency indicates the 
importance of silencing of PMS2 protein in ovarian cancer. Since PMS2 protein has 
endonuclease function and directs strand excision during the mismatch repair process 
[36], shutting down this protein may affect the function of the mismatch repair 
system significantly, and could finally lead to tumourigenesis. As defects of PMS2 
protein could also result from MLH1 protein loss, perhaps silencing of MLH1 serves 
to cause PMS2 deficiency and affects the related downstream activities. Therefore, it 
is important to investigate MLH1 protein and PMS2 protein expression and 
regulation in ovarian cancer.  
In summary, MMR deficiency in ovarian cancer is associated with non-serous 
subtypes, and overall earlier stage of diagnosis. However, MMR deficient patients 
did not have an advantage in treatment response and survival under current standard 
treatment. Therefore, better treatment may be needed to target this subgroup of 
patients. In this patient cohort, apart from the high grade serous subtype, the sample 
size of other subtypes of ovarian cancer was low, leading to low statistical power. 
Therefore further studies on each non-high grade serous subtype should be based on 
larger patient cohorts. At the molecular level PMS2 was the most frequently 
downregulated MMR protein and that MMR protein loss tended to appear in grouped 
fashion (MLH1 with PMS2; MSH2 with MSH6). Further studies should focus on 
MLH1 and PMS2 expression and regulation.  In addition, it is worth to mention that 
compared with colorectal cancer, the clinical utility of IHC to detect MMR 
deficiency in ovarian cancer is less validated (eg. The overall frequency of MMR 
protein loss in full section slides was lower compared to TMA slides [104] ).  This is 
probably associated with heterogeneity of ovarian tumours as different histological 
subtypes arise from distinct tissues and each has distinct genetic fingerprints [106, 
107]. Future efforts are needed to validate and standardize IHC methodologies before 





Identification of cell lines with MMR deficiency and 
establishment of an in vitro model 
 
4.1 Introduction 
The clinical data in chapter 3 shows that the vast majority of ovarian cancers are of 
serous subtype. However, non-serous subtypes have a higher incidence of MMR 
deficiency. In addition, in most cases MLH1 loss is accompanied by the loss of 
PMS2, while MSH2 loss is accompanied by the loss of MSH6. In order to 
characterize the features of MMR deficiency in ovarian cancer at the molecular level, 
an in vitro cell line model was required. 
 
The first step was to identify cell lines with MMR deficiency. Hence, 19 cell lines 
including 17 ovarian cancer cell lines and 2 ovarian epithelial cell lines were 
screened with regard to MMR status. RNA and protein from each cell line were 
extracted. qRT-PCR was performed to assess mRNA expression of all 7 MMR genes. 
Western blot was used to detect expression of the 5 most frequently mutated MMR 
proteins in HNPCC: MLH1, MSH2, PMS2, MSH6 and MSH3 (Antibodies for the 
other two proteins were not available). After screening, three MMR deficient cell 
lines (SKOV3, TOV21G and IGROV1) were identified, and used as in vitro cell line 
models to characterize the features of MMR deficiency in ovarian cancer. In addition 
an isogeneic cell line model was established by introducing a plasmid encoding 
MLH1 and the corresponding empty vector to MLH1-deficient SKOV3 for further 
study.  Since the three cell lines (SKOV3, TOV21G and IGROV1) showed MLH1 
deficiency as well as defects in PMS2 protein expression (consistent with clinical 
results in Chapter3), and dysfunction of MutLα complex (formed by MLH1 and 
PMS2) affects the function of MMR system and therefore is associated with 
multistep tumourigenesis, further studies focussing on co-expression and regulation 




4.2 Determination of expression of seven MMR genes at the mRNA level in the 
19 ovarian cell lines  
To identify MMR deficient cell lines, mRNA of the 19 cell lines (Figure 4.1) was 
extracted. Three independent qRT-PCR experiments were performed to evaluate 
expression of the seven MMR genes: MLH1, PMS2, MSH2, MSH6, MLH3, MSH3 
and PMS1. The Double delta Ct (∆∆Ct) method [129] was used to analyse the 
relative expression level of the genes. MMR genes were normalized against 
housekeeping gene TBP (TATA-binding protein), which has been reported as one of 
the most constantly expressed genes [139, 140]. Then the expression level of each 
MMR gene was normalized to that of cell line PEO1 which has a relatively moderate 
expression level of all MMR genes. Another housekeeping gene HPRT1 (Appendix 
1) was not chosen for normalization because its expression across the 19 cell lines 
was not as constant as that of TBP. 
SKOV3 and TOV21G showed complete loss of MLH1 mRNA, while IGROV1 
showed very low expression of MLH1 and MSH6 mRNA (Figure 4.1). The other 16 
cell lines showed expression of mRNA of all seven MMR genes (Figure 4.1). The 
Pearson correlation test was performed using GraphPad Prism6 to evaluate the 
correlation of the MMR gene expression. Interestingly, at the mRNA level, each 
MMR gene has positive correlation with some other MMR genes (Table 4.1). MLH1 
has positive correlation with MLH3 (R=0.832; p<0.001), MSH3 (R=0.674; p<0.01), 
MSH6 (R=0.759; p<0.001) and PMS2 (R=0.527; p<0.05). Another main player 
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Figure 4.1 mRNA expression of MMR genes in the 19 ovarian cell lines.  
mRNA of these cell lines was extracted and was reverse transcribed to cDNA which was then amplified. For each gene, 3 independent qRT-PCRs were 
performed. Expression level of MMR genes was normalized against housekeeping gene TBP using Double delta Ct (∆∆Ct) method. Afterwards, mRNA 
expression level of (A)MLH1, (B)PMS2 ,  (C)MSH2 , (D)MSH6 , (E) MLH3 ,(F)MSH3  and (G) PMS1  were normalized to that of cell line PEO1. (H) 



































































































P: 0.163706 - 
Table 4.1 Correlation analysis of MMR gene mRNA expression in the 19 cell lines.  
mRNA of these cell lines was extracted and was reverse transcribed to cDNA which was then amplified. For each gene, 3 independent qRT-PCR 
reactions were performed. Double delta Ct (∆∆Ct) method was used to analyse the relative expression level of genes. MMR genes were normalized 
against housekeeping gene-TBP. Expression level of each MMR gene in these cell lines was then normalized to that of cell line PEO1. Pearson 
Correlation analysis was performed by using GraphPad Prism6. Correlation coefficients (R) and p values (P) are reported.  Positive correlation is 





4.3 Determination of MMR protein expression in the 19 ovarian cell lines 
After evaluating MMR gene expression at the mRNA level, western blot analysis 
was performed to determine expression at the protein level. The expression level of 
the 5 most frequently lost MMR proteins in HNPCC: MLH1, MSH2, PMS2, MSH6 
and MSH3 were determined using the Li-Cor Odyssey imaging system. The 
expression level of each MMR gene was first normalized to β-tubulin and then 
expressed relative to that of cell line PEO1. As shown in Figure 4.2 (A), IGROV1, 
TOV21G and SKOV3 do not express MLH1 protein. Interestingly, these 3 cell lines 
also show deficiency in PMS2 protein expression, suggesting that PMS2 deficiency 
may be associated with the loss of MLH1 protein. IGROV1 is also MSH6 deficient 
and has very low expression of MSH3. This deficiency in MLH1 protein expression 
is supported by  reports that SKOV3 has a deletion in exons 4-19 in the MLH1 gene 
[141]; IGROV1 carries frameshift deletions in MLH1, MSH3 and MSH6 [142]; 
TOV21G has promoter methylation in MLH1[143]. However, all three cell lines 
express PMS2 mRNA.  This suggests that the loss of PMS2 protein expression does 
not originate at the transcriptional level. The other 16 cell lines express all other 
MMR proteins tested. In addition, TOV21G is of clear cell subtype; IGROV1 is 
mixed subtype, and SKOV3 is very unlikely to be high grade serous subtype (Table 
4.3). This is consistent with data shown in chapter 3 that MMR deficiency is more 
likely to appear in non-serous types of ovarian cancers. 
To evaluate the correlation in MMR protein expression, the Pearson correlation test 
was performed by using GraphPad Prism6. Each tested MMR gene has positive 
correlation in protein expression with some other MMR genes (Table 4.2). MLH1 
has positive correlation with PMS2 (R=0.72; p<0.001), MSH2 (R=0.53; p<0.05) and 
MSH6 (R=0.72; p<0.001). MSH2 has positive correlation with MLH1 (R=0.53; 
p<0.05) and MSH6 (R=0.88; p<0.001). However, for these MMR genes, protein 
expression level (Figure 4.2, Table 4.3) is not always consistent with mRNA 
expression level (Figure 4.1, Table 4.3). Table 4.3 shows that many cell lines have 
high mRNA expression of some MMR genes but the relevant proteins are not 
overexpressed.  For example, PEO14 has high expression of MSH2 and PMS2 at 
mRNA level, which is over 5 fold of that of PEO1. However, at the protein level, 
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PEO14 and PEO1 express similar level of MSH2 and PMS2. This suggests that 
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Figure 4.2 Expression of MMR proteins in the 19 cell lines. (A) Cells were lysed, protein was extracted, and the expression level of MLH1, MSH2, 
PMS2, MSH6 and MLH3 were determined by western blot using the Li-Cor Odyssey imaging system. Protein expression level of (B) MLH1, (C)PMS2, 

























































Table 4.2 Correlation of MMR gene protein expression in the 19 cell lines. Cells were lysed and protein was extracted, and the expression level of 
MLH1, MSH2, PMS2, MSH6 and MLH3 were determined by western blot using the Li-Cor Odyssey imaging system. Expression level of the 5 
proteins was normalized to that of cell line PEO1. Pearson Correlation test was performed by using GraphPad Prism6. Correlation coefficients (R) and p 





Histology Subtype  
and  Reference 
mRNA  and protein expression level relative to  cell line PEO1 
MLH1 PMS2 MSH2 MSH6 MSH3 MLH3 PMS1 
PEO1 Serous [144] 
mRNA:   1.00 
protein:  1.00 
mRNA:   1.00 
protein:  1.00 
mRNA:   1.00 
protein: 1.00 
mRNA:   1.00 
protein:  1.00 
mRNA:   1.00 
protein:  1.00 
mRNA:  1.00 mRNA:   1.00 
HOSE11 N/A 
mRNA:   1.72±0.11 
protein: 0.77 
mRNA:  2.12±0.86 
protein:0.66 
mRNA:  0.59±0.10 
protein:0.45 
mRNA:  1.22±0.30 
protein:0.42 
mRNA:  1.03±0.43 
protein:0.32 
mRNA:  1.40±0.32 mRNA:  1.04±0.12 
HOSE12 N/A 
mRNA:   4.27±0.12 
protein: 0.55 
mRNA:  4.41±2.17 
protein:0.49 
mRNA:  2.74±0.65 
protein:0.43 
mRNA:  2.89±0.61 
protein:0.23 
mRNA:  2.07±1.16 
protein:0.19 
mRNA:  4.07±1.11 mRNA:  2.09±0.41 
IGROV1 Mixed [142] 
mRNA:   0.11±0.01 
protein: 0.00 
mRNA:  3.80±1.04 
protein:0.00 
mRNA:  0.95±0.21 
protein:0.21 
mRNA:  0.07±0.03 
protein:0.00 
mRNA:  0.43±0.20 
protein:0.03 
mRNA:  1.20±0.28 mRNA:  0.93±0.14 
PEO23 Serous [144] 
mRNA:   1.14±0.10 
protein: 1.11 
mRNA:  3.88±1.18 
protein:0.96 
mRNA:  1.00±0.7 
protein:0.98 
mRNA:  1.38±0.44 
protein:0.84 
mRNA:  1.92±0.42 
protein:0.70 
mRNA:  0.77±0.14 mRNA:  0.99±0.16 
SKOV3 
Clear cell [145] 
Not specified [142] 
mRNA:   0.00 
protein: 0.00 
mRNA:  1.14±0.25 
protein:0.00 
mRNA:  0.53±0.09 
protein:0.55 
mRNA:  0.61±0.20 
protein:0.35 
mRNA:  0.66±0.32 
protein:0.27 
mRNA:  0.60±0.14 mRNA:  1.11±0.19 
PEO14 Serous [144] 
mRNA:   1.74±0.08 
protein: 1.15 
mRNA:  5.43±1.88 
protein:0.99 
mRNA:  5.76±1.04 
protein:0.98 
mRNA:  2.70±0.93 
protein:1.10 
mRNA:  1.34±0.43 
protein:0.22 
mRNA:  2.16±0.46 mRNA:  1.19±0.19 
TOV21G Clear cell [142] 
mRNA:   0.00 
protein: 0.00 
mRNA:  2.51±0.52 
protein:0.00 
mRNA:  1.02±0.20 
protein:0.51 
mRNA:  0.73±0.24 
protein:0.34 
mRNA:  0.83±0.22 
protein:0.18 
mRNA:  0.48±0.11 mRNA:  2.60±0.25 
OVCAR3 Not specified [142] 
mRNA:   0.73±0.04 
protein: 1.70 
mRNA:  4.44±1.88 
protein:1.45 
mRNA:  1.97±0.32 
protein:0.76 
mRNA:  0.97±0.25 
protein:0.61 
mRNA:  1.24±0.61 
protein:0.42 
mRNA:  1.80±0.38 mRNA:  1.15±0.23 
59M Mixed [142] 
mRNA:   0.41±0.07 
protein: 0.58 
mRNA:  1.37±0.45 
protein:0.45 
mRNA:  0.14±0.03 
protein:0.49 
mRNA:  0.26±0.12 
protein:0.28 
mRNA:  0.31±0.12 
protein:0.19 
mRNA:  0.29±0.06 mRNA:  1.13±0.18 
PEA1 Not specified [144] 
mRNA:   0.92±0.17 
protein: 1.33 
mRNA:  2.97±0.56 
protein:1.01 
mRNA:  0.36±0.05 
protein:0.67 
mRNA:  1.29±0.47 
protein:0.60 
mRNA:  0.36±0.14 
protein:0.08 
mRNA:  2.11±0.46 mRNA:  1.49±0.26 
PEA2 Not specified [144] 
mRNA:   1.96±0.20 
protein: 0.42 
mRNA:  5.09±1.70 
protein:0.54 
mRNA:  2.74±0.57 
protein:0.62 
mRNA:  1.54±0.61 
protein:0.39 
mRNA:  2.04±0.81 
protein:0.73 
mRNA:  1.91±0.46 mRNA:  2.76±0.53 
PEO4 Serous [144] 
mRNA:   1.56±0.15 
protein: 0.26 
mRNA:  2.47±0.94 
protein:0.32 
mRNA:  1.78±0.27 
protein:1.21 
mRNA:  1.47±0.26 
protein:0.84 
mRNA:  1.43±0.56 
protein:1.40 
mRNA:  1.59±0.48 mRNA:  1.41±0.08 
CAOV3 Not specified [142] 
mRNA:   1.04±0.04 
protein: 0.57 
mRNA:  1.26±0.42 
protein:0.34 
mRNA:  1.25±0.22 
protein:1.02 
mRNA:  1.21±0.30 
protein:1.19 
mRNA:  1.56±0.57 
protein:1.66 
mRNA:  0.65±0.08 mRNA:  2.00±0.08 
A2780 
Endometrioid [146] 
Not specified [142] 
mRNA:   2.26±0.29 
protein: 2.99 
mRNA:  7.33±3.46 
protein:0.73 
mRNA:  0.32±0.06 
protein:1.11 
mRNA:  0.93±0.54 
protein:2.20 
mRNA:  1.00±0.46 
protein:1.20 
mRNA:  1.60±0.31 mRNA:  1.65±0.29 
OVCAR4 Not specified [142] 
mRNA:   0.32±0.03 
protein: 0.86 
mRNA:  1.20±0.41 
protein:0.51 
mRNA:  0.55±0.09 
protein:1.44 
mRNA:  0.57±0.17 
protein:1.39 
mRNA:  0.35±0.14 
protein:0.94 
mRNA:  0.71±0.19 mRNA:  0.50±0.10 
OVCAR5 Not specified [147] 
mRNA:   1.04±0.06 
 protein: 1.47 
mRNA:  3.98±1.55 
protein:0.69 
mRNA:  1.70±0.29 
 protein:1.16 
mRNA:  1.07±0.41 
protein:0.76 
mRNA:  0.54±0.21 
protein:0.60 
mRNA:  1.08±0.22 mRNA:  0.71±0.16 
OAW42 Serous [142] 
mRNA:   0.86±0.09 
protein: 1.24 
mRNA:  1.73±0.65 
protein:0.58 
mRNA:  0.77±0.22 
protein:0.96 
mRNA:  0.47±0.21 
protein:0.65 
mRNA:  0.51±0.14 
protein:0.64 
mRNA:  0.40±0.07 mRNA:  0.68±0.16 
41M Not specified [147] 
mRNA:   0.77±0.05 
protein: 1.87 
mRNA:  1.48±0.65 
protein:1.11 
mRNA:  2.30±0.50 
protein:2.04 
mRNA:  1.85±0.56 
protein:2.68 
mRNA:  0.33±0.09 
protein:0.43 
mRNA:  1.39±0.34 mRNA:  0.59±0.12 
Table 4.3 Summary of characteristics of the 19 ovarian cell lines.  
mRNA expression level of the 7 MMR genes was normalized against housekeeping gene-TBP, and then normalized to cell line PEO1. For mRNA expression level, 
the results shown are mean±SEM  (n=3). Protein expression level of the 5 MMR genes was normalized to β-tubulin, and then normalized to cell line PEO1. 
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4.4 Correlation of MLH1 and PMS2 expression 
The three cell lines (SKOV3, TOV21G and IGROV1) that lack expression of MLH1 
protein are also deficient in PMS2 protein expression and this is consistent with 
clinical data (chapter 3) that MLH1 protein and PMS2 protein are paired in loss. This 
suggests that there may be correlation between expression of the two proteins.  The 
correlation between MLH1 and PMS2 in the 19 cell lines were determined by 
Pearson’s correlation test and the results  show that there is moderate positive 
correlation at  mRNA level (R=0.53, p=0.02; Table 4.1 and Figure 4.3A) and strong 
positive correlation at protein level  (R=0.72, p=0.0006; Table 4.2 and Figure 4.3B). 
In addition, MLH1 also has strong positive correlation with MSH6 protein (R= 0.71, 
p=0.0006; Table 4.2); whereas PMS2 does not have significant correlation with other 
tested proteins besides MLH1 (Table 4.2).  
As MLH1 protein dimerizes with PMS2 protein during the mismatch repair process 
[148], and there is a positive correlation between MLH1 and PMS2 at both mRNA 
and protein level, it may be  that the two proteins which are paired in loss are also 
paired in expression. The loss of MLH1 protein expression is caused by defects in its 
mRNA, whereas the defect of PMS2 protein expression is not (Table 4.3 shows that 
all three cell lines express higher level of PMS2 mRNA than PEO1 does). Therefore, 
perhaps re-introduction of MLH1 to MLH1 deficient cells can result in re-expression 
of PMS2 protein. In order to study MLH1-PMS2 co-expression, MLH1 (pCMV6-
AC-MLH1) plasmid was transfected into MMR deficient cell lines-SKOV3, 
TOV21G and IGROV1. The results (Figure 4.4) indicate that re-introducing MLH1 
to MLH1-deficient and PMS2-deficient cells leads to PMS2 protein expression. For 
IGROV1 (Figure 4.4 A and B) and TOV21G (Figure 4.4 C and D) the expression 
levels of MLH1 and PMS2 show positive correlation after transient transfection as  
an observed decrease of MLH1 expression level over the 5 days post transfection 
was accompanied by a decrease of PMS2 expression.  For  SKOV3 (Figure 4.4 E and 
F) the expression of PMS2 was kept at fairly constant low level despite MLH1 
expression level dropping throughout the five days.  
As re-introduction of MLH1 to MLH1 deficient cells resulted in increased expression 
of PMS2 protein, we hypothesised that conversely, knocking down of MLH1 in 
MLH1 proficient cells may lead to decreased PMS2 expression. In order to test this 
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hypothesis, two different siRNA duplexes targeting MLH1 (MLH1 siRNA B and 
MLH1 siRNA C, Origene) were transfected to A2780 cells. The results (Figure 4.5) 
show that after 96 hours of transfection of either siRNA targeting MLH1, both 
MLH1 and PMS2 protein expression levels drop significantly compared with that of 
cells transfected with scrambled control siRNA. Therefore this provides further 
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Figure 4.3 Correlation of MLH1 and PMS2 expression in the 19 Cell lines. Correlation 
of MLH1 and PMS2 expression was evaluated at both (A) mRNA level and (B) protein level. 
mRNA expression level of MLH1 and PMS2 was normalized against housekeeping gene 
TBP, and then normalized to cell line PEO1. Protein expression level of MLH1 and PMS2 
was normalized to β-tubulin, and then normalized to cell line PEO1. Pearson Correlation 
analysis was performed by using GraphPad Prism6, and the results suggest that there is 
moderate positive correlation at mRNA level (R=0.53, p=0.02) and strong positive 
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Figure 4.4 Assessment of MLH1 and PMS2 expression in cells transiently transfected 
with MLH1. Cells were seeded in 6cm plates and grown for 24h prior to transfection with 
MLH1. Cells were lysed and protein was extracted over five days (from 24 hours after 
transfection), and the expression of MLH1 and PMS2 in (A) IGROV1, (C) TOV21G and (E) 
SKOV3 was determined by western blot. The expression levels of MLH1 and PMS2 in (B) 



















































































Figure 4.5 Assessment of MLH1 and PMS2 expression in A2780 cells transiently 
transfected with MLH1 siRNA. (A) Cells were seeded in a 6 well plate and grown for 24h 
prior to transfection with MLH1 siRNA. Cells were lysed and protein was extracted 96 hours 
after transfection, and the expression of MLH1 and PMS2 was determined by western blot. 
The expression levels of MLH1 and PMS2 were normalized to β-tubulin. (B) Results are 
expressed as percentages of untransfected control. Two-way ANOVA analysis was 
performed by using GraphPad Prism6 to compare the difference between cells transfected 
with MLH1 siRNA and cells transfected with scrambled control siRNA duplex. Each data 
point is the mean (±SEM) of three (MLH1 siRNA C) or four (MLH1 siRNA B) independent 
experiments. ** p≤0.01, *** p≤0.001, ****p≤0.0001. 
 
4.5 Creation of isogeneic cell lines 
In order to further investigate MMR deficiency in ovarian cancer at the molecular 
level, the three cell lines-IGROV1, TOV21G and SKOV3 were used to establish 
isogeneic cell lines. Plasmid Pcmv6-AC-MLH1 and Pcmv6-neo were transfected to 
these cell lines and single cell colonies were selected after growing in selection 
media containing G418. Isogeneic cell lines of SKOV3 were successfully established 
with six positive clones expressing MLH1 and six negative control clones lacking 
MLH1. However, stable transfection of IGROV1 and TOV21G was unsuccessful. 
The expression level of MLH1 and PMS2 in the six SKOV3 clones was quantified. 





MLH1. SAC-1, SAC-2, SAC-3 and SAC-8 express similar level of MLH1 to PEO1. 
SAC-1 expresses the highest level of PMS2 among the six clones (Figure 4.6). In 
order to examine MLH1 expression in individual cells of SKOV3 clones, 
immunocytochemistry was performed to detect MLH1 protein in the six positive 
clones, one negative control clone and the parental SKOV3. The results showed that 
the negative clone SN-3 and parental SKOV3 do not express MLH1 at all, and that 
compared with other positive clones, SAC-1 and SAC-2 have more homogenous 
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Figure 4.6 Assessment of MLH1 and PMS2 Expression in SKOV3 Cells stably 
transfected with MLH1. Cells of SKOV3 clones were lysed and protein was extracted. 
(A)The expression of MLH1 and PMS2 in SKOV3 clones was determined by western blot. 
(B) The expression levels of MLH1 and PMS2 in SKOV3 clones was quantified and 





   
 








































Figure 4.7 Assessment of MLH1 Expression in SKOV3 cells by Immunocytochemistry. 
Cells were seeded in 6 well plates and grown on coverslips for 24h prior to staining. The results indicate that the 6 clones of SKOV3 transfected with MLH1 
all express MLH1 protein, while the clone transfected with the empty plasmid (negative control) and SKOV3 parental cells do not express MLH1 protein.  
















4.6 Mechanism of MLH1 protein and PMS2 protein co-expression 
The above results indicate that there is strong positive correlation between expression 
of MLH1 protein and PMS2 protein. Re-introduction of MLH1 in MLH1-deficient 
cell lines results in re-expression of PMS2 protein and knocking down of MLH1 in a 
MLH1 proficient cell line leads to decreased PMS2 expression.  This suggests that 
MLH1 may play an important role in stabilizing PMS2 protein expression. However, 
the mechanism by which PMS2 protein expression is regulated is unknown. As the 
three MLH1 and PMS2 deficient cell lines (SKOV3, TOV21G and IGROV1) all 
express PMS2 mRNA (Figure 4.1B), the regulation of PMS2 expression is likely to 
be at the translational or post-translational level. One hypothesis is that PMS2 protein 
is synthesised in MLH1 deficient cells but it is rapidly degraded in the absence of 
MLH1 protein.  
To investigate whether MLH1 protein regulates PMS2 protein levels by influencing 
its degradation by the proteasome, the protease inhibitors MG132 and lactacystin 
were used to inhibit proteasomal degradation.  Lactacystin specifically inhibits the 
20s proteasome, while MG132 inhibits different types of proteases, and strongly 
inhibits the activity of 26s proteasome (which contains in addition to the 20s 
proteasome a 19s regulatory complex) and calpain [149-151].  First of all, SAC-1 
cells (MLH1+, PMS2+) were treated with CHX (cycloheximide) to determine half-
lives of MLH1 and PMS2 protein. This was to determine the stability of these 
proteins and an appropriate exposure time to proteasome inhibitors. The results 
(Figure 4.8) showed that the half-life of PMS2 is approximately 96 hours, while the 
half-life of MLH1 is longer than 96 hours in these cells. As a 20 to 40 percent 
decrease of both proteins was seen after 48 hours treatment of CHX (Figure 4.8), this 
time period was considered sufficient to detect protein expression level changes after 
treatment with proteasome inhibitors.  
Therefore, SAC-1 (MLH1+, PMS2+) and SKOV3 (MLH1-, PMS2-) cells were 
treated with proteasome inhibitors (MG132 or Lactacystin) for 48 hours. The results 
show that in the parental SKOV3 cells which lack MLH1 but expresses PMS2 
mRNA, PMS2 protein expression was not improved after treatment with MG132.  
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This indicates that proteases inhibited by MG132 are not able to increase PMS2 
protein expression levels in the absence of MLH1 expression.   
On the other hand, (Figure 4.9 A, B) MG132 increased the expression level of MLH1 
protein to nearly 3 fold in SAC-1 cells after 48 hours treatment (p<0.0001), but it did 
not affect the expression level of PMS2 protein in SAC-1 cells. This suggests that 
proteases inhibited by MG132 play an important role in regulating expression of 
MLH1 but not PMS2.  
Combination of CHX and MG132 treatment in SAC-1 cells led to reduced 
expression of both MLH1 and PMS2. The MLH1 expression level of SAC-1 cells 
treated with both CHX and MG132 was slightly higher than that of SAC-1 cells 
treated with CHX alone; whereas the expression level of PMS2 in SAC-1 cells 
treated with both CHX and MG132 was similar to that of SAC-1 treated with CHX 
alone.  This further supports the suggestion that proteases inhibited by MG132 play a 
role in regulating MLH1 expression.  For PMS2 protein, since neither treatment with 
MG132 alone nor treatment with both MG132 and CHX increased PMS2 expression 
in SAC-1 cells, this suggests that proteases inhibited by MG132 do not play a role in 
regulating PMS2 expression.  
After treatment with Lactacystin (Figure 4.9 C, D) for 48 hours, no improvement in 
PMS2 protein expression was seen in SKOV3 cells which lack MLH1 but expresses 
PMS2 mRNA. This suggests that proteases inhibited by Lactacystin are not able to 
increase PMS2 protein expression levels in the absence of MLH1 expression. 
However Lactacystin increased the expression level of PMS2 protein significantly 
(p<0.01) and increased MLH1 protein expression slightly in SAC-1 cells which 
express both MLH1 protein and PMS2 protein. This suggests that in these cells 
proteasomal enzymes inhibited specifically by Lactacystin can regulate expression 
level of both MLH1 protein and PMS2 protein. 
As PMS2 expression was not improved in SKOV3 cells when the proteasomal 
degradation pathway was blocked, regulation of MLH1 and PMS2 expression by an 
alternative protein degradation pathway, the lysosomal protein degradation pathway, 





-ATPase that plays a pivotal role in acidification and protein 
degradation in the lysosomes [152]. 
SAC-1 and SKOV3 cells were treated with 1µM Bafilomycin A1 for 48 hours. The 
results (Figure 4.9 E, F) show that treatment with BA1 could not increase PMS2 
expression in SKOV3 cells, whereas it increased PMS2 expression significantly 
(p<0.05) and increased MLH1 expression marginally in SAC-1 cells. This suggests 
that in the absence of MLH1 expression, inhibition of lysosomal degradation is 
unable to increase PMS2 protein expression. However, when MLH1 is present and 
thus PMS2 is expressed, inhibition of the lysosomal degradation pathway 
significantly improves PMS2 expression. 
In summary, neither proteasomal nor lysosomal inhibitors could increase the 
expression level of PMS2 protein in cells lacking MLH1. This suggests that MLH1 
does not regulate PMS2 protein expression levels by preventing its degradation via 
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Figure 4.8 MLH1 and PMS2 stability in SAC-1 (SKOV3 stably transfected with 
MLH1).  
(A) Cells were seeded in 6cm plates and grown for 24h prior to exposure to 10µg/ml CHX 
(cycloheximide). Cells were lysed and protein was extracted over four days (from 24 hours 
after dosing CHX), and the expression level of MLH1 and PMS2 was determined by western 
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Figure 4.9 Effect of proteasome and lysosome inhibitors on MLH1 and PMS2 protein 
stability in SAC-1 cells. Cells were seeded in 6cm plates and grown for 24h prior to 
exposure to 10µg/ml CHX (cycloheximide), 10 µM MG132, 10 µM LAC (Lactacystin) or 
Bafilomycin A1 (BA1). Cells were lysed and protein was extracted 48 hours post- treatment, 
and the expression level of MLH1 and PMS2 was determined by western blot. (A) Western 
blot showing the effect of MG132 on SAC-1 and SKOV3 cells. (B) Quantification of 
expression level of MLH1 and PMS2 in SAC-1 cells after treatment with MG132. (C) 
Western blot showing the effect of LAC on SAC-1 and SKOV3 cells. (D) Quantification of 
expression of MLH1 and PMS2 in SAC-1 cells after treatment with LAC. (E) Western blot 
showing the effect of BA1 on SAC-1 and SKOV3 cells. (F) Quantification of expression of 
MLH1 and PMS2 in SAC-1 cells after treatment with BA1. Results are expressed as 
percentages of DMSO treated control.  Two-way ANOVA analysis was performed by using 
GraphPad Prism6. Each data point is the mean (±SEM) of three independent experiments. 
*p≤0.05, ** p≤0.01, ****p≤0.0001.  
 
4.7 Discussion and conclusion 
The expression levels of mRNA of the seven mismatch repair (MMR) genes and 
expression levels of protein of five MMR genes were measured in 19 cell lines. 
Three cell lines (SKOV3, TOV21G and IGROV1) were found to exhibit MMR 
deficiency. All three cell lines have deficiency in MLH1 and PMS2 expression at the 
protein level. IGROV1 has the most MMR defects; besides deficiency in MLH1 and 
PMS2, it also lacks expression of MSH6 protein and has very low expression level of 




express MLH1 mRNA; IGROV1 expresses a very low level of MLH1 and MSH6 
mRNA. All three cell lines express PMS2 mRNA and MSH3 mRNA. This suggests 
that the deficiency in MLH1 protein in the three cell lines and the deficiency in 
MSH6 protein in IGROV1 are caused by unsuccessful transcription, whereas the 
deficiency in PMS2 protein in the three cell lines and MSH3 deficiency in IGROV1 
are not.  
Interestingly, at both mRNA level and protein level, each MMR gene has positive 
correlation with some other MMR genes (Table 4.1, Table 4.2). This is in line with 
the fact that the MMR proteins interact with each other and work as a team during 
the MMR process. However, for each MMR gene, the expression level of mRNA did 
not always correlate well with its protein expression level (Figure 4.1, Figure 4.2). 
Take PMS2 for example, as shown in Table 4.3, 12 cell lines express over 2 fold 
higher level of PMS2 mRNA compared to PEO1 but they all have lower PMS2 
protein expression than PEO1 does. This suggests that the expression level of MMR 
protein is not solely driven by its transcripts; other mechanisms are playing a role in 
regulating expression of MMR proteins. 
After identifying these three MMR deficient cell lines more work was performed to 
investigate the correlation of MLH1 and PMS2 protein expression, as they have 
strong positive correlation and show a paired loss pattern in both cell line models and 
clinical samples (shown in chapter 3). The MutLα complex formed by MLH1 and 
PMS2 plays a crucial role in mediating the mismatch repair process from recognition 
to all downstream activities [24] and the endonuclease function of PMS2 directs 
excision of the mismatched DNA [36]. Since the two proteins show paired loss in 
clinical samples; they may also have paired expression. After transfection of MLH1 
into the three MLH1-deficient and PMS2-deficient cell lines, PMS2 protein was re-
expressed, and the expression level of PMS2 and MLH1 showed positive correlation 
in TOV21G and IGROV1; while in SKOV3 the expression of PMS2 was kept at a 
fairly constant low level (Figure 4.4). In addition, knocking down expression of 
MLH1 in the MMR proficient cell line A2780 led to decreased expression of PMS2 
protein (Figure 4.5), further supporting the hypothesis that PMS2 protein is regulated 
by MLH1. The results are consistent with the fact that MLH1 dimerizes with PMS2 
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during mismatch repair process, and this suggests that MLH1 plays a role in 
regulating PMS2 protein expression.  
However, the process by which MLH1 stabilizes PMS2 protein expression is unclear. 
As the three cell lines all express PMS2 mRNA but are deficient at the protein level, 
MLH1 may regulate PMS2 protein at the translational or post-translational level. If 
MLH1 regulates PMS2 expression at the post-translational level, it is possible that 
PMS2 protein is degraded in the absence of MLH1 protein. As the proteasome 
degradation pathway is responsible for degradation of most cellular proteins, two 
proteasome inhibitors lactacystin and MG132 were used to block protein degradation. 
The results show that addition of MG132 increases MLH1’s expression level by 
nearly 3 fold, while addition of lactacystin increases PMS2’s expression level 
significantly and increases MLH1’s expression slightly in MLH1 and PMS2-
expressing SAC-1 cells (Figure 4.9). As Lactacystin inhibits 20s proteasome 
specifically and MG132 inhibits different proteases besides 20s proteasome, this 
indicates that both MLH1 and PMS2 can be degraded by the proteasome degradation 
pathway to some extent and that other proteases may play a role in MLH1 
degradation.  Importantly, PMS2 protein expression was not increased in (MLH1 and 
PMS2-deficient) SKOV3 cells following treatment with either lactacystin or MG132 
(Figure 4.9 A, B, C, D). Afterwards, MLH1 and PMS2 regulation by lysosome 
degradation pathway was tested using Bafilomycin A1. The result was similar to that 
of Lactacystin: In SAC-1 cells PMS2 expression was increased significantly and 
MLH1expression was increased marginally; whereas in SKOV3 cells PMS2 
expression was not improved (Figure 4.9 E, F).  
As the expression of PMS2 protein was not increased in the absence of MLH1, even 
when the proteasomal and lysosomal protein degradation pathways were blocked (as 
seen with SKOV-3 cells), it is possible that cells are not able to make enough PMS2 
protein in the absence of MLH1. Therefore MLH1 protein may play a role in 
regulating synthesis of PMS2 protein at the translational level, rather than preventing 
the degradation of PMS2.   
As shown in table 4.3, most of the MMR+ cell lines had relatively high expression 
level of PMS2 mRNA but very low level of PMS2 protein. This suggests that there is 
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a mechanism that down regulates the translation of PMS2 mRNA. In addition, the 
three MMR deficient (MLH1-, PMS2-) cell lines SKOV3, TOV21G and IGROV1 all 
had higher expression of PMS2 mRNA than cell line PEO1 but the PMS2 protein 
level of these cell lines was not detectable (as they lack MLH1 expression). Since re-
introduction of MLH1 into MLH1 deficient cells resulted in increased expression of 
PMS2 protein, it is possible that the presence of MLH1 to some extend relieved the 
inhibition of PMS2 translation.  What mechanism might be? It is known that 
microRNAs function by annealing to complementary sites on coding sequences or 
3’-UTR of target mRNAs, where they promote the recruitment of protein complexes 
that inhibit translation and/or decrease the stability of mRNA, leading to decreased 
expression in target protein [153, 154]. Here we hypothesize that there are 
microRNAs that can bind to PMS2 mRNA and impair PMS2 translation. In addition, 
these microRNAs may also able to bind a MLH1 related molecule (might be MLH1 
mRNA, MLH1 processed pseudogene or MLH1 protein). When MLH1 presents, a 
certain proportion of these microRNAs can bind to the MLH1 related molecule, and 
less microRNAs can bind to the PMS2 mRNA leading to decreased inhibition of 
PMS2 translation, and increased PMS2 protein expression (similar to the mechanism 
described by Poliseno et al [154]). Thus, to investigate the mechanism by which 
PMS2 protein levels are regulated by MLH1, future work should focus on 
translational regulation of PMS2.  
In addition, it is worth to look at the protein expression level of PMS1 and MLH3 
because apart from PMS2, MLH1 also partner with these two proteins to form 
MLH1/PMS1 and MLH1/MLH3 heterodimers [29, 155]. Compared with 
MLH1/PMS2, the contributions of the other two heterodimers to mismatch repair 
functions are poorly understood. Chen et al [156] suggested that there is some degree 
of functional overlap between the PMS2, MLH3, and PMS1; and that DNA 
mismatch repair system requires both PMS2 and MLH3 to prevent tumourgenesis. It 
is known that the endonuclease activities of MLH1/PMS2 complex are essential for 
mismatch repair [36]. Recently, Rogacheva et al [157] reported that MLH1/MLH3 
complex is a metal-dependent and MSH2/MSH3-stimulated endonuclease that makes 
single-strand breaks in supercoiled DNA. This newly discovered function supports 
the role of MLH1/MLH3 in DNA mismatch repair. Although MLH1/PMS2 is 
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generally thought to have the major MutL activity, MLH1/MLH3 complex may to 
some extent substitute the function of MLH1/PMS2 complex (via competition 
between PMS2 and MLH3 in MLH1 binding). This may explain the overall low 





















Targeting MMR deficiency in ovarian cancer 
 
 
5.1 Introduction  
The results in chapter 3 show that overall 15.7% of ovarian cancer patients carry 
MMR deficiency, and that current platinum-based therapy does not give any clinical 
benefit to MMR deficient patients over MMR proficient patients. Therefore if a more 
effective treatment that selectively targets ovarian cancers with MMR deficiency can 
be developed, this proportion of patients may obtain significant clinical benefit. One 
way to achieve this goal is developing a synthetic lethality strategy on the MMR 
deficient background.  
Synthetic lethality is based on the premise that loss of function of two or more genes 
or pathways (in tumour cells of a patient) leads to cell death, whereas inactivation of 
one of these genes or pathways (within non-tumour cells of the patient) does not 
[121]. This strategy can lead to a high therapeutic index. Recent studies using colon 
cancer and endometrial cancer models have demonstrated that targeting diydrofolate 
reducatase (DHFR),  DNA polymerase β (POLβ) and DNA polymerase γ (POLγ), as 
well as PTEN-induced putative kinase 1 (PINK1) are synthetically lethal to specific 
MMR defects (MLH1, MSH2 and MSH6) [126-128]. However, synthetic lethality 
with MMR deficiency in ovarian cancers has not been studied in depth and there 
have been no synthetic lethal screens performed in matched MMR proficient and 
deficient ovarian cancer cells with si/shRNA libraries or compounds. Therefore, we 
performed a small-molecule compound library screening on an ovarian cancer model 
of MMR deficiency. 
After establishment of an isogenic cell line model of MMR deficiency  (SKOV3 
MLH1+ clone : SAC-1 and SKOV3 MLH1- clone: SN-5 were selected for drug 
screening) and selection of Alamar Blue cell viability assay for high throughput 
screening, a kinase inhibitor library provided by GlaxoSmithKline which contains 
362 compounds was screened. Two compounds targeting PLK1 were confirmed to 
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have greater growth inhibition of SN-5 cells (MMR deficient) compared with SAC-1 
(MMR proficient). As the two compounds had similar structure, another PLK1 
inhibitor, BI2536, with different structure was purchased and tested to confirm target 
hypothesis; and a 2 to 6 fold difference in growth inhibition between the two cell 
lines was observed. Next, two different siRNAs that target PLK1 were transfected 
into the two cell lines. Compared with SAC-1, SN-5 was found to be slightly more 
sensitive to PLK1 depletion, showing lower cell growth. These data indicate that 
PLK1 is a potential synthetic lethal target for MLH1 deficiency in ovarian cancer. 
However, BI2536 is not recommended to treat MLH1 deficient tumours in 
combination with cisplatin, one standard platinum-based therapeutic for this disease, 
because marginal antagonistic effect was observed in SN-5 cells.    
Compared with SN-5 cells, SAC-1 cells had greater induction of phospho H2AX 
(S139) and more significant change in G0/G1 phase and S phase of the cell cycle 
after inhibition of PLK1. This indicates that the mechanism of PLK1-MLH1 
synthetic lethality maybe associated with (1) different response to DNA damage or 
replication stress between MMR proficient cells and MMR deficient cells (2) PLK1’s 
role in promoting cell survival under condition of stress: regulation of DNA 
replication and response to DNA damage. To further investigate the mechanism, 
future study needs to focus on DNA damage response pathways and DNA replication 
stress pathways after inhibition of PLK1.   
 
5.2 Sensitivity of SKOV3 clones to cisplatin 
As platinum-based therapy is used as standard treatment in ovarian cancer, it is 
necessary to determine whether MMR deficiency is associated with different 
treatment response. Data in chapter3 show that there is no difference in treatment 
response between patients with and without MMR deficiency under platinum-based 
therapy. To investigate sensitivity to cisplatin at the molecular level, three MLH1+ 
SKOV3 clones (SAC-1, SAC-2 and SAC-7) and one MLH1- SKOV3 clone (SN-3) 
were selected randomly and treated with cisplatin. Cell viability was subsequently 
analysed by MTT assay. The parental SKOV3 cell line was also used as a reference. 
As shown in Figure 5.1, there is no significant difference in cell growth inhibition 
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(upper part of the graph) between MLH1+ and MLH1- clones. However, from the X 
axis to the lower part of the graph,  we can see that overall the MLH1- clone (SN-3) 
is slightly more sensitive to cisplatin than the  three MLH1+ clones, with a TGI (total 
growth inhibition) value of 9.45µM and LC50 (50% lethal concentration) value of 
14.57µM (Table 5.1) respectively. In addition, there is significant difference between 
SN-3 and two MLH1+ clones in TGI (SAC-2 and SAC-7) and LC50 (SAC-1 and SN-
7) (Table 5.1). The results indicate that cisplatin cytotoxicity may be more selective 
towards MMR- tumours at higher doses.  
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Figure 5.1 Sensitivity of SKOV3 clones to Cisplatin. Cells were grown in RPMI and 
seeded in 96 well flat bottomed microtitre plates at a density of 2000 cells per well 
and grown for 24h prior to exposure to increasing concentrations of Cisplatin for 72 hours. 
Cell viability was assessed by MTT assay. Each data point is the mean (±SEM) of three 












(µM) TGI (µM) 
SAC-1 4.92±0.96 33.14±0.93 13.08±0.99 
SAC-2 8.88±0.55 48.12±10.53 18.03±0.53 
SAC-7 8.89±1.53 32.72±1.70 16.86±0.80 
SN-3 5.97±0.30 14.57±1.82 9.45±0.69 
SKOV3 2.58±0.26 66.53±7.27 11.42±1.42 
 
Table 5.1 Viability of SKOV3 clones treated with Cisplatin. The results (mean ± SEM, 
n=3) indicate that there is no significant difference in GI50 between MLH1+ clones (SAC-1, 
SAC-2, SAC-7) and MLH1-clone (SN-3). For TGI, there is significant difference between 
SN-3 and two MLH1+ clones (SAC-2 and SAC-7). For LC50, there is significant difference 
between SN-3 and two MLH1+ clones (SAC-1 and SN-7). One-way ANOVA analysis was 
performed by using GraphPad Prism6. *p<0.05.  
 
5.3 Determination of proliferation rate of isogeneic cell lines 
The above results show that at molecular level (Figure 5.1), MMR deficiency has no 
survival disadvantage compared to MMR proficiency under lower dose treatment of 
Cisplatin but has significant survival disadvantage at higher dose (TGI level or LC50 
level) treatment of Cisplatin. However, clinical data in Chapter 3 shows that there is 
no significant difference in response to platinum based treatment at conventional 
doses between MMR proficient and MMR deficient patients. This indicates that 
higher dose of Cisplatin is unlikely to be used on patients because this compound is 
not cancer specific and has a narrow therapeutic window. In order to develop a 
synthetic lethality strategy based on the MMR deficient background, an isogenic cell 
model with one MMR+ clone and one MMR- clone that have similar growth rates to 
that of parental SKOV3 cells is required. Cell proliferation rate was determined by 
Incucyte Zoom imaging system, which measures confluence of tested cells by 
acquiring sequential images and performing automated image analysis every three 
hours.  An example of images (SKOV3 cells) taken by Incucyte Zoom at different 
time points is shown in Figure 5.2 (A-C). Images of other SKOV3 clones are not 
shown. Growth curves (Figure 5.2, D-P) of SKOV3 and its 12 clones were plotted 






1 (doubling time 34.7 hours) and MLH1- clone SN-5 (doubling time 33.5 hours) 
were selected (Table 5.2) for drug screening. In addition to similar cell proliferation 
rate, the two cell lines also have similar phenotype (image based) to that of parental 
SKOV3; and SAC-1 has relatively better homogeneity in MLH1 expression 
compared with other MLH1+ clones (chapter 4). The MLH1- clone SN-3 that used in 
the previous experiment was not selected for further drug screening because its 
disadvantage in doubling time (38.6 hours). For further experiments using SAC-1 
and SN-5 cells, the expression of MLH1 protein was checked constantly (an ICC 
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Figure 5.2 Determination of cell growth rate of SKOV3 clones by Incucyte Zoom imaging system. SKOV3 clones were seeded into 96 well NUNC 
black optical bottom 96 well plates at the density of 500 cells/well. Cell growth was measured for 96 hours by Incucyte Zoom imaging system. Images of each well (4 
per well) were taken every three hours at 10X magnification and confluence at different time points was determined by Incucyte software. Growth curve of each cell 
line was plotted by GraphPad Prsim 6. Image of SKOV3 at (A) day 0 (B) day 2 (C) day 4 showing false colour overlay (pink) of area of the well was used to determine 








Cell line MMR status Average doubling time (hour) 
SKOV3  MMR- 29.9±0.95 
SAC-1   MMR+ 34.7±1.35 
SAC-2 MMR+ 36.2±0.76 
SAC-3 MMR+ 33.5±1.43 
SAC-7 MMR+ 44.0±1.67 
SAC-8 MMR+ 35.5±0.76 
SAC-9 MMR+ 52.5±1.01 
SN-1 MMR- 37.8±3.30 
SN-3 MMR- 38.6±1.42 
SN-5 MMR- 33.5±1.54 
SN-6 MMR- 41.6±3.33 
SN-7 MMR- 30.8±1.61 
SN-10 MMR- 29.9±0.94 
 
Table 5.2 Average doubling time of SKOV3 clones. The results shown in the table are 
mean ± SEM (n=3). 
 
5.4 Selecting viability assay for high throughput screening and determination of 
z’ 
Currently, MTT assay and AlamarBlue assay are widely used in determination of cell 
viability. Before conducting high throughput screening (HTS) it is necessary to select 
a suitable assay. Therefore, it is important to determine which assay is optimal for 
the cell model under study. One way to quantify/score the quality of an assay is to 
determine z’ which describes the available signal window for an assay in terms of the 
separation between negative and positive controls minus the error associated with 
each type of control [158]. The formula below shows how z’ factor is calculated.   
 
Where σ+c, σ-c, are the standard deviations of the positive (+c) and negative (-c) controls; 
µ+c, and µ-c are the means of the positive (+c) and negative (-c) controls. 
In this study, 10µM of cisplatin (diluted in 0.9% NaCl) was used as positive control 
because this concentration inhibits 90-95% of cell growth of SKOV3 clones. 20 
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times diluted 0.9% NaCl (vehicle) was used as negative control. After four 
independent experiments using MTT and AlamarBlue, average z’ factor of each 
assay was calculated and AlamarBlue assay was found  to be superior to MTT assay 
for HTS (Figure 5.3, Table 5.3) because AlamarBlue assay provided larger signal 
window. In addition, as a z’ factor between 0.5 and 1.0 is considered as an excellent 





Figure 5.3 Examples of signal window of AlamarBlue assay and MTT assay. Cells were 















































exposure to  either 10µM cisplatin or 20 times diluted 0.9% NaCl for 72 hours. Four 
independent experiments were performed with triplicate per experiment. (A) AlamarBlue 
assay, z’=0.71. (B) MTT assay, z’=0.49. The results indicate that AlmarBlue assay provides 





mean ± SEM (n=4) 
Z’ factor 
MTT 
mean ± SEM (n=4) 
SKOV3 0.58± 0.07 0.46± 0.08 
SAC-1 0.52± 0.10 0.23± 0.19 
SN-5 0.56± 0.10 0.50± 0.10 
Table 5.3 Average z’ factor of AlamarBlue assay and MTT assay.  
 
5.5 Pre-screening of selected DNA damaging agents 
As MMR proteins are involved in DNA repair, six known DNA damaging agents 
were used to test the drug screening model of MMR deficiency (using AlamarBlue 
assay) because these DNA damaging agents might be synthetically lethal with MMR 
deficiency. The SKOV3 clones showed dose-dependent decrease in viability with 
four (Etoposide, Daunorobicin, Doxorubicin and Oxaliplatin) of these six drugs 
(Figure 5.4), but no dose-dependent decrease in viability was seen after treatment 
with 5-fluorouracil and Methothexate. The results show that there was no difference 
in sensitivity to Etoposide and Oxaliplatin between SAC-1 and SN-5. However, 
compared with SAC-1, SN-5 was initially found to be more sensitive to 
Daunorobicin and Doxorubicin when examining both growth inhibition and 
cytotoxic effects (Figure 5.4, Table 5.4), with 2 to 3 folds lower GI50, TGI and LC50 
values. To make a firm conclusion, three independent follow up experiments were 
performed by treating SAC-1 and SN-5 cells with daunorobicin or doxorubicin. As 
shown in Figure 5.5, confirmatory experiments indicate it is SAC-1 cells rather than 
SN-5 cells that are more sensitive to Daunorobicin and Doxorubicin, with nearly 2-
folds less GI50, >2 folds less TGI and >3 folds less LC50 values (Table 5.5).  
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Figure 5.4 Sensitivity of SKOV3 clones to DNA damaging agents. Cells were grown in RPMI and seeded in 96 well flat bottomed microtitre plates at 
a density of 1000 cells per well and grown for 24h prior to the exposure to increasing concentrations of different DNA damaging agents  for 72hours. 








DNA damaging agent Cell line GI
50 




SKOV3 1.04 5.71 - 
SAC-1 0.72 - - 
SN-5 0.59 1.82 - 
Daunorubicin 
SKOV3 0.06 0.14 0.39 
SAC-1 0.04 0.20 0.60 
SN-5 0.02 0.09 0.40 
Doxorubicin 
SKOV3 0.06 0.21 0.83 
SAC-1 0.03 0.16 1.02 
SN-5 0.01 0.07 0.35 
Oxaliplatin 
SKOV3 2.65 22.65 - 
SAC-1 1.59 5.0 - 
SN-5 1.02 5.14 34.9 
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Figure 5.5 Confirmation of Sensitivity of SKOV3 clones to Daunorubicin and Doxorubicin. Cells were grown in RPMI and seeded in 96 well flat 
bottomed microtitre plates at a density of 1000 cells per well and grown for 24h prior to the exposure to increasing concentrations of different DNA 
damaging agents  for 72hours. Cell viability was assessed by AlamarBlue assay. (A) Daunorubicin. (B) Doxorubicin. Three independent experiments 









DNA damaging agent Cell line GI
50 




SKOV3 0.083±0.003 0.327±0.041 1.507±0.311 
SAC-1 0.047±0.009 0.133±0.015 0.387±0.067 
SN-5 0.083±0.003 0.310±0.042 1.383±0.391 
Doxorubicin 
SKOV3 0.133±0.012 0.553±0.058 3.663±0.581 
SAC-1 0.073±0.009 0.217±0.032 0.667±0.137 
SN-5 0.110±0.006 0.493±0.070 5.497±3.121 
Table 5.5 Confirmation of treatment response of SKOV3 clones to Daunorubicin and 
Doxorubicin. The results shown are Mean ± SEM (n=3). 
 
5.6 High throughput screening of GSK kinase inhibitor library  
After pre-screening, a GSK kinase inhibitor library containing 362 compounds [159, 
160] was screened (for each compound, four doses with log differences in 
concentration were used) using the above model of MMR deficiency.  The parental 
cell line SKOV3 was used as a reference. Z’ factor of each cell line during the 
screening is reported in Table 5.6. Afterwards, seven drugs (GSK2186269A, 
GW620972X, GW775608X, GSK586581A, SB-814597, GSK326090A and 
GSK317314A) were selected as hits. The criteria for inclusion as a hit are: (1) at 
least one concentration of the drug decreases SN-5 (MMR-) cell viability by 50%, (2) 
at least one concentration of the drug causes a 1.5 fold difference in cell viability 
between SAC-1 and SN-5 cells (SN-5 is more sensitive to the drug than SAC-1) and 
(3) there is a possible indication of a dose-dependent effect of the drug. The criteria 1 
and 2 are compulsory, while the third criterion is additional.   
Cell line Z’ factor 








5.7 Confirmation of hits 
In order to confirm whether the seven hits are actual synthetic lethal targets with 
MMR deficiency, each drug was tested on the three cell lines again (eight doses in 
half log series dilution). As shown in Figure 5.6 (G), compared with SAC-1, SN-5 is 
more sensitive to PLK1 inhibitor GSK317314A. Another PLK1 inhibitor 
GSK326090A (Figure 5.6 F) also shows greater inhibition in SN-5 cells although the 
separation of the curves is smaller than that of GSK317314A. The other five drugs 
were considered not synthetic lethal with MMR deficiency after the confirmation 
experiment. Since the two PLK1 inhibitors have similar structure, the three cell lines 
were treated with another PLK1 inhibitor, BI2536, with different structure (Figure 
5.7). Strikingly, compared with treatment with GSK317314A (Figure 5.6 G), the 
three cell lines showed similar pattern after treatment with BI2536 (Figure 5.8 A). 
There is significant difference (p<0.01) in total growth inhibition between SAC-1 
and SN-5 (Figure 5.8 B), with TGI of 25.12nM and 9.92nM respectively (Table 5.7). 
These results indicate that inhibition of the kinase activity of PLK1 is potentially 
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Figure 5.6 Confirmation of sensitivity of SKOV3 clones to the seven hits. Cells were grown in RPMI and seeded in 96 well flat bottomed 
microtitre plates at a density of 1000 cells per well and grown for 24h prior to the exposure to increasing concentrations of different DNA damaging 
agents  for 72hours. Cell viability was assessed by AlamarBlue assay. (A) GSK2186269A. (B) GW620972X. (C) GW775608X. (D) GSK586581A. (E) 






Figure 5.7 Structures of the PLK1 inhibitors. 
 








































S A C -1
S N -5









































Figure 5.8 Confirmation of Sensitivity of SKOV3 clones BI2536. 
Cells were grown in RPMI and seeded in 96 well flat bottomed microtitre plates at a density 
of 1000 cells per well and grown for 24h prior to the exposure to increasing concentrations 
of BI2536 for 72hours. Cell viability was assessed by AlamarBlue assay. Three independent 
experiments were performed with triplicates per experiment. (A)Dose response of SKOV3 
clones to BI2536. (B) Comparison of GI50 and TGI values between SAC-1 and SN-5 after 








mean ± SEM (n=3) 
TGI(nM) 
mean ± SEM (n=3) 
SAC-1 8.24±0.64 25.12±2.70 
SN-5 5.91±0.56 9.92±0.45 
SKOV3 10.68±0.71 - 
Table 5.7 Treatment response of SKOV3 clones to BI2536.  
 
5.8. Combination of PLK1 inhibitor and Cisplatin 
The above results show that compared with SAC-1 cells (MMR+), SN-5 cells 
(MMR-) are more sensitive to PLK1 inhibitors at TGI level; SN-5 cells are also more 
sensitive to Cisplatin at TGI and LG50 level. However, compared with Cisplatin, 
PLK1 can be used at much lower dosage (nM vs µM). Since Cisplatin has been used 
as standard chemotherapy in ovarian cancer, it is necessary to determine whether 
combination of PLK1 inhibitor and Cisplatin can give benefit to ovarian cancers with 
MMR deficiency. Therefore SAC-1 and SN-5 cells were treated with increasing 
concentrations of BI2536 and/or Cisplatin. The results indicate that compared with 
SN-5 cells, SAC-1 cells are slightly more sensitive to combination treatment with 
higher fraction inhibition (Table 5.8). In addition, with increase of concentrations, 
combination of BI2536 and Cisplatin provided synergistic effect on SAC-1 cells with 
CI<1(Table 5.8 C, Figure 5.9). However, for SN-5 cells, combination of the two 
drugs provided marginal antagonistic effect, with CI values between 1.0 and 1.4 
(Table 5.8 C, Figure 5.9). Thus, simultaneous combination of BI2536 and Cisplatin 

















Table 5.8 Combination treatment of BI2536 and Cisplatin on SAC-1 and SN-5 cells. 
Cells were grown in RPMI and seeded in 96 well flat bottomed microtitre plates at a 
density of 1000 cells per well and grown for 24h prior to the exposure to increasing 
concentrations of BI2536 and/or Cisplatin for 72hours. Cell viability was assessed by 
AlamarBlue assay. Four independent experiments were performed with triplicates per 
experiment. (A and B) Matrix of fractional inhibition of SAC-1 and SN-5. Where most 
inhibition occurred, the value is close to 1 and the colour is red. Where 0.5 fractional 
inhibition occurred, the value is close to 0.5 and the colour is yellow. Where least inhibition 
occurred, the value is close to 0 and the colour is green. (C) Combination index table. CI<1, 
C1=1, and CI>1 indicate synergism, additivity, and antagonism, respectively. Total dose 
equals ratio of cisplatin: BI2536 (600:1) CI values were determined using CompuSyn. 
Cell line Total Dose (nM) Fractional Inhibition CI Value 
SAC-1 
1878.13 0.54 1.12757 
3756.25 0.79 0.69178 
7512.5 0.87 0.79617 
15025.0 0.96 0.51369 
SN-5 
1878.13 0.35 1.29767 
3756.25 0.65 1.08583 
7512.5 0.78 1.38398 






Figure 5.9 Combination index plot of BI2536 and Cisplatin treatment on SAC-1 and 
SN-5 cells. Cells were grown in RPMI and seeded in 96 well flat bottomed microtitre plates 
at a density of 1000 cells per well and grown for 24h prior to the exposure to increasing 
concentrations of BI2536 and/or Cisplatin for 72hours. Cell viability was assessed by 
AlamarBlue assay. Four independent experiments were performed with triplicates per 
experiment. Fa stands for fractional inhibition. CI<1, C1=1, and CI>1 indicate synergism, 
additivity, and antagonism, respectively. 
 
5.9. Mechanism of synthetic lethality betweenPLK1 inhibition and MMR 
deficiency in ovarian cancer 
In order to investigate the mechanism of synthetic lethality between PLK1 inhibition 
and MMR deficiency in ovarian cancer, SAC-1 (MMR+) and SN-5 (MMR-) cells 
were treated either with two different siRNAs targeting PLK1 (distinct duplexes 
targeting different parts of the mRNA), or with PLK1 inhibitor, BI2536, at two 
different concentrations for 72 hours. As shown in Figure 5.10 (A), transfection with 
either siRNA (5nM) targeting PLK1 caused cytotoxic effect in both cells lines 
compared with transfection of scrambled (non-targeting) control siRNA (p<0.0001). 
Compared with SAC-1 cells, SN-5 cells were slightly more sensitive to PLK1 
depletion, showing higher percentage of cell death (Figure 5.10 A).   
Figure 5.10 (B) shows that 5nM BI2536 caused significant growth inhibition in both 
cell lines (SAC-1, p<0.001; SN-5, p<0.0001) compared with treatment of DMSO 
control. In addition, compared with SAC-1, SN-5 was significantly more sensitive to 
treatment with 5nM BI2536 (p<0.0001), with much lower percentage of cell growth 
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(SAC-1, 64.03% ± 5.31%; SN-5, 9.21± 6.86%; n=4) (Figure 5.10 B). However, 
higher concentration of BI2536 (25nM) induced cytotoxic effect in both cell lines, 
and there was no significant difference in cell death between SAC-1 and SN-5 
(Figure 5.10 B). Together with previous results (Figure 5.8), the results further 
support the idea that inhibition of kinase activity of PLK1 to some extent is 
synthetically lethal with MMR deficiency in ovarian cancer. However, once 
inhibition of PLK1 reaches a certain level, non-specific cytotoxic effects will be 
induced and there is no significant difference in cell death between MMR+ and 
MMR- cells. As the two experiments (Figure 5.8 and Figure 5.10) were performed in 
different conditions, the same concentration of BI2536 may not give the same level 
of PLK1 inhibition, which explains the fact that 25nM of BI2536 caused total growth 
inhibition in SAC-1 cells in the previous experiment (Figure 5.8) but cytotoxic effect 
in this cell line in the second experiment (Figure 5.10).   
In parallel with examining cell growth, protein expression levels of PLK1 after 
treatment with the above siRNAs or BI2536 was also determined. Both PLK1-
targeting siRNAs knocked down PLK1 protein expression significantly (p<0.0001) 
in the two cell lines (>90% knock down) (Figure 5.11 A and C). Although the knock 
down of PLK1 in SAC-1 was slightly greater than that in SN-5, this difference was 
not statistically significant (Figure 5.11 A and C). Thus, in these experiments, any 
observed decrease in cell growth of both cell lines can reasonably be attributed to 
PLK1 knock down. 
Interestingly, PLK1 protein expression level in the two cell lines increased after 
treatment with BI2536 (Figure 5.11 B and D). For SAC-1 cells, 25nM BI2536 
increased PLK1 protein expression level greater than treatment with 5nM BI2536 but 
the increase was not significant. For SN-5 cells, 25nM BI2536 increased PLK1 
protein expression marginally, while 5nM BI2536 increased PLK1 protein 
expression significantly (p<0.001). In addition, compared with SAC-1 cells, PLK1 
protein expression level increased significantly more in SN-5 cells after treatment 
with 5nM BI2536 (p<0.05). However, under 25nM BI2536 treatment, there is no 
significant difference in PLK1 protein expression between SAC-1 and SN-5. This 
result suggests that although BI2536 inhibits kinase activity of PLK1, the compound 
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can cause stabilization of the protein instead of removal of the protein as seen with 
siRNA. Two mechanisms may be involved: (1) BI2536 binds the protein and affects 
its degradation. (2) Inhibition of kinase activity of PLK1 leads to compensation in 
affected cells; causing cells to produce more PLK1 protein. 
As PLK1 depletion is associated with accumulation of DNA damage [161], PLK1 
participates in DNA replication stress response [162], and phosphorylation of H2AX 
at Ser139 site is critical for signalling/repair protein recruitment to DNA damage 
sites [163, 164], expression level of phospho H2AX (s139) protein  was determined 
in parallel with examining cell growth. Figure 5.11(E F) shows that basal expression 
level of phospho H2AX (s139) protein was very low in both SAC-1 and SN-5, and 
there is no significant difference in basal expression level of this protein between the 
two cell lines. Figure 5.11 (E F G H) shows that after treatment with either siRNA 
targeting PLK1 or BI2536, expression level of phospho H2AX (s139) protein 
increased in both cell lines. In addition, expression of this protein in SAC-1 increased 
more than that in SN-5 under either treatment. Figure 5.11 (G) shows that after 
transfection of either of the two siRNAs targeting PLK1, expression level of phospho 
H2AX (s139) protein increased significantly (siRNA29, 9 fold compared to control, 
p<0.001; siRNA31, 7 fold compared to control, p<0.01) in SAC-1 cells; while the 
increase of this protein in SN-5 cells was not statistically significant (siRNA29, 3 
fold to control; siRNA31, 3 fold to control). The expression level of phospho H2AX 
(s139) protein in SAC-1 cells was increased significantly (p<0.01) compared to that 
in SN-5 cells after treatment with siRNA29 or siRNA31.  
Treatment with 5nM BI2536 increased expression level of phospho H2AX (s139) 
protein in SAC-1 and SN-5 to 7 fold and 4 fold of control respectively but there was 
no statistically significant difference in expression level of the protein between the 
two cell lines (Figure 5.11 H). When the concentration of BI2536 was increased to 
25nM, expression level of phospho H2AX (s139) protein increased to 18 fold of 
control (p<0.0001) in SAC-1 cells, while in SN-5 cells, this protein increased to only 
5 fold of control. The difference in expression level of phospho H2AX (s139) protein 
between the two cell lines was significant (p<0.01).  
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The results indicate that phospho H2AX (s139) protein is expressed at very low level 
in the absence of treatment in both SAC-1(MMR+) and SN-5 (MMR-) cells. 
Knocking down PLK1 protein or inhibition of kinase activity of PLK1 leads to 
increased expression level of phospho H2AX (s139) protein. In addition, for both 
cell lines, higher dose of treatment is associated with higher expression of phospho 
H2AX (s139) protein (Figure 5.11 H). This indicates either higher DNA damage 
response or higher DNA replication stress response. Overall, compared with SN-5 
(MMR-) cells, SAC-1(MMR+) cells had better response to DNA damage or 
replication stress after treatment with either siRNAs targeting PLK1 or PLK1 kinase 
inhibitor as indicated by higher expression of phospho H2AX (s139) protein. This 
may explain the fact that overall SAC-1 cells had better cell survival than SN-5 cells 
after PLK1 inhibition.  As PLK1 protein is known for its roles  in mitosis (M phase), 
DNA replication and DNA damage responses (interphase) in cell cycle [162, 165, 
166], it is necessary to determine whether growth inhibition in SN-5 cells after 
treatment with 5nM of BI2536 is associated with PLK1’s action in cell cycle . Figure 
5.12 (C D E F) shows that the number of SN-5 cells is significantly lower (p<0.05) 
after drug treatment compared to treatment with vehicle. In addition, the population 
of G0/G1 phase decreased slightly and the population of S phase increased 
marginally after treatment. However, the change in cell cycle was not statistically 
significant. As shown in Figure 5.12 (A B E F) 5nM of BI2536 had marginal effect 
in growth inhibition on SAC-1 cells but compared with untreated cells,  treated cells 
had about 10% lower population  (p<0.01) in G0/G1 phase and small accumulation 
in S phase. These results indicate that inhibition of PLK1 activity lead to decreased 
population in G0/G1 phase and increased population in S phase, which is consistent 
with PLK1’s involvement in DNA synthesis and DNA damage response in S phase. 
A recent study [9] reported that inhibition of PLK1 reduces DNA synthesis and 
slows S phase progression. In addition, since PLK1 promotes cell survival in 
response to replication stress and/or DNA damage, depletion of PLK1 can cause 
accumulation of DNA damage in early S phase [8]. Thus, after treatment with 5nM 
BI2536, the increased population of S phase in both SAC-1 and SN-5 cells may be 
due to the slowdown of S phase progression caused by losing PLK1’s function of 
regulating DNA synthesis and response to DNA damage.  
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As MMR proteins function as a damage sensor recognizing various DNA lesions and 
triggering multiple cellular signalling pathways to repair the lesions [43], MMR 
deficiency can cause increased DNA damage and therefore increased replication 
stress. Thus, compared with SAC-1 (MMR+) cells, SN-5 (MMR-) cells may suffer 
increased replication stress. In addition, PLK1 promotes DNA replication under 
replication stress [162]. Phospho H2AX(s139)  is a marker used to detect replication 
stress response [167].  Overall, after treatment with BI2536 or siRNAs targeting 
PLK1, SAC-1 (MMR+) cells had better survival and greater induction of phospho 
H2AX (s139) than SN-5 (MMR-) cells.  Therefore, when the activity of PLK1 is 
inhibited to certain level, MMR proficient cells may be more likely to survive 
compared with MMR deficient cells because they are able to mount a better 
replication stress response even in the absence of PLK1. Taken together, overall, 
compared with SAC-1 (MMR+) cells, SN-5 (MMR-) cells are more sensitive to 
PLK1 inhibition, either by treatment with PLK1 inhibitor or by siRNA targeting 
PLK1. Significant difference in cell growth between the two cell lines was observed 
after inhibition of PLK1. 5nM of siRNA29 and siRNA31 efficiently knocked down 
PLK1 protein by over 90%, while BI2536 stabilized PLK1 protein expression 
(although the kinase activity of PLK1 was inhibited). PLK1 is involved in DNA 
replication and response to DNA damage in interphase. Both depletion of PLK1 and 
inhibition of kinase activity of PLK1 can induce accumulation of DNA damage and 
replication stress, and result in increased expression level of phospho H2AX (s139) 
in the two cell lines. Results from cell cycle analysis show that inhibition of PLK1 
reduces population in G0/G1 phase and increases population in S phase, which is in 
line with PLK1’s role in S phase. Compared with SN-5 (MMR-) cells, SAC-1 (MMR 
+) cells had higher increase of phospho H2AX (s139) after treatment with either 
siRNAs targeting PLK1 or BI2536. As phospho H2AX (s139) protein is crucial in 
recruiting DNA repair proteins to sites of DNA damage, and also reflects response 
under DNA replication stress, higher expression of this protein in SAC-1 cells may 
facilitate repair of damaged DNA and better response to replication stress. In 
addition MMR deficient cells lack proper function of MMR system, they are more 
likely to have unrepaired DNA lesions which is one of the most commonly 
recognized sources of replication stress [167]. Therefore, under condition of 
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replication stress or DNA damage, SAC-1 cells are more likely to survive than SN-5 
cells because MMR proficient cells are more capable of upregulating phospho H2AX 





























































































































Figure 5.10 Cell growth of SAC-1 and SN-5 after treatment with siRNA targeting 
PLK1 or PLK1 inhibitor BI2536. Cells were grown in RPMI and seeded in 6 well  plates 
at a density of 120000 cells per well and grown for 24h prior to the exposure to two different 
siRNA targeting PLK1 (5nM) or BI2536 (5 nM or 25nM) for 72hours. Cell viability was 
assessed by AlamarBlue assay and expressed relative to viability at the beginning of the 
assay (using NCI formulae for growth inhibition). (A) Cell growth of SAC-1 and SN-5 cells 
after PLK1 knockdown by siRNA29 or siRNA31. (B) Cell growth of SAC-1 and SN-5 cells 
after treatment with BI2536. Three independent experiments were performed. Two-way 
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Figure 5.11 Protein expression level of PLK1 and phospho H2AX (s139) in SAC-1 and 
SN-5 cells after treatment with siRNA targeting PLK1 or PLK1 inhibitor BI2536. Cells 
were grown in RPMI and seeded in 6 well plates at a density of 120000 cells per well 
and grown for 24h prior to the exposure to two different siRNA targeting PLK1 (5nM) or 
BI2536 (5nM or 25nM) for 72hours. Cells were lysed and protein was extracted 72 hours 
post-treatment, and the expression level of PLK1 and phospho H2AX (s139) was determined 
by western blot. (A) Western blot showing PLK1 protein knockdown by siRNA29 or 
siRNA31 on SAC-1 and SN-5 cells. (B) Western blot showing PLK1 protein expression in 
SAC-1 and SN-5 cells after treatment with BI2536. (C) Quantification of expression level of 
PLK1 protein in SAC-1 and SN-5 cells after transfection with siRNA29 or siRNA31. (D) 
Quantification of expression level of PLK1 protein in SAC-1 and SN-5 cells after treatment 
with BI2536. (E) Western blot showing phospho H2AX (s139) protein expression in SAC-1 
and SN-5 cells after transfection with siRNA29 or siRNA31, (F) Western blot showing 
phospho H2AX (s139) protein expression in SAC-1 and SN-5 cells after treatment with 
BI2536. (G) Quantification of expression level of phospho H2AX (s139) protein in SAC-1 
and SN-5 cells after transfection with siRNA29 or siRNA31. (H) Quantification of 
expression level of phospho H2AX (s139) protein in SAC-1 and SN-5 cells after treatment 
with BI2536. Three independent siRNA knockdown experiments were performed. Four 
independent BI2536 inhibition experiments were performed. Two-way ANOVA analysis 
was performed by using GraphPad Prism6. Each data point is mean ± SEM. * p<0.05, ** 
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Figure 5.12 Cell cycle analysis of SAC-1 and SN-5 after treatment with PLK1 inhibitor 
BI2536. Cells were grown in RPMI and seeded in 96 well plates at a density of 1000 cells 
per well and grown for 24h prior to the exposure to 5nM BI2536 for 72hours. Cells were 
stained with blue fluorescent dye Hoechst 33342 which specifically binds DNA. Plates were 
scanned by ImageExpress Micro system. Data was analysed by MetaXpress Software. 
Determination of each stage of cell cycle was based on intensity of fluorescent DNA. (A) 
Image of Hoechst 33342 stained SAC-1 cells after treatment with BI2536. (B) Image of 
Hoechst 33342 stained SAC-1 cells after treatment with DMSO. (C) Image of Hoechst 
33342 stained SN-5 cells after treatment with BI2536. (D) Image of Hoechst 33342 stained 
SN-5 cells after treatment with DMSO. (E) Quantification of number of cells after treatment. 
(F) Quantification of stages of cell cycle of SAC-1 and SN-5 after treatment with BI2536 or 
DMSO. Two-way ANOVA analysis was performed by using GraphPad Prism6. Each data 
point is the mean (±SEM) of three independent experiments. * p<0.05, ** p<0.01. (Dr John 
Dawson performed plate scanning using ImageExpress Micro system and data analysis using 
MetaXpress Software). 
 
5.10. Discussion and conclusion  
In order to identify synthetic lethal strategies to target MMR deficiency in ovarian 
cancer, ovarian cancer isogeneic cell lines were established by stable transfection of 
MLH1 and its corresponding empty vector to SKOV3 cell line (six MLH1+ clones 
and six MLH1- clones). Sensitivity to Cisplatin (standard treatment) was tested in 
randomly selected SKOV3 clones following dose-response testing, and the MMR- 
clone (SN-3) was found to be more sensitive to Cisplatin at higher doses (TGI level 




MMR- clones was observed. Clinical data in chapter 3 shows that there is no 
significant difference in response to platinum based treatment between MMR 
proficient and MMR deficient patients. Since Cisplatin is not cancer specific, it is 
very likely that higher doses (which can achieve TGI or LC50 level) of this 
compound are beyond its therapeutic window, and therefore cannot be used in 
clinical practice.  
For further studies, the MLH1+ cell line SAC-1 and MLH1- cell line SN-5 were 
selected for drug screening based on their phenotype and growth rate. After 
comparing with MTT assay, the AlamarBlue assay, with z’ factor consistently above 
0.5, was chosen for drug screening and a kinase inhibitor library containing 362 
drugs of known targets was screened. Two drugs with similar structures that targeted 
PLK1 showed greater growth inhibition of SN-5 compared with SAC-1. When the 
two cell lines were treated with another PLK1 inhibitor, BI2536, with different 
structure, 2 to 6 fold differences in growth inhibition between SAC-1 and SN-5 
clones was also observed, suggesting PLK1 is a potential synthetic lethal target for 
MLH1 deficiency in ovarian cancer. Subsequently, two different siRNAs targeting 
PLK1 were transfected into the two cell lines, and SN-5 cells were demonstrated to 
be slightly more sensitive to PLK1 knockdown, showing lower cell growth. This 
result further supports the findings with drug from the kinase inhibitor library 
screening which suggested that inhibition of PLK1 activity may confer selective 
benefit for MMR deficiency.  Compared with Cisplatin, PLK1 inhibitor may have a 
relatively larger therapeutic window because PLK1 is upregulated in many cancers 
[165]. Thus, the dose (between GI50 level and TGI level) that may confer significant 
clinical benefit to MMR- patients is more likely to be used in clinical practice.  
However, BI2536 is not recommended to be used in combination with Cisplatin to 
treat MMR deficient patients as the combination produced minor antagonistic effect 
on SN-5 cells when added simultaneously.  
PLK1 is well known for its role in mitosis in M phase, and is also involved in DNA 
synthesis and response to DNA damage in interphase. Recent studies reported that 
PLK1 promotes DNA replication under replication stress [162] and that PLK1 
depletion induces accumulation of  DNA damage in early S phase [161], which may 
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also happen in the treatment of SAC-1 and SN-5 with tools which hamper PLK1 
function. To investigate mechanisms involved in synthetic lethality between PLK1 
inhibition and MLH1 deficiency, expression of phospho H2AX (s139) was 
determined in parallel with measurement of cell growth after treatment with siRNA 
targeting PLK1 or the PLK1 inhibitor BI2536. This is because (1) phosphorylation of 
H2AX plays a critical role in DNA damage response; (2) phospho H2AX is required 
for the recruitment of DNA repair proteins to the sites containing damaged chromatin; 
(3) phospho H2AX reflects response of DNA replication stress [163, 167, 168].   
After either treatment, the expression of phospho H2AX (s139) increased in both cell 
lines but the increase in SAC-1 was greater than that in SN-5 cells (Figure 11 F and 
J). This suggests that SAC-1 cells had better response to DNA damage and 
replication stress. Therefore, SAC-1 cells maybe more efficient in assembling DNA 
repair proteins to damaged sites and dealing with replication stress.  
Cell cycle analysis after treatment of BI2536 on SAC-1 and SN-5 cells shows that 
inhibition of PLK1 results in reduced population in G0/G1 phase, and a small 
accumulation in S phase in both cell lines. In addition there is a significant difference 
(p<0.01) in population in G0/G1 phase in SAC-1 after treatment of BI2536.  These 
results are consistent with PLK1’s role in S phase – regulation of DNA synthesis and 
response to DNA damage.  The above change in cell cycle after PLK1 inhibition may 
be caused by the slowdown of S phase progression under treatment of BI2536. 
A recent study demonstrated that PLK1 plays an important role in a direct link 
between recognition of DNA damage and homologous recombination (HR) [166]: 
PLK1 phosphorylates Rad51 at serine 14 in response to DNA damage, which 
stimulates phospho-dependent interaction between NBS1 and Rad51. This BRCA2 
independent mechanism helps recruitment of Rad51 to sites of DNA damage and 
facilitates HR; leading to increased cellular resistance to genotoxic stresses.  
Both HR and MMR are critical for the maintenance of genome integrity. Compared 
with MMR proficient cells, MMR deficient cells have less stable genome and 
therefore more likely to have increased DNA replication stress. When accumulation 
of DNA damage and replication stress are induced by inhibition of PLK1,  MMR+ 
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cells are more likely to have better survival than MMR- cells as they may suffer less 
stress and have better response to overcome the stress. However, high level of PLK1 
inhibition can also heavily affect other functions of this protein, such as its main role 
in mitosis, causing cytotoxic effect on both MMR+ and MMR- cells. Therefore high 
dose of PLK1 inhibitor may not benefit cells with MMR deficiency. To further study 
the mechanism of PLK1-MLH1 synthetic lethality, further work should focus on 
DNA damage response pathways and DNA replication stress pathways after 























General discussion and conclusion 
 
 
Women with HNPCC have an increased lifetime risk of developing ovarian cancer  
and a proportion (2-29%) of unselected ovarian cancers have been reported to exhibit 
defects in MMR protein expression [72, 135]. Compared with MMR deficiency in 
colorectal cancer, MMR in ovarian cancer is relatively under-investigated. The goal 
of this project was to study MMR deficiency in ovarian cancer at both the clinical 
and molecular level. Using in vitro cell line models in combination with clinical data 
from a large patient cohort, this study characterizes the features of MMR deficiency 
in ovarian cancer, and aims to identify synthetic lethal strategies for the treatment of 
this subgroup of patients. 
The first part of this project characterises the clinical consequence of MMR 
deficiency in ovarian cancer. MMR status and histology subtypes of 536 tumours 
were determined, and the data was examined in relation to clinical records. 
Consistent with published data, high grade serous is the most common subtype and 
accounts for approximately 70% of all epithelial ovarian cancers. However, in the 
background of MMR deficiency, non-serous subtypes account for half of all cases; 
and there is a significant difference in incidence of MMR deficiency between high 
grade serous subtype and non-serous subtypes (p<0.01).  In addition, clear cell and 
mucinous subtypes are particularly associated with higher incidence of MMR 
deficiency. Compared with serous subtypes, non-serous subtypes are associated with 
early stage of diagnosis, with the majority of patients diagnosed at stage I or II. In 
contrast, serous subtypes (both high grade serous and low grade serous) are 
associated with advanced stage of diagnosis, with over 80% of cases diagnosed at 
stage III or IV. Compared with MMR proficient patients, MMR deficient patients are 
more likely to be diagnosed at early stages, and this is probably due to the 
association between MMR deficiency and non-serous histology.  
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The results of treatment response indicate that platinum-based therapy did not give 
any advantage to MMR deficient patients over MMR proficient patients, with 
approximately 56.2% of MMR deficient cases having complete or partial response 
compared with 68.5% of MMR proficient cases having complete or partial response. 
In this study treatment response between each histology subtype of ovarian cancers 
was not comparable because sample sizes of each non-serous subtype were too low. 
The results of survival show that patients with high grade serous ovarian cancers had 
the worst survival compared with other subtypes of ovarian cancer. This is consistent 
with the fact that the vast majority (88.2%) of patients with high grade serous ovarian 
cancers were diagnosed at advanced stages. However, less than 50% of non-serous 
subtypes of ovarian cancers were diagnosed at advanced stage. Patients diagnosed at 
early stages might be cured by surgery alone, while patients with advanced stages of 
ovarian cancer, in general, had much worse prognosis. Nevertheless, low grade 
serous ovarian cancer was an exception because although over 80% of cases were 
diagnosed at advanced stages, these patients in general had better survival. This 
indicates that this subtype of ovarian cancer may have unique clinical and biological 
features which give patients who are diagnosed at advanced stages some advantage 
in survival. Survival between MMR proficient patients and MMR deficient patients 
was also compared but there is no significant difference. Thus, compared with MMR 
proficient patients, MMR deficient patients do not have an advantage following 
current platinum-based treatment. Better treatments for this subgroup of patients are 
needed.  
The IHC results from tissue microarrays show that the incidence of MMR deficiency 
in unselected ovarian cancers is 15.7%, and that PMS2 protein is the most frequently 
lost protein, with genetic mutation /or protein lost in 9.7% of unselected ovarian 
cancers. In addition, and consistent with studies in colorectal cancers, MMR 
deficiency in ovarian cancer tends to appear in a grouped fashion, with MLH1 loss 
combining with PMS2 loss, MSH2 loss combining with MSH6 loss. For the 84 
MMR deficient cases, 52 (61.9%) had PMS2 deficiency. This high frequency 
suggests that silencing PMS2 protein may play an important role in tumourigenesis. 
Switching off PMS2 protein can affect its endonuclease function as well as its role in 
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directing strand excision during the mismatch repair process [36, 148], and therefore 
compromises the function of the mismatch repair system. As these PMS2 deficient 
cases show either loss of PMS2 alone (55.8%) or combined with MLH1 loss (44.2%), 
but over 90% of MLH1 deficient cases are combined with PMS2 loss, silencing of 
MLH1 might serve to cause PMS2 deficiency and affect its related downstream 
activities. Therefore further investigation of MLH1 and PMS2 expression and 
regulation in ovarian cancer is needed.    
Following the above study at the clinical level using clinical data and ovarian cancer 
tissue samples, the molecular characteristics of MMR deficiency across a panel of 
human ovarian cancer cell lines were investigated in the second part of this project. 
An in vitro cell line model of MMR deficiency in ovarian cancer was also 
established.  
The first step was quantification of mRNA and protein expression of MMR genes in 
19 ovarian cell lines. Three cell lines, SKOV3, TOV21G and IGROV1, were found 
to carry MLH1 deficiency at both the mRNA and protein level. Interestingly, these 
cell lines also had a defect in PMS2 protein expression, which is consistent with IHC 
data showing that MLH1 protein and PMS2 protein are paired in loss.  However, at 
the mRNA level, all three cell lines expressed PMS2 mRNA. This indicates that in 
the three cell lines the deficiency in MLH1 protein is caused by unsuccessful 
transcription, while the deficiency in PMS2 protein is not. Interestingly, across the 19 
cell lines, each MMR gene has positive correlation with some other MMR genes. 
Taking MLH1 and PMS2 as an example, they showed positive correlation at both the 
mRNA level (R=0.53, p=0.02) and protein level (R=0.72, p=0.0006). This is 
consistent with the fact that within the MMR system, these MMR proteins interact 
with each other and work as a team during the MMR process. 
After identifying the three MMR deficient cell lines from the 19 cell lines examined, 
further work was focused on the correlation of MLH1 and PMS2 protein expression, 
as they have strong positive correlation and show a pattern of paired loss in both cell 
line models and clinical samples. In order to study co-expression of MLH1 and 
PMS2, a plasmid encoding the cDNA for MLH1 was transfected into the three 
MLH1 deficient cell lines; and conversely siRNA targeting MLH1 was transfected 
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into the MMR proficient cell line A2780 and expression of MLH1 protein and PMS2 
protein was quantified. The results showed that re-introduction of MLH1 into MLH1 
deficient cells resulted in increased expression of PMS2 protein, and the expression 
level of PMS2 and MLH1 showed positive correlation in TOV21G and IGROV1; 
while in SKOV3 the expression of PMS2 was kept at a fairly constant low level. 
Knocking down expression of MLH1 in the MMR proficient cell line A2780 led to 
decreased expression of PMS2 protein. The results are consistent with the fact that 
MLH1 and PMS2 form a dimer during the MMR process, and also further support 
the idea that MLH1 is playing a crucial role in regulating PMS2 protein expression.  
Afterwards, further experiments were conducted to study the mechanism by which 
MLH1 protein stabilizes PMS2 protein. As the three MLH1 and PMS2 protein 
deficient cell lines all express PMS2 mRNA, MLH1 may regulate PMS2 protein at 
the translational or post-translational level. If MLH1 regulates PMS2 expression at 
the post-translational level, it is possible that PMS2 protein is degraded in the 
absence of MLH1 protein. Therefore two proteasome inhibitors lactacystin and 
MG132, and a lysosome inhibitor Bafilomycin A1 were used to block protein 
degradation in SKOV3 (MLH1-, PMS2-) cells and its isogeneic cell line SAC-1 
(MLH1+, PMS2+) cells. The results show that the expression of PMS2 protein 
increased significantly in SAC-1 cells but did not increase in SKOV3 cells when the 
proteasomal and lysosomal protein degradation pathways were blocked. This 
indicates that PMS2 protein can be degraded by the two pathways in the presence of 
MLH1 protein. However, protein stability studies indicate that PMS2 protein 
deficiency in SKOV3 cells is not due to rapid degradation of this protein. It is very 
likely that in the absence of MLH1, cells are not able to make enough PMS2 protein 
although they have enough PMS2 mRNA. Thus, MLH1 may play a role in regulating 
the synthesis of PMS2 protein at the translational level, rather than preventing the 
degradation of PMS2. Thus, to investigate the mechanism by which PMS2 protein 
levels are regulated by MLH1, future work should focus on translational regulation 
of PMS2. 
Following characterization of MMR deficiency of ovarian cancer at the molecular 
level, the third part of this project was focused on identifying synthetic lethal 
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strategies for the treatment of ovarian cancer to maximise cytotoxicity in a MMR-
deficient background. 
After establishment of isogenic cell lines of MMR deficiency by stable transfection 
of a plasmid for MLH1 and its corresponding empty vector into SKOV3 cells, 
sensitivity to Cisplatin was tested in randomly selected SKOV3 clones. The results 
show that there is no significant difference in GI50 between MMR proficient cells and 
MMR deficient cells. However, the MLH1- clone SN-3 was significantly more 
sensitive to Cisplatin compared with two MLH1+ clones in terms of TGI (SAC-2 
and SAC-7) and LC50 (SAC-1 and SN-7). This indicates that Cisplatin cytotoxicity 
may be more selective to MMR- tumours at higher doses. Clinical data in chapter 3 
shows that there is no significant difference in response to platinum based treatment 
between MMR proficient and MMR deficient patients. Therefore it is very likely that 
the higher dosage of Cisplatin that may appear more selective to MMR- patients is 
beyond its therapeutic window because Cisplatin is not cancer specific at such doses.  
The MLH1+ cell line SAC-1 and MLH1- cell line SN-5 were selected for drug 
screening based on their similar morphology and growth rate. The AlamarBlue assay, 
with z’ factor consistently above 0.5, demonstrative of high signal-to-noise, was 
chosen for drug screening and a kinase inhibitor library (The GSK Published Kinase 
Inhibitor Set) containing 362 compounds of known targets was screened [159, 160]. 
Two compounds with similar structures that targeted PLK1 showed greater growth 
inhibition of SN-5 compared with SAC-1. When the two cell lines were treated with 
another structurally distinct PLK1 inhibitor, BI2536, a 2 to 6 fold difference in 
growth inhibition between SAC-1 and SN-5 clones was also observed, suggesting 
PLK1 is a potential synthetic lethal target for MLH1 deficiency in ovarian cancer. 
Subsequently, two different siRNAs targeting PLK1 were transfected into the two 
cell lines, and a cytotoxic effect was observed in both cell lines. Compared with 
SAC-1 cells, SN-5 cells were slightly more sensitive to PLK1 depletion, showing a 
higher percentage of cell death. This result, together with the results from PLK1 
inhibitors, indicates that inhibition of PLK1 activity may confer selective benefit for 
MMR deficiency. Compared with Cisplatin, the PLK1 inhibitor may have relatively 
larger therapeutic window because a wide range of cancers express upregulated 
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PLK1. However combination of BI2536 and Cisplatin caused minor antagonistic 
effects on SN-5 cells. Thus BI2536 is not recommended to be used in combination 
with Cisplatin based standard treatment.  
Apart from its well-known role in mitosis, PLK1 also plays a role in regulating DNA 
synthesis and response to DNA damage in interphase [169]. Recent studies reported 
that PLK1 phosphorylates DNA topoisomerase IIα (topoIIα) starting from S phase, 
and the phosphorylation positively regulates topoIIα’s activity [170].  In addition, 
PLK1 promotes cell survival under replication stress and depletion of PLK1 induces 
accumulation of DNA damage [161, 162].  In order to investigate whether synthetic 
lethality between PLK1 inhibition and MLH1 deficiency is associated with PLK1’s 
role in DNA replication and the DNA damage response, expression of phospho 
H2AX (s139) was determined in parallel with measurement of cell growth after 
treatment of siRNA targeting PLK1 or BI2536. This is because (1) phosphorylation 
of H2AX plays a critical role in the DNA damage response; (2) phospho H2AX is 
required for the recruitment of DNA repair proteins to the sites containing damaged 
chromatin; (3) phospho H2AX reflects response to DNA replication stress [163, 167, 
168]. After either treatment with BI2536 or siRNAs targeting PLK1, SAC-1 cells 
showed greater induction of phospho H2AX (s139) compared to SN-5 cells, 
suggesting SAC-1 cells had enhanced response to DNA damage and replication 
stress. Thus, compared with SN-5 cells, SAC-1 cells maybe more capable of 
recruiting DNA repair proteins to damaged chromatin. In addition, inhibition of 
PLK1 by BI2536 also reduces the population in G0/G1 phase and increases the 
population in S phase in the cell cycle, which is consistent with PLK1’s involvement 
in S phase: regulating DNA synthesis and response to DNA damage. 
In addition to the above evidence supporting PLK1’s role in interphase, Yata and 
colleagues demonstrated that PLK1 plays an important role in a direct link between 
recognition of DNA damage and homologous recombination (HR) [166]: in response 
to DNA damage, PLK1 phosphorylates Rad51 at serine 14, which stimulates a 
phospho-dependent interaction between NBS1 and Rad51. This BRCA2 independent 
mechanism facilitates recruitment of Rad51 to sites of DNA damage, causing 
increased cellular resistance to genotoxic stresses.  
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Both HR and MMR play an important role in DNA repair and are crucial in 
maintenance of genome stability. Compared with MMR proficient cells, MMR 
deficient cells lack a properly functioning MMR system, and their genome is less 
stable. Therefore MMR deficient cells are more likely to have unrepaired DNA 
lesions which is one of the most commonly recognized sources of replication stress 
[167]. Since PLK1 positively interacts with a number of proteins (such as topoIIα 
and Rad51) which play important roles in DNA replication or DNA damage repair, 
PLK1 inhibition can lead to accumulation of DNA damage and increased replication 
stress.  Thus under the condition of PLK1 inhibition, MMR proficient cells are more 
likely to survive compared to MMR deficient cells because MMR proficient cells’ 
genome is more stable and therefore they may suffer less replication stress and less 
DNA damage. In addition, under conditions of DNA damage and/or replication stress, 
MMR proficient cells are more capable of inducing expression of phospho H2AX 
(s139) to facilitate DNA repair. However, as PLK1 has multiple roles in the cell 
cycle, high levels of PLK1 inhibition can severely affect its other functions, causing 
a serious cytotoxic effect on both MMR proficient and MMR deficient cells. Thus 
high dose of PLK1 inhibitor may not benefit cells with MMR deficiency. To further 
study the mechanism of PLK1-MLH1 synthetic lethality, further work should focus 
on DNA damage response pathways and DNA replication stress pathways after 
inhibition of PLK1.   
In recent years several PLK1 inhibitors have been tested in clinical trials. 
Unfortunately, after phase II trials clinical development of the first-generation PLK1 
inhibitor BI2536 was terminated because BI2536 showed modest clinical activity 
[171]. The lack of clinical efficacy was thought to be attributable to its poor 
pharmacokinetic profile, particularly its relatively short terminal half-life and low 
intratumoral exposure [172]. Currently, the second-generation PLK1 inhibitor 
volasertib (BI6727) with improved pharmacokinetic profile has shown clinical 
efficacy in a range of malignancies, with the most promising results seen in patients 
with acute myeloid leukemia (AML) [171]. BI6727 is now under phase III 
development as a potential treatment for AML.  BI6727 was also tested in ovarian 
cancer patients who were resistant or refractory to platinum-based therapy in a phase 
II trial [173]: Single-agent BI6727 showed antitumor activity in ovarian cancers 
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comparable with investigators’ best choice single-agent chemotherapy.  Drug-related 
adverse events (AEs) of BI6727 were mainly hematologic and manageable, with 
fewer non-hematologic AEs than other single-agent chemotherapy [173]. In addition, 
in a phase I study BI6727 was combined with platinum chemotherapy at full single-
agent doses to treat 61 heavily pretreated patients with advanced solid tumours, and 
the combination treatment was well tolerated [174]. These clinical trials of BI6727 
demonstrated that inhibition of PLK1 can achieve good clinical efficacy in different 
cancers and is generally well tolerated. Further investigation is required to determine 
whether MMR deficiency correlates with improved clinical response to PLK1 
inhibitors undergoing clinical development. 
To summarize, at the clinical level MMR deficiency in ovarian cancer is associated 
with non-serous subtypes, and overall earlier stage of diagnosis. The overall 
incidence of MMR deficiency is 15.6%, with PMS2 being the most frequently lost 
protein (9.7%). In addition, MMR deficiency tends to appear in a grouped fashion: 
MLH1 with PMS2; MSH2 with MSH6. At the molecular level, the grouped fashion 
of MLH1-PMS2 protein loss was also observed in cell lines, and MLH1 may 
regulate the synthesis of PMS2 protein at the translational level rather than 
preventing degradation of PMS2. Current platinum based treatment does not benefit 
MMR deficiency over MMR proficiency. However, inhibiting PLK1 activity may 
confer selective benefit to this subgroup of patients, and the mechanism is likely 
associated with PLK1’s involvement in regulating DNA synthesis and the DNA 
damage response in interphase.  
So far this is the largest study that characterises the consequences of MMR 
deficiency in epithelial ovarian cancer. Together these data demonstrate that: 1. 
Clinically, MMR deficiency is associated with non-serous subtypes of ovarian cancer 
and specific MMR proteins are paired in loss. 2. While current standard therapy 
offers no selective benefit to ovarian cancer patients with MMR deficiency, 
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Appendix 1. QRT-PCR standard curves    
 standards;  unknowns. Reaction efficiency between 0.90-1.10 and R
2
 value> 0.98 
were considered acceptable for further data analysis. 

























































































2 CARBOPLATIN NOT EVALUABLE 53 3 0 0 0 0 0 0 Low grade serous 18/11/2002 Last seen 10/10/2008 71 71
3 CARBOPLATIN COMPLETE RESPONSE 73 3 0 2 0 0 0 0 High grade serous 04/01/2002 25/08/2003 Died 14/02/2005 20 37
4 CRB/TXL COMPLETE RESPONSE 47 2 0 0 0 0 0 0 High grade serous 12/06/2003 Last seen 16/04/2008 58 58
5 CRB/TXL PARTIAL RESPONSE 45 3 0 0 0 0 0 0 High grade serous 25/11/2003 07/10/2004 Died 23/05/2006 10 30
6 CARBOPLATIN NOT EVALUABLE 77 3 0 0 0 1 1 1 Endometrioid 28/09/2003 Last seen 16/07/2008 58 58
7 CARBOPLATIN NOT EVALUABLE 58 1 0 0 0 0 0 0 Endometrioid 29/06/2004 Last seen 25/02/2009 56 56
8 CRB/TXL PROGRESSIVE DISEASE 27 3 2 2 2 2 0 0 Mucinous 21/09/2005 26/12/2005 Died 27/02/2006 3 5
9 CRB/GMC/TXL COMPLETE RESPONSE 35 3 0 0 0 0 0 0 High grade serous 08/04/2006 13/03/2008 Last seen 21/05/2009 23 37
10 CRB/TXL PARTIAL RESPONSE 41 - 0 0 0 0 0 0 High grade serous 06/11/2005 15/07/2006 Died 08/08/2006 8 9
11 CARBOPLATIN PARTIAL RESPONSE 70 4 0 0 0 0 0 0 High grade serous 18/11/2005 26/06/2007 Died 13/11/2007 19 24
12 CRB/TXL NOT APPLICABLE 70 2 0 0 0 0 0 0 High grade serous 09/12/2004 16/04/2007 Last seen 11/03/2009 28 51
13 CARBOPLATIN NOT EVALUABLE 64 3 0 0 0 0 0 0 High grade serous 23/03/2004 09/02/2005 Died 18/06/2005 11 15
14 CARBOPLATIN NOT EVALUABLE 72 2 1 0 0 1 2 1 Endometrioid 13/08/2004 Last seen 25/07/2008 47 47
15 CARBOPLATIN NOT EVALUABLE 71 4 0 0 0 0 0 0 High grade serous 22/11/2004 18/02/2006 Last seen 17/06/2009 15 55
16 CARBOPLATIN NOT EVALUABLE 63 2 0 0 0 0 0 0 Endometrioid 08/06/2006 Last seen 13/05/2009 35 35
17 CRB/TXL COMPLETE RESPONSE 56 3 0 0 0 0 0 0 High grade serous 11/05/2005 31/05/2006 Died 26/06/2007 13 26
18 CRB/TXL NOT EVALUABLE 60 3 0 0 0 0 0 0 Endometrioid 24/10/2005 04/01/2007 Died 03/03/2007 14 16
19 CRB/TXL PARTIAL RESPONSE 57 3 0 0 0 0 0 0 High grade serous 15/06/2004 22/04/2005 Died 05/12/2006 10 30
20 CRB.TXL PARTIAL RESPONSE 66 4 0 0 0 0 0 0 High grade serous 30/03/2004 25/09/2006 Last seen 20/07/2009 30 64
21 CARBOPLATIN NOT EVALUABLE 76 2 0 0 0 0 0 0 High grade serous 16/03/2004 Last seen 20/05/2009 62 62
22 CRB/TXL COMPLETE RESPONSE 68 3 0 0 0 0 0 0 High grade serous 26/07/2004 Last seen 25/03/2009 56 56
23 CARBOPLATIN PARTIAL RESPONSE 75 3 0 0 0 0 0 0 High grade serous 20/09/2004 28/09/2005 Died 25/09/2006 12 24
24 CRB/TXL NOT EVALUABLE 50 3 0 0 0 0 0 0 High grade serous 09/11/2001 31/12/2003 Last seen 07/08/2008 26 81
25 CRB/TXL NOT EVALUABLE 71 - 0 0 0 0 0 0 High grade serous 21/09/2001 28/08/2002 Died 24/11/2002 11 14
26 CRB/TXL NOT EVALUABLE 43 4 0 0 0 0 0 0 High grade serous 22/07/2003 31/08/2004 Died 03/11/2005 13 27
27 CRB/TXL COMPLETE RESPONSE 58 3 0 0 0 0 0 0 High grade serous 07/05/2003 08/06/2005 Died 21/10/2006 25 42
28 CARBOPLATIN PARTIAL RESPONSE 67 3 0 0 0 0 0 0 High grade serous 29/05/2002 07/03/2005 Died 15/07/2005 33 38
29 CARBOPLATIN NOT EVALUABLE 68 4 0 0 0 0 0 0 High grade serous 30/01/2002 Died 12/03/2002 1




31 CARBOPLATIN PROGRESSIVE DISEASE 63 3 0 1 1 0 2 1 Clear cell 24/12/2001 15/04/2002 Died 02/08/2002 4 7
32 CARBOPLATIN NOT EVALUABLE 85 3 0 0 0 0 0 0 High grade serous 04/04/2001 12/08/2003 Died 03/12/2004 28 44
33 CARBOPLATIN PARTIAL RESPONSE 56 4 0 0 0 0 0 0 High grade serous 08/12/2003 Last seen 19/11/2007 47 47
34 CRB/TXL PARTIAL RESPONSE 48 3 0 0 0 1 1 1 High grade serous 28/11/2002 30/10/2003 Died 13/09/2004 11 22
35 CARBOPLATIN NOT EVALUABLE 83 3 0 0 0 0 0 0 High grade serous 09/12/2003 28/09/2004 Died 01/11/2005 10 23
36 CARBOPLATIN PARTIAL RESPONSE 82 3 0 0 0 0 0 0 High grade serous 16/05/2002 19/09/2003 Last seen 05/08/2008 16 75
37 CRB/TXL NOT EVALUABLE 69 4 0 0 0 0 0 0 Clear cell 03/04/2001 Died 10/05/2001 1
38 CARBOPLATIN COMPLETE RESPONSE 76 3 0 0 0 0 0 0 High grade serous 29/12/2004 18/01/2006 Died 10/08/2006 13 19
39 CARBOPLATIN NOT EVALUABLE 78 1 0 0 0 0 0 0 Undifferentiated 17/04/2001 05/11/2002 Died 06/03/2004 19 35
40 CRB/TXL NOT APPLICABLE 65 2 0 0 0 0 0 0 Clear cell 13/10/1999 23/05/2001 Died 29/03/2006 19 78
41 CARBOPLATIN NOT APPLICABLE 62 1 0 0 0 0 0 0 Clear cell 03/08/2001 27/01/2004 Died 10/03/2005 30 43
42 CARBOPLATIN NOT EVALUABLE 45 2 0 0 0 0 0 0 Endometrioid 14/01/2003 Last seen 01/05/2009 76 76
43 CARBOPLATIN PARTIAL RESPONSE 58 3 0 0 0 0 0 0 High grade serous 19/01/2001 05/02/2003 Died 19/11/2004 25 46
44 CRB/TXL NOT EVALUABLE 58 3 0 0 0 0 0 0 High grade serous 16/05/2002 15/12/2003 Died 07/11/2005 19 42
45 CRB/TXL PARTIAL RESPONSE 65 3 0 0 0 0 0 0 High grade serous 07/06/2002 23/04/2003 Died 10/09/2003 11 15
46 CARBOPLATIN COMPLETE RESPONSE 76 3 0 0 0 0 0 0 High grade serous/undifferentiated18/11/2003 01/06/2005 Died 19/12/2006 18 37
47 CRB/TXL NOT EVALUABLE 60 3 0 0 0 0 0 0 High grade serous 23/09/2003 29/07/2004 Died 09/01/2005 10 16
48 CRB/TXL NO CHANGE 73 4 0 0 0 0 0 0 High grade serous 16/03/2001 15/05/2002 Died 18/04/2005 14 49
49 CARBOPLATIN NOT EVALUABLE 39 1 0 0 0 0 0 0 Mucinous 27/09/2001 Last seen 21/02/2009 89 89
50 CRB/TXL NOT EVALUABLE 60 2 0 0 0 0 0 0 Endometrioid 06/03/2001 27/06/2002 Died 01/03/2003 16 24
51 CARBOPLATIN PARTIAL RESPONSE 65 3 0 0 0 0 0 0 High grade serous 13/05/2003 13/07/2004 Died 14/12/2004 14 19
52 CRB/TXL NOT EVALUABLE 58 3 0 0 0 0 0 0 High grade serous 07/03/2001 03/10/2001 Died 23/01/2005 7 47
53 CRB/TXL NOT EVALUABLE   46 3 0 0 0 0 0 0 Endometrioid 22/01/2003 13/08/2004 Died 16/10/2005 19 33
54 CRB/TXL COMPLETE RESPONSE 41 3 0 0 0 0 0 0 High grade serous 09/06/2003 Last seen 13/05/2009 71 71
55 CRB/TXL NOT EVALUABLE 45 4 0 0 0 0 0 0 High grade serous 11/08/2005 31/07/2006 Died 26/10/2007 12 26
56 CRB/TXL NOT EVALUABLE 53 4 0 0 0 0 0 0 High grade serous 19/06/2006 16/03/2007 Died 09/02/2008 9 20
57 CARBOPLATIN NO CHANGE 58 3 0 0 0 0 0 0 High grade serous 03/03/2005 08/03/2006 Died 08/12/2006 12 21
58 CRB/TXL Not evaluable 34 2 0 0 0 0 0 0 Clear cell 19/04/2006 24/10/2007 Last seen 24/06/2009 18 38
59 CISPLATIN NOT EVALUABLE 63 - 0 0 0 0 0 0 High grade serous 07/08/2006 04/04/2008 Last seen 29/07/2009 20 36
60 CRB/TXL PARTIAL RESPONSE 53 3 0 0 0 0 0 0 High grade serous 05/07/2005 31/05/2007 Last seen 28/07/2009 23 49
61 CRB/TXL NOT EVALUABLE 61 3 0 0 0 0 0 0 High grade serous 08/06/2006 17/04/2007 Died 21/07/2007 10 13
62 CRB/TXL COMPLETE RESPONSE 45 3 0 0 0 0 0 0 High grade serous 30/05/2006 Last seen 17/07/2009 38 38
63 CRB/TXL NOT EVALUABLE 55 2 0 0 1 0 1 1 Clear cell 31/05/2005 Last seen 01/04/2009 46 46
64 CARBOPLATIN PARTIAL RESPONSE 70 3 0 0 0 0 0 0 High grade serous 23/09/2005 08/09/2006 Died 26/09/2007 12 24
65 CARBOPLATIN PARTIAL RESPONSE 72 3 0 0 0 0 0 0 High grade serous 09/08/2005 19/06/2006 Died 01/08/2006 10 12
66 CARBOPLATIN NOT EVALUABLE 56 1 0 0 1 1 2 1 grade 1 mucinous 12/01/2006 Last seen 01/07/2009 42 42
67 CARBOPLATIN PARTIAL RESPONSE 57 4 0 0 0 0 0 0 High grade serous 07/06/2005 23/10/2006 Died 30/11/2007 17 30
68 CRB/TXL NOT EVALUABLE 63 4 0 0 0 0 0 0 High grade serous 06/11/2005 06/09/2006 Died 28/08/2007 10 22
69 CRB/GMC/TXL COMPLETE RESPONSE 38 3 0 0 1 0 1 1 Mucinous 13/02/2006 07/09/2007 Died 01/04/2008 19 26




71 CARBOPLATIN NOT EVALUABLE 46 3 0 0 0 0 0 0 High grade serous 25/02/2005 06/01/2006 Died 17/08/2006 10 18
72 CRB/TXL COMPLETE RESPONSE 60 3 0 0 0 0 0 0 High grade serous 15/04/2005 12/12/2005 Died 14/01/2006 8 9
73 CARBOPLATIN COMPLETE RESPONSE 66 2 0 0 0 0 0 0 Endometrioid 20/05/2005 Last seen 20/05/2009 48 48
74 CARBOPLATIN PR RECIST 64 4 0 0 0 0 0 0 High grade serous 16/12/2005 19/07/2006 Died 14/09/2006 7 9
75 CRB/TXL COMPLETE RESPONSE 43 3 0 0 0 0 0 0 High grade serous 26/05/2006 24/09/2007 Last seen 31/07/2009 16 38
76 CRB/GMC/TXL COMPLETE RESPONSE 53 3 0 0 0 1 1 1 Endometrioid 18/11/2005 Last seen 15/07/2009 44 44
77 CRB/TXL COMPLETE RESPONSE 58 4 0 0 0 0 0 0 High grade serous 29/03/2006 12/02/2008 Last seen 22/04/2009 23 37
78 CRB/TXL PR RECIST 69 3 0 0 0 0 0 0 High grade serous 02/03/2006 18/12/2007 Last seen 13/08/2008 22 29
79 CARBOPLATIN NOT EVALUABLE 84 4 0 0 0 1 1 1 High grade serous 28/11/2005 18/10/2006 Died 25/12/2006 11 13
80 CARBOPLATIN NOT EVALUABLE 63 - 0 0 0 0 0 0 Endometrioid 04/07/2006 Died 31/01/2008 19
81 CRB/TXL PARTIAL RESPONSE 59 3 0 0 0 0 0 0 High grade serous 26/09/2003 24/11/2004 Died 06/05/2006 14 31
82 CRB/TXL NOT EVALUABLE 66 3 0 0 0 0 0 0 High grade serous 08/09/2003 09/11/2004 Last seen 15/07/2009 14 70
83 CRB/TXL NOT EVALUABLE 55 3 0 0 0 0 0 0 High grade serous 03/09/2003 17/08/2005 Died 24/03/2006 23 31
84 CRB/TXL NOT APPLICABLE 49 3 0 0 0 0 0 0 High grade serous 16/12/2003 24/11/2004 Died 09/05/2005 11 17
85 CARBOPLATIN NOT EVALUABLE 68 1 0 0 0 0 0 0 High grade serous 21/05/2003 08/10/2004 Died 26/10/2005 17 29
86 CARBOPLATIN NOT EVALUABLE 73 4 0 0 0 0 0 0 High grade serous 10/10/2003 20/04/2004 Died 22/12/2004 6 14
87 CRB/TXL NOT EVALUABLE 65 3 0 0 0 0 0 0 High grade serous 11/12/2001 29/10/2003 Died 06/07/2006 23 55
88 CRB/TXL NOT EVALUABLE 64 3 0 0 0 0 0 0 High grade serous 01/08/2001 07/07/2003 Died 04/04/2005 23 44
89 CRB/TXL PARTIAL RESPONSE 65 3 0 0 0 0 0 0 High grade serous 02/07/2001 10/06/2002 Died 11/12/2003 11 29
90 CRB/TXL PARTIAL RESPONSE 35 1 0 0 0 0 0 0 Mucinous 19/09/2001 Last seen 12/12/2007 75 75
91 CRB/TXL PARTIAL RESPONSE 51 3 0 0 0 0 0 0 High grade serous 24/08/2001 Last seen 18/05/2009 93 93
92 CRB/TXL NOT EVALUABLE 70 3 0 0 0 0 0 0 High grade serous 26/09/2001 22/09/2004 Died 08/12/2005 36 50
93 CRB/TXL PROGRESSIVE DISEASE 60 2 0 0 0 0 0 0 High grade serous 22/08/2001 04/02/2002 Died 27/05/2002 5 9
94 CRB/TXL NOT EVALUABLE 66 3 0 0 0 0 0 0 High grade serous 09/02/2001 25/04/2007 Last seen 14/07/2009 74 101
95 CRB/TXL PARTIAL RESPONSE 51 3 0 0 0 0 0 0 High grade serous 07/03/2001 05/11/2001 Died 24/11/2001 8 9
96 CRB/TXL NOT EVALUABLE 56 2 0 0 0 0 0 0 Clear cell 31/08/2001 03/10/2006 Died 06/07/2007 61 70
97 CRB/TXL NOT EVALUABLE 39 3 0 0 0 0 0 0 High grade serous 31/10/2001 04/10/2002 Died 19/01/2004 11 27
98 CRB/TXL NOT EVALUABLE 55 3 0 0 0 0 0 0 High grade serous 19/07/2002 19/01/2006 Last seen 13/07/2009 42 84
99 CARBOPLATIN NOT EVALUABLE 77 2 0 0 1 0 1 1 High grade serous 27/08/2002 Last seen 30/12/2008 76 76
100 CARBOPLATIN PROGRESSIVE DISEASE 58 3 0 0 0 0 0 0 High grade serous 31/01/2002 27/06/2002 Died 10/12/2003 5 22
101 CRB/TXL NOT EVALUABLE 62 3 0 0 0 0 0 0 High grade serous 11/03/2002 03/02/2004 Died 15/01/2006 23 46
102 CRB/TXL NOT EVALUABLE 63 3 0 0 0 0 0 0 High grade serous 12/06/2002 15/04/2003 Died 07/11/2005 10 41
103 CRB/TXL NOT EVALUABLE 44 3 0 0 0 0 0 0 High grade serous 17/12/2002 04/02/2004 Died 30/04/2006 14 40
104 CARBOPLATIN NOT APPLICABLE 28 1 0 0 0 0 0 0 Endometrioid 01/12/2002 Last seen 06/08/2009 80 80
105 CARBOPLATIN NOT EVALUABLE 77 4 0 0 0 0 0 0 High grade serous 22/10/2002 08/01/2003 Died 21/02/2003 3 4
106 CARBOPLATIN PARTIAL RESPONSE 60 3 0 0 0 0 0 0 High grade serous 23/10/2002 12/09/2003 Died 27/12/2003 11 14
107 CARBOPLATIN NO CHANGE 54 4 1 0 1 1 3 1 High grade serous 05/11/2002 15/07/2003 Died 15/07/2003 8 8
108 CRB/TXT PARTIAL RESPONSE 57 3 0 0 0 0 0 0 High grade serous 27/07/2002 Died 14/07/2003 12
109 CARBOPLATIN PARTIAL RESPONSE 72 4 0 0 0 1 1 1 High grade serous 14/02/2002 15/04/2003 Died 07/07/2005 14 41




111 CRB/TXL NOT EVALUABLE 59 4 0 0 0 2 0 0 High grade serous 22/11/2002 24/12/2003 Died 12/08/2004 13 21
112 CRB/TXL COMPLETE RESPONSE 75 3 0 0 0 0 0 0 High grade serous 04/09/2002 06/09/2005 Died 28/11/2006 36 51
113 CARBOPLATIN COMPLETE RESPONSE 76 4 0 0 0 0 0 0 High grade serous 08/10/2002 29/12/2003 Died 16/06/2004 15 20
114 CRB/TXL COMPLETE RESPONSE 46 3 2 2 0 2 0 0 High grade serous 28/03/2002 03/11/2006 Last seen 15/07/2009 55 88
115 CRB/TXL NOT EVALUABLE 63 3 0 0 0 1 1 1 Low grade serous 22/05/2002 27/06/2003 Died 10/12/2004 13 31
116 CRB/TXL NOT EVALUABLE 48 2 0 1 0 0 1 1 Clear cell 04/01/2002 17/02/2003 Died 11/07/2007 13 66
117 CRB/TXL NOT EVALUABLE 64 3 0 0 0 0 0 0 High grade serous 23/05/2002 15/07/2003 Died 14/01/2004 14 20
118 CRB/TXL NOT EVALUABLE 64 3 0 0 0 1 1 1 High grade serous 02/10/2002 01/04/2004 Died 31/07/2005 18 34
119 CARBOPLATIN NOT EVALUABLE 53 3 0 0 0 0 0 0 High grade serous 27/01/2004 08/04/2005 Died 01/01/2009 14 59
120 CARBOPLATIN COMPLETE RESPONSE 65 4 0 0 0 0 0 0 High grade serous 20/08/2004 Last seen 22/04/2009 56 56
121 CRB/TXL PARTIAL RESPONSE 55 4 0 0 0 0 0 0 High grade serous 23/09/2004 04/11/2005 Died 19/05/2006 13 20
122 CRB/TXL NOT EVALUABLE 55 1 0 0 0 0 0 0 Clear cell 10/05/2004 Last seen 03/06/2009 61 61
123 CARBOPLATIN NOT EVALUABLE 76 2 0 0 0 0 0 0 Clear cell 31/08/2004 Last seen 19/05/2008 45 45
124 CARBOPLATIN NOT EVALUABLE 43 4 0 0 0 0 0 0 High grade serous 22/12/2004 07/09/2006 Died 16/11/2008 21 47
125 CARBOPLATIN NOT APPLICABLE 72 1 0 0 0 0 0 0 High grade serous 09/08/2004 Last seen 23/03/2009 55 55
126 CARBOPLATIN COMPLETE RESPONSE 38 3 0 0 0 0 0 0 High grade serous 30/01/2004 11/02/2005 Died 12/12/2005 12 22
127 CARBOPLATIN NOT EVALUABLE 60 1 0 0 0 0 0 0 Endometrioid 11/06/2004 Last seen 29/04/2009 59 59
128 CRB/TXL NOT EVALUABLE 64 3 0 0 0 0 0 0 High grade serous 08/09/2004 15/08/2005 Died 22/03/2009 11 54
129 CARBOPLATIN PARTIAL RESPONSE 58 4 0 0 0 0 0 0 High grade serous/undifferentiated16/07/2004 21/10/2005 Last seen-having Rx in Spain14/05/2008 15 46
130 CISPLATIN PROGRESSIVE DISEASE (Ca125)7 3 0 0 0 0 0 0 High grade serous 29/12/2004 07/06/2005 Died 17/09/2005 5 9
131 CARBOPLATIN NOT EVALUABLE 69 4 0 0 0 1 1 1 High grade serous 15/03/2004 16/06/2005 Died 09/07/2005 15 16
132 CRB/TXL COMPLETE RESPONSE 65 3 0 0 0 0 0 0 Clear cell 19/03/2004 10/03/2005 Died 16/03/2006 12 24
133 CRB/TXL NOT EVALUABLE 62 2 0 0 0 1 1 1 Endometrioid 16/08/2004 Last seen 22/04/2009 56 56
134 CARBOPLATIN NOT EVALUABLE 76 3 0 0 0 0 0 0 High grade serous 09/03/2004 Last seen 29/06/2009 64 64
135 CARBOPLATIN NOT EVALUABLE 77 3 0 0 0 0 0 0 High grade serous 21/05/2004 30/11/2004 Died 01/07/2007 6 37
136 CRB/TXL NOT EVALUABLE 64 - 0 0 0 0 0 0 Clear cell 21/06/2004 Last seen 28/05/2009 59 59
137 CARBOPLATIN NOT EVALUABLE 65 3 0 0 0 0 0 0 Clear cell 02/07/2004 Last seen 12/02/2009 55 55
138 CARBOPLATIN PROGRESSIVE DISEASE 80 4 0 0 0 0 0 0 High grade serous 12/10/2004 26/04/2005 Died 05/04/2006 6 18
139 CRB/TXL NOT EVALUABLE 49 2 0 0 0 0 0 0 Endometrioid 15/04/2004 Last seen 10/06/2009 62 62
140 CRB/TXL PARTIAL RESPONSE 52 4 0 0 0 0 0 0 High grade serous 11/08/2000 28/05/2002 Died 02/04/2005 22 56
141 CRB/TXL PARTIAL RESPONSE 46 3 0 0 0 1 1 1 High grade serous 12/12/2000 31/03/2004 Last seen 16/07/2009 40 103
142 CARBOPLATIN NOT APPLICABLE 66 1 0 0 0 0 0 0 grade 1 endometrioid11/07/2000 Last seen 05/08/2009 109 109
143 CRB/TXL PARTIAL RESPONSE 60 3 0 0 0 0 0 0 High grade serous 12/01/2000 13/09/2000 Died 03/10/2000 8 9
144 CRB/TXL NO CHANGE 67 2 0 0 0 0 0 0 Endometrioid 21/11/2000 Last seen 31/07/2009 104 104
145 CRB/TXL COMPLETE RESPONSE 58 3 0 0 0 0 0 0 High grade serous 25/07/2000 10/08/2001 Died 04/02/2002 13 18
146 CRB/TXL NOT EVALUABLE 62 3 0 0 0 0 0 0 High grade serous/undifferentiated15/06/2000 31/10/2001 Died 26/01/2007 17 79
147 CARBOPLATIN NOT EVALUABLE 77 2 0 0 0 0 0 0 High grade serous 24/11/2000 15/05/2002 Died 07/10/2004 18 46
148 CRB/TXL NO CHANGE 49 3 0 0 0 0 0 0 High grade serous 11/07/2000 02/08/2001 Died 15/03/2005 13 56
149 CARBOPLATIN PROGRESSIVE DISEASE 74 - 0 0 0 0 0 0 High grade serous 10/10/2000 15/02/2001 Died 27/10/2001 4 13




151 CRB/TXL NOT EVALUABLE 49 3 0 0 0 1 1 1 High grade serous 27/10/2000 06/12/2001 Died 21/01/2004 13 39
152 CISPLATIN NOT EVALUABLE 62 3 0 0 0 0 0 0 High grade serous 17/09/1998 15/02/2000 Died 12/02/2003 17 53
153 CARBOPLATIN NO CHANGE 77 4 0 0 0 0 0 0 High grade serous 10/05/2000 13/06/2001 Died 13/11/2001 13 18
154 CARBOPLATIN PROGRESSIVE DISEASE 54 3 0 0 0 0 0 0 High grade serous 26/09/2005 06/06/2006 Died 17/07/2006 8 10
155 CARBOPLATIN NOT EVALUABLE 76 1 0 0 0 0 0 0 Clear cell 26/07/2006 19/08/2008 Died 10/11/2008 25 28
156 CRB/GMC/TXL PARTIAL RESPONSE 59 3 0 0 0 0 0 0 High grade serous 21/02/2006 29/03/2007 Died 13/04/2008 13 26
157 CRB/TXL COMPLETE RESPONSE 61 3 0 0 0 0 0 0 High grade serous 04/05/2005 28/08/2006 Died 10/05/2008 16 36
158 CRB/TXL NOT EVALUABLE 55 3 0 0 0 0 0 0 High grade serous 03/03/2000 10/09/2003 Died 26/04/2008 42 98
159 CRB/TXL NOT EVALUABLE 61 3 0 0 0 0 0 0 High grade serous 18/12/2000 15/06/2006 Died 10/08/2008 66 92
160 CRB/TXL COMPLETE RESPONSE 53 2 0 1 1 0 2 1 Clear cell 01/02/2005 01/09/2006 Died 12/06/2007 19 28
161 CRB/TXL NOT EVALUABLE 57 2 0 1 1 1 3 1 Clear cell 16/12/2005 Last seen - going back to Pakistan14/05/2008 29 29
162 CARBOPLATIN NOT EVALUABLE 78 2 0 0 0 1 1 1 High grade serous 26/02/2004 12/07/2005 Died 20/05/2008 17 51
163 CRB/TXL PROGRESSIVE DISEASE 57 4 0 0 0 0 0 0 High grade serous 15/01/2004 28/04/2004 Died 06/06/2005 3 17
164 CRB/TXL NOT APPLICABLE 64 2 0 0 0 2 0 0 High grade serous 23/10/2000 Last seen 17/06/2009 104 104
165 CARBOPLATIN PR RECIST 75 2 0 0 0 0 0 0 Endometrioid 09/03/2005 15/04/2009 Last seen 16/07/2009 49 52
166 CRB/TXL NO CHANGE 53 2 1 0 0 1 2 1 Clear cell 18/07/2000 17/12/2000 Died 22/02/2001 5 7
167 CARBOPLATIN NOT EVALUABLE 72 2 0 0 0 0 0 0 High grade serous 25/07/2000 Died 06/01/2001 5 5
168 CARBOPLATIN NOT EVALUABLE 75 3 0 0 0 0 0 0 High grade serous 09/10/2000 12/07/2001 Died 22/06/2004 9 44
169 CRB/TXL COMPLETE RESPONSE 55 3 0 0 0 0 0 0 High grade serous 20/04/2005 07/11/2006 Died 10/09/2008 19 41
170 CARBOPLATIN NOT EVALUABLE 76 - 0 0 0 0 0 0 High grade serous 11/08/2000 Last seen 03/07/2008 95 95
171 CRB/TXL PARTIAL RESPONSE 61 4 0 0 0 0 0 0 High grade serous 18/10/2000 14/12/2001 Died 07/04/2003 14 30
172 CARBOPLATIN NOT EVALUABLE 80 2 0 0 0 0 0 0 High grade serous 04/08/2000 16/01/2006 Died 07/11/2006 65 75
173 CARBOPLATIN PROGRESSIVE DISEASE 58 3 0 0 0 0 0 0 High grade serous 04/08/2000 07/01/2001 Died 17/03/2001 5 7
174 CARBOPLATIN NOT EVALUABLE 50 1 0 0 0 0 0 0 Endometrioid 09/02/2000 Last seen 05/02/2009 108 108
175 CRB/TXT COMPLETE RESPONSE 51 3 2 2 2 2 0 0 Endometrioid 09/02/2000 03/05/2001 Died 10/02/2003 15 36
176 CARBOPLATIN PARTIAL RESPONSE 64 4 0 0 0 0 0 0 Endometrioid 01/10/1999 21/08/2000 Died 07/01/2001 11 15
177 CRB/TXT NOT EVALUABLE 52 2 0 0 0 0 0 0 High grade serous 25/02/1999 Died 26/12/1999 10
178 CRB/TXL PARTIAL RESPONSE 62 3 0 0 0 0 0 0 High grade serous 29/01/1999 20/12/1999 Died 03/06/2001 11 28
179 CRB/TXT COMPLETE RESPONSE 42 3 2 2 2 2 0 0 Endometrioid 29/10/1999 07/01/2001 Died 18/07/2001 14 21
180 CARBOPLATIN NOT EVALUABLE 72 3 0 0 0 0 0 0 High grade serous 29/01/1999 03/02/2000 Died 14/03/2000 12 13
181 CRB/TXL NO CHANGE 54 4 0 0 0 0 0 0 Endometrioid 10/08/1999 11/05/2000 Died 12/08/2000 9 12
182 CARBOPLATIN PROGRESSIVE DISEASE 58 3 0 0 0 0 0 0 High grade serous 19/05/1999 23/08/1999 Died 06/09/1999 3 4
183 CARBOPLATIN NOT EVALUABLE 62 1 0 0 1 0 1 1 Clear cell 17/03/1999 26/06/2003 Died 19/10/2005 51 79
184 CARBOPLATIN NOT EVALUABLE 66 1 0 1 1 1 3 1 Endometrioid 03/08/1999 Last seen 05/05/2009 117 117
185 CRB/TXL NOT EVALUABLE 60 3 0 0 2 0 0 0 High grade serous 11/12/2000 22/05/2003 Died 30/07/2004 29 44
186 CARBOPLATIN NOT EVALUABLE 64 1 0 0 1 0 1 1 High grade serous 03/01/2000 Died 16/05/2009 112
187 CARBOPLATIN PROGRESSIVE DISEASE 79 3 0 0 0 0 0 0 High grade serous 28/07/2005 21/11/2005 Died 29/06/2006 4 11
188 CRB/TXL NOT EVALUABLE 48 3 0 0 0 0 0 0 High grade serous 30/05/2000 10/10/2001 Died 08/07/2002 16 25
189 CARBOPLATIN NOT EVALUABLE 70 3 0 0 0 0 0 0 High grade serous 06/12/2000 11/09/2002 Died 05/01/2004 21 37




191 CARBOPLATIN NOT EVALUABLE 74 3 0 0 0 0 0 0 High grade serous 07/01/2005 23/11/2005 Last seen 01/07/2009 11 54
192 CARBOPLATIN CLINICAL DETERIORATION 67 3 0 0 0 0 0 0 High grade serous 25/12/2003 09/03/2004 Died 02/04/2004 2 3
193 CISPLATIN COMPLETE RESPONSE 64 3 0 0 0 0 0 0 High grade serous 14/06/1994 17/04/1997 Died 27/06/1997 34 36
194 CRB/TXL NOT EVALUABLE 54 3 0 0 0 0 0 0 High grade serous 11/05/2005 05/04/2006 Died 21/11/2006 11 18
195 CRB/TXL NOT EVALUABLE 59 3 0 0 0 0 0 0 High grade serous 20/04/2006 21/02/2007 Died 05/08/2008 10 28
196 CARBOPLATIN NOT EVALUABLE 67 4 2 0 2 2 0 0 High grade serous 27/02/2006 06/12/2006 Died 25/04/2007 9 14
197 CRB/TXL NOT EVALUABLE 60 2 0 0 0 0 0 0 High grade serous 16/02/2006 Last seen 15/04/2009 38 38
198 CARBOPLATIN NOT EVALUABLE 36 3 0 0 0 0 0 0 High grade serous 30/08/2005 23/03/2007 Died 07/04/2007 19 19
199 CRB/TXL NOT EVALUABLE 43 2 0 0 0 0 0 0 Endometrioid 21/12/2005 07/02/2007 Last seen 29/04/2009 14 40
200 CARBOPLATIN NO CHANGE 70 - 0 0 0 0 0 0 High grade serous/undifferentiated23/11/2005 05/04/2007 Died 09/04/2008 16 29
201 CRB/TXL PARTIAL RESPONSE 46 - 0 0 0 0 0 0 High grade serous 19/10/2004 24/11/2005 Died 10/08/2006 13 22
202 CARBOPLATIN NOT EVALUABLE 52 3 0 0 0 0 0 0 High grade serous 20/10/1999 Died 16/09/2002 35 35
203 CARBOPLATIN NOT EVALUABLE 68 1 0 0 0 0 0 0 Endometrioid 11/05/1999 Last seen 16/04/2009 119 119
204 CISPLATIN NOT APPLICABLE 57 1 0 0 0 0 0 0 High grade serous 09/08/1994 15/05/2000 Died 12/08/2002 69 96
205 CARBOPLATIN NOT EVALUABLE 30 3 0 0 0 0 0 0 Low grade serous 17/06/1999 Last seen 15/05/2008 107 107
206 CARBOPLATIN COMPLETE RESPONSE 62 3 0 0 0 0 0 0 high grade serous 01/10/1996 04/03/1999 Died 16/07/2002 29 70
207 CARBOPLATIN NOT EVALUABLE 75 3 0 0 0 0 0 0 High grade serous 24/05/1996 20/02/1998 Died 12/02/2000 21 45
208 CRB/TXL COMPLETE RESPONSE 60 3 0 0 0 0 0 0 High grade serous 08/09/1999 04/07/2000 Died 29/11/2004 10 63
209 CARBOPLATIN NOT EVALUABLE 62 3 0 0 0 0 0 0 Endometrioid 20/05/1998 08/07/1999 Died 11/05/2002 14 48
210 CARBOPLATIN NOT EVALUABLE 79 3 0 0 0 0 0 0 Endometrioid 10/05/1999 05/04/2000 Died 18/03/2002 11 34
211 CARBOPLATIN NOT EVALUABLE 58 1 0 0 0 0 0 0 Mucinous 29/10/1999 Died 29/04/2002 30
212 CARBOPLATIN NOT EVALUABLE 69 2 0 0 0 0 0 0 High grade serous/undifferentiated22/09/1999 22/08/2001 Died 25/12/2004 23 63
213 CRB/TXT COMPLETE RESPONSE 49 3 0 0 0 0 0 0 High grade serous/undifferentiated16/06/1999 19/06/2002 Died 03/04/2003 36 46
214 CARBOPLATIN NOT APPLICABLE 54 3 0 0 0 0 0 0 Endometrioid 07/06/1999 26/02/2001 Last seen 22/06/2009 21 121
215 CRB/TXT PROGRESSIVE DISEASE 27 2 1 0 0 0 1 1 Clear cell 26/10/1999 16/04/2000 Died 31/08/2000 6 10
216 CARBOPLATIN NOT EVALUABLE 58 4 2 2 2 2 0 0 High grade serous 26/02/1999 10/11/1999 Died 30/05/2000 8 15
217 CARBOPLATIN PROGRESSIVE DISEASE 58 4 0 0 0 0 0 0 High grade serous 07/10/1997 03/02/1998 Died 05/03/2002 4 53
218 CARBOPLATIN PARTIAL RESPONSE 74 4 2 0 2 2 0 0 Mucinous 26/08/1998 05/08/1999 Died 18/02/2000 11 18
219 CARBOPLATIN PROGRESSIVE DISEASE 56 4 0 0 0 0 0 0 High grade serous 24/03/1998 09/09/1998 Died 24/04/1999 6 13
220 CARBOPLATIN PROGRESSIVE DISEASE 72 3 0 0 0 0 0 0 High grade serous 26/05/1998 14/10/1998 Died 10/04/1999 5 10
221 CARBOPLATIN NOT EVALUABLE 62 3 0 0 0 0 0 0 High grade serous 15/10/1998 01/07/1999 Died 05/10/1999 9 12
222 CARBOPLATIN NOT EVALUABLE-but markers rising at end of Carbo51 3 0 0 0 0 0 0 High grade serous 24/05/1998 17/03/1999 Died 21/05/1999 10 12
223 CARBOPLATIN NOT EVALUABLE 66 3 0 0 0 0 0 0 High grade serous 13/11/1998 05/08/1999 Died 27/03/2000 9 16
224 CISPLATIN NOT EVALUABLE 65 3 0 0 0 0 0 0 High grade serous 13/01/1998 13/05/1999 Died 18/11/2000 16 34
225 CISPLATIN NOT EVALUABLE 69 3 0 0 0 2 0 0 High grade serous 16/03/1998 28/01/1999 Died 04/08/2005 10 89
226 CARBOPLATIN NOT EVALUABLE 56 3 0 0 0 1 1 1 Endometrioid 24/02/1998 07/10/1998 Died 02/01/1999 7 10
227 CARBOPLATIN NOT APPLICABLE 81 3 0 0 0 0 0 0 High grade serous 23/02/1998 19/03/1999 Died 19/08/2004 13 78
228 CARBOPLATIN NOT EVALUABLE 58 3 0 0 0 0 0 0 Endometrioid 03/03/1998 16/11/1998 Died 29/03/1999 8 13
229 CRB/TXL NOT EVALUABLE 57 1 0 0 0 0 0 0 High grade serous 30/11/1998 Last seen 18/07/2008 116 116




231 CARBOPLATIN NOT EVALUABLE 80 3 0 0 0 0 0 0 High grade serous 28/08/1998 28/05/1999 Died 27/08/1999 9 12
232 CARBOPLATIN NOT EVALUABLE 68 3 0 0 0 0 0 0 High grade serous 21/10/1998 13/05/1999 Died 21/10/1999 7 12
233 CARBOPLATIN PROGRESSIVE DISEASE 58 3 0 0 0 0 0 0 High grade serous 05/08/1998 28/10/1998 Died 06/09/1999 3 13
234 CARBOPLATIN NOT EVALUABLE 57 4 0 0 0 0 0 0 High grade serous 02/07/1998 04/10/1999 Died 28/07/2001 15 37
235 CARBOPLATIN NOT EVALUABLE 49 1 1 1 1 1 4 1 Mucinous 23/03/1998 10/03/1999 Died 14/05/1999 12 14
236 CRB/TXL NOT EVALUABLE 61 2 2 2 2 2 0 0 Endometrioid 02/12/1998 11/11/2002 Died 20/06/2003 47 55
237 CARBOPLATIN NOT APPLICABLE 58 1 0 0 0 0 0 0 High grade serous 12/10/1998 08/08/2000 Died 15/06/2002 22 44
238 CARBOPLATIN NOT EVALUABLE 59 3 0 0 0 0 0 0 Endometrioid 06/08/1998 18/01/2000 Died 08/06/2001 17 34
239 CISPLATIN NOT EVALUABLE 56 3 0 0 0 0 0 0 High grade serous 27/10/1998 25/10/1999 Died 16/03/2001 12 29
240 CISPLATIN NOT EVALUABLE 64 2 0 0 1 0 1 1 Endometrioid 28/07/1998 19/04/2000 Died 14/09/2004 21 74
241 CARBOPLATIN NO CHANGE 69 4 0 0 0 0 0 0 High grade serous 14/04/1998 28/01/1999 Died 14/10/2000 10 30
242 CSP/TXL PARTIAL RESPONSE 46 3 0 0 0 0 0 0 High grade serous 09/11/1998 28/02/2001 Died 30/10/2002 28 48
243 CARBOPLATIN NOT EVALUABLE 52 1 0 0 0 1 1 1 High grade serous 31/07/1998 15/12/2004 Died 20/03/2007 77 104
244 CARBOPLATIN NOT EVALUABLE 77 3 0 0 0 0 0 0 High grade serous 17/09/1998 07/06/1999 Died 26/07/1999 9 10
245 CRB/TXT PROGRESSIVE DISEASE 60 4 0 0 0 0 0 0 High grade serous 14/05/1999 01/09/1999 Died 14/01/2000 4 8
246 CARBOPLATIN NOT EVALUABLE 56 3 0 0 0 0 0 0 High grade serous 05/05/1998 25/05/2000 Died 16/03/2004 25 70
247 CISPLATIN NOT EVALUABLE 33 1 0 0 0 0 0 0 High grade serous 25/11/1998 08/09/1999 Died 28/07/2002 9 44
248 CARBOPLATIN NOT AV 55 3 0 0 0 0 0 0 High grade serous 24/02/1999 20/10/2000 Died 29/06/2004 20 64
249 CARBOPLATIN NOT EVALUABLE 63 3 0 0 0 1 1 1 High grade serous 07/08/1995 11/04/1996 Died 29/07/1996 8 12
250 CARBOPLATIN NOT EVALUABLE 49 4 1 0 1 1 3 1 High grade serous/undifferentiated05/12/1995 15/09/1996 Died 16/11/1996 9 11
251 CISPLATIN NOT EVALUABLE 67 3 0 0 0 0 0 0 High grade serous 27/01/1995 04/12/1995 Died 03/05/1996 10 15
252 CARBOPLATIN COMPLETE RESPONSE 55 4 0 0 0 0 0 0 High grade serous 12/07/1995 24/07/1997 Died 06/05/1998 24 34
253 CISPLATIN NOT EVALUABLE 53 3 0 0 0 0 0 0 High grade serous 05/12/1995 29/08/1996 Died 23/04/1997 9 17
254 CARBOPLATIN NOT EVALUABLE 66 3 0 0 0 0 0 0 Clear cell 18/04/1995 15/02/1996 Died 13/04/1996 10 12
255 CISPLATIN NOT APPLICABLE 52 3 0 0 0 0 0 0 High grade serous 09/01/1995 23/01/1997 Died 02/02/1998 24 37
256 CISPLATIN NOT EVALUABLE 58 3 0 1 1 1 3 1 High grade serous 14/06/1994 27/07/1995 Died 13/02/1996 13 20
257 CISPLATIN NOT EVALUABLE 44 3 0 0 0 0 0 0 High grade serous 09/05/1994 19/01/1995 Died 23/03/1995 8 10
258 CARBOPLATIN PROGRESSIVE DISEASE 56 3 0 0 0 0 0 0 High grade serous 04/07/1994 02/03/1995 Died 10/08/1995 8 13
259 CISPLATIN NOT EVALUABLE 58 3 0 0 0 0 0 0 High grade serous 13/12/1994 29/09/1995 Died 05/01/1996 10 13
260 CISPLATIN NOT EVALUABLE 52 3 0 0 0 1 1 1 High grade serous 10/05/1994 14/12/1995 Died 30/06/1998 19 50
261 CARBOPLATIN NO CHANGE 45 4 0 0 0 0 0 0 High grade serous 16/04/1993 28/10/1993 Died 08/12/1994 6 20
262 CISPLATIN NOT EVALUABLE 57 - 0 0 0 0 0 0 High grade serous 19/05/1995 25/04/1996 Died 14/06/1996 11 13
263 CSP/TPT PARTIAL RESPONSE 50 3 0 0 0 0 0 0 High grade serous/undifferentiated01/11/1996 26/09/1997 Died 13/06/1998 11 19
264 CARBOPLATIN NOT EVALUABLE 73 3 0 0 0 0 0 0 High grade serous 23/07/1996 30/06/1997 Died 05/07/1997 11 11
265 CARBOPLATIN NOT EVALUABLE 62 3 0 0 1 0 1 1 High grade serous 02/08/1996 22/05/1997 Died 27/08/1998 10 25
266 CISPLATIN NOT APPLICABLE 65 3 0 0 0 0 0 0 High grade serous 21/06/1996 29/04/1997 Died 16/01/2000 10 43
267 CISPLATIN NOT EVALUABLE 53 3 0 0 0 0 0 0 High grade serous 01/04/1996 14/10/2003 Died 11/06/2006 90 122
268 CARBOPLATIN NOT EVALUABLE 60 3 0 0 0 0 0 0 High grade serous 29/11/1994 19/12/1996 Died 07/02/1999 25 50
269 CARBOPLATIN NOT EVALUABLE 67 3 0 0 0 0 0 0 High grade serous 09/01/1996 04/04/1997 Died 29/12/1997 15 24




271 CSP/TPT NOT EVALUABLE 55 3 0 0 0 0 0 0 High grade serous 03/07/1996 23/01/1997 Died 22/08/1999 7 38
272 CISPLATIN NOT EVALUABLE 53 1 0 0 0 0 0 0 High grade serous 16/10/1990 03/12/1996 Died 20/01/2003 74 147
273 CISPLATIN NOT EVALUABLE 68 2 0 0 0 1 1 1 High grade serous 04/06/1994 Last seen 16/04/2009 179 179
274 CISPLATIN NOT EVALUABLE 49 3 0 0 0 0 0 0 High grade serous 11/03/1996 Last seen 14/05/2009 158 158
275 CARBOPLATIN PARTIAL RESPONSE 59 4 0 0 1 0 1 1 High grade serous 29/10/1996 13/11/1997 Died 12/05/1998 12 18
276 CARBOPLATIN NOT EVALUABLE 70 4 0 0 0 0 0 0 High grade serous 20/02/1996 02/10/1996 Died 13/12/1996 7 10
277 CARBOPLATIN PARTIAL RESPONSE 60 4 0 0 0 0 0 0 High grade serous 21/10/1997 09/04/1998 Died 05/06/1998 6 7
278 CARBOPLATIN NOT EVALUABLE 70 3 0 0 0 0 0 0 High grade serous 06/05/1997 14/07/1998 Died 27/05/1999 14 25
279 CARBOPLATIN NOT EVALUABLE 56 3 0 0 1 0 1 1 Mucinous 10/06/1997 Last seen 17/07/2009 145 145
280 CISPLATIN PROGRESSIVE DISEASE 60 3 1 0 0 1 2 1 Endometrioid 08/09/1997 09/01/1998 Died 02/06/1998 4 9
281 CARBOPLATIN NOT EVALUABLE 61 1 0 0 0 0 0 0 Clear cell 25/08/1997 Last seen 19/05/2009 141 141
282 CISPLATIN NOT EVALUABLE 71 3 0 0 0 0 0 0 Endometrioid 01/03/1994 11/09/1995 Died 14/10/1996 18 31
283 CARBOPLATIN NOT EVALUABLE 44 1 0 0 0 0 0 0 Endometrioid 04/08/1997 Last seen 23/10/2008 135 135
284 CARBOPLATIN NOT EVALUABLE 75 3 0 0 0 0 0 0 High grade serous 26/02/1997 19/11/1998 Died 25/07/2002 21 65
285 CARBOPLATIN NOT EVALUABLE 77 3 0 0 0 0 0 0 High grade serous 30/04/1997 02/09/1998 Died 21/12/1998 16 20
286 CSP/TPT NO CHANGE 52 3 0 0 1 0 1 1 High grade serous 21/10/1996 02/05/1997 Died 14/06/1997 6 8
287 CARBOPLATIN NOT EVALUABLE 62 3 0 0 0 0 0 0 Endometrioid 12/11/1997 02/05/2001 Died 01/04/2003 42 65
288 CARBOPLATIN NO CHANGE 58 4 0 0 0 0 0 0 High grade serous 26/11/1997 07/04/1998 Died 14/07/1998 4 8
289 CISPLATIN NOT EVALUABLE 47 3 0 0 0 0 0 0 High grade serous 17/10/1997 Last seen 26/03/2009 137 137
290 CARBOPLATIN PARTIAL RESPONSE 70 3 0 0 0 0 0 0 High grade serous 29/05/1997 27/11/1997 Died 09/12/1997 6 6
291 CARBOPLATIN NOT EVALUABLE 61 3 0 0 0 0 0 0 High grade serous 09/05/1997 15/12/2000 Died 23/05/2005 43 97
292 CARBOPLATIN NOT EVALUABLE 67 - 0 0 0 0 0 0 High grade serous 07/04/1997 Last seen 23/03/2009 144 144
293 CSP/TPT PROGRESSIVE DISEASE 48 3 0 0 0 0 0 0 High grade serous/undifferentiated11/11/1997 23/03/1998 Died 24/05/1998 4 6
294 CARBOPLATIN NOT EVALUABLE 58 3 0 0 0 0 0 0 High grade serous 17/01/1997 27/01/1998 Died 28/10/2000 12 45
295 CISPLATIN NOT EVALUABLE 55 1 0 0 0 0 0 0 High grade serous 04/08/1997 15/11/2005 Last seen 12/08/2009 99 144
296 CARBOPLATIN 57 3 0 0 0 0 0 0 High grade serous 30/12/1997 Died on treatment16/03/1998 2
297 CSP/TPT NOT EVALUABLE 59 4 0 0 1 0 1 1 Endometrioid 15/02/1997 03/07/1997 Died 02/12/1997 5 10
298 CISPLATIN NOT EVALUABLE 64 4 0 0 1 0 1 1 High grade serous 01/04/1997 16/04/1999 Died 02/05/2001 24 49
299 CARBOPLATIN NOT EVALUABLE 59 1 0 0 0 0 0 0 Endometrioid 02/04/1997 Last seen-CVA SJH ?survival25/07/2008 136 136
300 CARBOPLATIN NOT EVALUABLE 47 1 0 0 0 0 0 0 Endometrioid 26/02/1997 Last seen 17/11/2008 141 141
301 CSP/TPT NOT EVALUABLE 50 4 0 0 0 0 0 0 High grade serous 04/08/1997 Died 07/02/2004 78
302 CARBOPLATIN PARTIAL RESPONSE 61 3 0 0 0 0 0 0 Endometrioid 19/12/1997 24/07/1998 Died 04/09/1999 7 21
303 CARBOPLATIN NOT EVALUABLE 60 3 0 0 0 0 0 0 High grade serous/undifferentiated20/06/1997 Last seen 24/04/2009 142 142
304 CISPLATIN PROGRESSIVE DISEASE 35 3 0 0 0 0 0 0 Endometrioid 18/09/1995 23/11/1995 Died 23/05/1996 2 8
305 CISPLATIN COMPLETE RESPONSE 72 3 0 0 0 0 0 0 High grade serous 31/10/1995 13/06/1997 Died 19/08/1998 19 34
306 CISPLATIN PROGRESSIVE DISEASE 68 3 0 0 0 0 0 0 High grade serous 07/10/1995 30/01/1996 Died 28/09/1996 4 12
307 CARBOPLATIN NOT EVALUABLE 47 1 0 0 1 1 2 1 Clear cell 03/04/2006 Last seen 20/03/2009 36 36
308 CISPLATIN NOT APPLICABLE 46 2 0 0 0 0 0 0 High grade serous 19/07/1994 Last seen 02/02/2009 175 175
309 CARBOPLATIN NOT EVALUABLE 37 4 0 0 0 0 0 0 High grade serous 12/11/1996 08/01/1997 Died 08/01/1997 2 2




311 CISPLATIN COMPLETE RESPONSE 64 3 0 0 0 1 1 1 High grade serous 18/06/1996 17/07/1997 Died 15/11/1999 13 41
312 CSP/TPT NOT EVALUABLE 66 3 0 0 0 0 0 0 High grade serous 23/07/1996 03/07/1997 Died 28/09/2000 11 50
313 CARBOPLATIN COMPLETE RESPONSE 61 3 0 0 0 0 0 0 High grade serous 01/02/1996 18/02/1997 Died 09/11/1998 13 33
314 CSP/TPT NO CHANGE 59 4 0 0 0 0 0 0 Endometrioid 09/07/1996 13/02/1997 Died 24/02/1998 7 20
315 CARBOPLATIN NOT APPLICABLE 67 2 1 1 1 1 4 1 Mucinous 19/08/1996 15/01/1997 Died 10/02/1997 5 6
316 CISPLATIN NOT EVALUABLE 62 3 0 0 0 0 0 0 High grade serous 11/11/1996 04/02/1999 Died 18/08/2000 27 45
317 CARBOPLATIN PROGRESSIVE DISEASE 69 3 0 0 0 0 0 0 Clear cell 29/05/1996 30/07/1996 Died 29/08/1996 2 3
318 CISPLATIN NOT EVALUABLE 62 3 2 0 0 0 0 0 High grade serous 21/11/1997 28/01/1999 Died 07/12/2000 14 37
319 CISPLATIN NOT EVALUABLE 49 3 0 0 0 0 0 0 High grade serous 22/04/1994 24/05/1995 Died 26/01/1996 13 21
320 CISPLATIN NOT EVALUABLE 52 2 0 0 0 0 0 0 High grade serous 05/07/1994 14/03/1996 Died 07/01/1997 20 30
321 CISPLATIN NOT APPLICABLE 64 1 0 0 0 0 0 0 High grade serous 24/08/1993 Died 25/07/2007 167 167
322 CISPLATIN NOT EVALUABLE 52 3 0 0 0 0 0 0 High grade serous 13/01/1993 25/10/1993 Died 26/09/1994 9 20
323 CISPLATIN NOT EVALUABLE 54 1 0 0 0 0 0 0 Clear cell 07/06/1993 Last seen 16/06/2009 192 192
324 CISPLATIN NOT EVALUABLE 68 3 0 0 0 0 0 0 High grade serous 01/06/1993 21/01/1994 Died 25/03/1994 8 10
325 CISPLATIN NOT EVALUABLE 69 3 0 0 0 0 0 0 High grade serous 22/07/1993 24/11/1994 Died 17/03/1995 16 20
326 CARBOPLATIN PARTIAL RESPONSE 38 3 0 0 0 0 0 0 High grade serous 26/07/1993 19/09/1996 Died 04/09/1998 38 61
327 CISPLATIN NOT EVALUABLE 54 2 0 0 0 0 0 0 High grade serous 29/11/1993 03/03/1998 Died 27/03/2001 51 88
328 CARBOPLATIN NOT EVALUABLE 71 4 0 0 0 0 0 0 Endometrioid 14/09/1993 21/10/1993 Died 21/10/1993 1 1
329 CARBOPLATIN NOT EVALUABLE 68 3 0 0 0 1 1 1 High grade serous 12/09/1998 05/09/2001 Died 06/08/2003 36 59
330 CARBOPLATIN NOT EVALUABLE 51 3 0 0 0 0 0 0 High grade serous 18/06/1998 10/06/2002 Died 06/02/2005 48 80
331 CRB/TXL NOT EVALUABLE 75 3 0 0 0 0 0 0 High grade serous 29/11/1999 Last seen 11/12/2008 108 108
332 CARBOPLATIN NOT EVALUABLE 70 3 0 0 0 0 0 0 High grade serous 29/09/1999 Last seen 25/02/2009 113 113
333 CRB/TXL COMPLETE RESPONSE 61 3 0 0 0 0 0 0 High grade serous 28/12/1999 16/05/2001 Died 01/04/2002 17 27
334 CARBOPLATIN NOT EVALUABLE 57 3 0 0 0 1 1 1 Endometrioid 27/04/1999 15/04/2000 Died 08/05/2001 12 24
335 CARBOPLATIN NOT EVALUABLE 62 4 0 0 0 0 0 0 High grade serous 22/06/1999 08/06/2000 Died 01/07/2000 12 12
336 CRB/TXT NOT EVALUABLE 66 3 0 0 0 0 0 0 High grade serous 07/04/1999 21/12/2000 Died 19/08/2002 21 40
337 CRB/TXL PARTIAL RESPONSE 62 3 0 0 0 0 0 0 High grade serous 14/06/2000 10/11/2001 Died 24/04/2003 17 34
338 CARBOPLATIN NOT EVALUABLE 76 4 0 0 0 0 0 0 High grade serous 04/04/2000 18/06/2001 Died 07/11/2002 14 31
339 CARBOPLATIN COMPLETE RESPONSE 78 3 0 1 1 1 3 1 High grade serous 06/05/2000 21/08/2001 Died 02/05/2002 16 24
340 CRB/TXL NOT APPLICABLE 53 1 0 0 0 0 0 0 Endometrioid 14/02/2000 Last seen 20/05/2009 111 111
341 CRB/TXL PARTIAL RESPONSE 52 4 0 0 0 0 0 0 High grade serous 15/08/2000 06/02/2002 Died 19/03/2003 18 31
342 CRB/TXL NOT EVALUABLE 46 3 0 0 0 0 0 0 High grade serous 12/12/2000 14/09/2004 Died 25/11/2007 45 83
343 CARBOPLATIN NOT EVALUABLE 75 3 0 0 0 0 0 0 High grade serous 04/07/2000 12/02/2001 Died 22/05/2001 7 11
344 CRB/TXL NO CHANGE 60 2 0 0 0 0 0 0 Endometrioid 26/02/2001 14/01/2003 Died 29/11/2005 23 57
345 CRB/TXL PROGRESSIVE DISEASE 58 3 0 0 0 0 0 0 Clear cell 20/06/2001 12/10/2001 Died 23/03/2002 4 9
346 CARBOPLATIN NOT APPLICABLE 49 1 0 1 1 0 2 1 Endometrioid 29/05/2001 Last seen 21/10/2008 89 89
347 CRB/TXL PARTIAL RESPONSE 62 3 0 0 0 1 1 1 High grade serous 09/10/2001 21/01/2004 Died 21/07/2005 27 45
348 CRB/TXL NOT EVALUABLE 52 3 0 0 0 0 0 0 High grade serous 25/09/2001 06/08/2003 Died 12/02/2004 22 29
349 CARBOPLATIN PARTIAL RESPONSE 78 3 0 0 0 0 0 0 High grade serous 30/08/2002 08/12/2003 Died 27/03/2005 15 31




351 CRB/TXL PARTIAL RESPONSE 52 3 0 0 0 0 0 0 High grade serous 26/03/2002 14/08/2003 Died 07/08/2004 17 28
352 CRB/TXL NOT EVALUABLE 53 2 0 0 0 1 1 1 High grade serous 28/05/2002 03/08/2005 Died 29/05/2007 38 60
353 CARBOPLATIN NOT APPLICABLE 60 1 0 0 1 0 1 1 Endometrioid 19/01/2002 Last seen 19/08/2009 91 91
354 CARBOPLATIN NOT EVALUABLE 86 3 0 0 0 0 0 0 High grade serous 14/02/2003 01/10/2003 Died 09/11/2003 8 9
355 CRB/TXL NOT EVALUABLE 65 3 0 0 0 0 0 0 High grade serous 10/12/2003 11/08/2004 Died 21/08/2004 8 8
356 CRB/TXT NOT EVALUABLE 60 3 0 0 0 0 0 0 High grade serous 06/05/2003 18/01/2005 Died 27/02/2006 20 34
357 CARBOPLATIN 69 2 0 0 0 0 0 0 High grade serous 10/09/2003 Last seen 30/01/2009 65 65
358 CRB/TXL PARTIAL RESPONSE 68 3 0 0 0 0 0 0 High grade serous 26/02/2003 19/01/2004 Died 02/04/2004 11 13
359 CRB/TXL NO CHANGE 53 4 0 0 0 0 0 0 High grade serous 26/08/2004 09/09/2005 Died 26/07/2006 12 23
360 CARBOPLATIN NOT EVALUABLE 70 3 0 0 0 0 0 0 High grade serous 05/04/2004 21/02/2007 Last seen 03/08/2009 35 64
361 CARBOPLATIN NO CHANGE 68 4 0 0 0 0 0 0 Endometrioid 15/06/2004 09/02/2005 Died 09/02/2005 8 8
362 CARBOPLATIN PARTIAL RESPONSE 73 3 0 0 0 0 0 0 High grade serous 25/05/2005 01/05/2006 Died 07/08/2006 11 14
363 CRB/TXL NOT EVALUABLE 55 3 0 0 0 0 0 0 High grade serous 24/05/2005 26/04/2006 Died 09/01/2007 11 20
364 CRB/TXL NOT EVALUABLE 65 3 0 0 0 0 0 0 Low grade serous 25/01/2005 21/03/2006 Died 25/11/2007 14 34
365 CPC/CSP COMPLETE RESPONSE 71 - 0 0 0 0 0 0 High grade serous 23/10/2005 Last seen 24/06/2009 44 44
366 CISPLATIN COMPLETE RESPONSE 53 3 0 0 0 0 0 0 High grade serous 13/05/1991 19/05/1993 Last seen 07/10/2008 24 209
367 CISPLATIN PROGRESSIVE DISEASE 49 3 0 0 1 0 1 1 Clear cell 24/04/1990 13/08/1990 Died 05/10/1990 4 5
368 CISPLATIN PROGRESSIVE DISEASE 59 4 0 1 0 0 1 1 Endometrioid 27/05/1991 11/09/1991 Died 20/04/1992 4 11
369 CISPLATIN PARTIAL RESPONSE 42 4 0 0 0 0 0 0 High grade serous 02/05/1985 08/01/1986 Died 14/12/1986 8 19
370 CISPLATIN NOT EVALUABLE 48 3 0 0 0 0 0 0 High grade serous 19/10/1992 23/07/1993 Died 07/07/1994 9 21
371 CARBOPLATIN NOT EVALUABLE 57 2 0 0 0 0 0 0 High grade serous/undifferentiated17/11/1992 Died 25/12/1993 13
372 CISPLATIN NOT EVALUABLE 69 1 0 0 0 0 0 0 Endometrioid 23/11/1990 Last seen 31/07/2009 224 224
373 CARBOPLATIN NO CHANGE 72 4 0 0 0 1 1 1 High grade serous 26/04/1990 22/11/1990 Died 15/06/1991 7 14
374 CISPLATIN NOT EVALUABLE 56 4 0 0 0 0 0 0 High grade serous/undifferentiated13/03/1991 Died 06/07/1991 4
375 CISPLATIN NOT EVALUABLE 51 1 0 0 0 0 0 0 Clear cell 01/05/1992 Last seen 07/05/2009 204 204
376 CARBOPLATIN PARTIAL RESPONSE 54 3 0 0 0 0 0 0 High grade serous 03/03/1991 24/03/1992 Died 27/07/1993 13 29
377 CISPLATIN NOT APPLICABLE 66 1 0 1 1 1 3 1 Endometrioid 17/04/1992 Died 18/06/1999 86
378 CISPLATIN NO CHANGE 43 3 0 0 0 0 0 0 High grade serous 29/01/1990 26/10/1990 Died 27/04/1991 9 15
379 CISPLATIN COMPLETE RESPONSE 41 3 0 1 1 1 3 1 Endometrioid 10/12/1984 Died 12/11/2003 227
380 CISPLATIN COMPLETE RESPONSE 70 3 0 0 0 0 0 0 High grade serous 11/07/1991 25/01/1994 Died 11/05/1995 31 46
381 CARBOPLATIN NOT EVALUABLE 72 3 0 0 0 0 0 0 High grade serous 30/07/1990 19/06/1991 Died 05/12/1991 11 16
382 CISPLATIN PROGRESSIVE DISEASE 52 3 0 0 0 0 0 0 High grade serous 12/09/1991 31/01/1992 Died 10/04/1992 5 7
383 CISPLATIN NOT EVALUABLE 61 3 0 0 0 1 1 1 High grade serous 19/04/1991 13/05/1992 Died 07/07/1994 13 39
384 CISPLATIN NOT EVALUABLE 62 3 0 0 0 0 0 0 Endometrioid 02/11/1990 19/08/1992 Died 27/01/1994 22 39
385 CISPLATIN PROGRESSIVE DISEASE 59 2 0 0 0 0 0 0 High grade serous 27/03/1987 08/09/1987 Died 23/11/1998 5 140
386 CRB/TXL PARTIAL RESPONSE 63 3 0 0 0 1 1 1 High grade serous 13/08/2001 11/11/2002 Died 23/07/2004 15 35
387 CRB/TXL COMPLETE RESPONSE 47 3 0 0 0 0 0 0 High grade serous 05/01/2001 02/09/2002 Died 04/09/2003 20 32
388 CARBOPLATIN NO CHANGE 78 3 0 0 0 0 0 0 High grade serous 02/10/2002 Last seen 29/10/2008 73 73
389 CRB/TXL NOT EVALUABLE 32 3 0 0 0 0 0 0 High grade serous 01/11/2001 26/11/2002 Died 24/06/2005 13 44




391 CRB/TXL COMPLETE RESPONSE 68 3 0 0 0 0 0 0 High grade serous 16/01/2003 09/01/2004 Died 18/05/2007 12 52
392 CRB/TXL NOT EVALUABLE 59 4 2 0 0 0 0 0 High grade serous 06/09/2001 19/12/2002 Died 31/05/2003 15 21
393 CARBOPLATIN NOT EVALUABLE 64 1 0 0 0 0 0 0 Endometrioid 27/11/1998 Last seen 21/05/2009 126 126
394 CARBOPLATIN NOT EVALUABLE 72 1 0 0 0 0 0 0 Low grade serous 17/03/2000 Died 23/09/2004 54
395 CRB/TXL COMPLETE RESPONSE 60 3 0 1 1 2 2 1 Endometrioid 20/01/2000 12/09/2000 Died 28/10/2000 8 9
396 CARBOPLATIN PROGRESSIVE DISEASE 59 4 0 0 0 0 0 0 High grade serous 25/09/1992 19/02/1993 Died 10/05/1993 5 7
397 CISPLATIN PARTIAL RESPONSE 62 3 0 0 0 0 0 0 High grade serous 22/08/1990 08/09/1991 Died 24/10/1991 13 14
398 CISPLATIN NOT EVALUABLE 51 3 0 0 0 0 0 0 High grade serous 12/07/1991 19/02/1992 Died 23/04/1993 7 21
399 CISPLATIN PARTIAL RESPONSE 65 3 0 0 0 0 0 0 High grade serous 02/12/1988 26/04/1990 Died 27/06/1990 17 19
400 CISPLATIN NOT EVALUABLE 52 3 0 0 0 0 0 0 High grade serous 04/09/1992 07/04/1994 Died 27/04/1996 19 44
401 CISPLATIN NOT APPLICABLE 53 1 0 0 0 0 0 0 High grade serous 27/11/1990 03/08/1992 Died 04/05/1993 20 29
402 CISPLATIN NOT EVALUABLE 67 3 0 0 0 0 0 0 Undifferentiated 17/01/1991 13/05/1992 Died 27/12/1993 16 35
403 CISPLATIN PROGRESSIVE DISEASE 64 3 0 0 0 0 0 0 Endometrioid 09/02/1990 11/06/1990 Died 27/12/1990 4 11
404 CISPLATIN COMPLETE RESPONSE 58 3 0 0 0 0 0 0 High grade serous 18/12/1989 09/11/1992 Died 23/08/1995 35 68
405 CRB/GMC/TXL PARTIAL RESPONSE 64 2 0 0 0 1 1 1 Clear cell 01/12/2005 05/12/2006 Died 16/06/2008 12 31
406 CRB/GMC/TXL PARTIAL RESPONSE 54 3 0 0 0 0 0 0 High grade serous 03/11/2005 04/10/2006 Died 01/01/2007 11 14
407 CRB/GMC/TXL PARTIAL RESPONSE 55 3 0 0 0 0 0 0 High grade serous 05/10/2005 13/02/2008 Last seen 20/07/2009 28 46
408 CRB/TXL NOT EVALUABLE 47 3 1 0 0 1 2 1 High grade serous 23/06/2005 Last seen 25/02/2009 44 44
409 CRB/TXL NOT EVALUABLE 62 4 0 0 0 0 0 0 High grade serous 20/05/2005 30/06/2006 Died 25/07/2006 13 14
410 CRB/TXL PARTIAL RESPONSE 62 3 0 0 0 0 0 0 High grade serous 17/11/2005 07/02/2007 Died 17/11/2008 15 36
411 CARBOPLATIN PARTIAL RESPONSE 69 3 0 0 0 0 0 0 High grade serous 18/10/2005 01/03/2007 Died 21/06/2009 16 44
412 CARBOPLATIN NOT EVALUABLE 57 1 0 0 0 0 0 0 High grade serous 08/12/2005 Last seen 19/08/2009 44 44
413 CRB/TXL COMPLETE RESPONSE 58 3 0 0 0 0 0 0 High grade serous 05/08/2005 16/11/2006 Died 13/01/2008 15 29
414 CRB/TXL NOT EVALUABLE 53 1 0 0 0 0 0 0 Low grade serous 04/05/2006 Last seen 22/04/2009 36 36
415 CRB/TXL COMPLTE RESPONSE 64 3 0 0 0 0 0 0 High grade serous 25/07/2006 15/07/2007 Died 31/10/2008 12 27
416 CARBOPLATIN PARTIAL RESPONSE 70 - 0 0 0 0 0 0 High grade serous 19/04/2006 22/10/2007 Died 21/03/2008 18 23
417 CRB/TXL NOT EVALUABLE 51 4 0 0 0 0 0 0 High grade serous 24/03/2005 22/02/2008 Died 11/04/2009 35 49
418 CRB/TXL PROGRESSIVE DISEASE 30 3 0 0 1 1 2 1 Low grade serous 16/02/2006 18/05/2006 Died 19/11/2007 3 21
419 CRB/TXL COMPLTE RESPONSE 56 3 0 0 0 0 0 0 High grade serous 15/06/2006 Last seen 15/04/2009 34 34
420 CARBOPLATIN PROGRESSIVE DISEASE 69 3 0 0 0 0 0 0 High grade serous/undifferentiated05/02/2004 24/05/2004 Died 30/05/2004 4 4
421 CRB/TXL COMPLETE RESPONSE 68 3 1 1 1 1 4 1 High grade serous 23/12/2004 07/12/2005 Died 04/11/2006 11 22
422 CRB/TXL COMPLETE RESPONSE 49 2 0 0 0 0 0 0 Endometrioid 11/11/2004 Last seen 25/02/2009 52 52
423 CRB/TXL NOT EVALUABLE 63 3 0 0 0 0 0 0 Endometrioid 08/04/2004 16/11/2004 Died 02/02/2005 7 10
424 CRB/TXL COMPLETE RESPONSE 59 3 0 0 0 0 0 0 High grade serous 06/01/2005 17/05/2008 Last seen 13/08/2009 40 55
425 CRB/TXL NOT EVALUABLE 45 3 0 0 0 0 0 0 High grade serous 10/03/2005 05/03/2007 Last seen 08/07/2009 24 52
426 CRB/TXL NOT EVALUABLE 51 1 0 1 1 1 3 1 High grade serous 13/04/2005 Last seen 27/05/2009 49 49
427 CARBOPLATIN NOT EVALUABLE 58 1 1 1 1 1 4 1 Endometrioid 04/03/2005 27/04/2006 Died 28/12/2007 14 34
428 CRB/TXL NOT EVALUABLE 57 3 0 1 1 0 2 1 High grade serous 24/03/2005 17/02/2006 Dead 23/12/2006 11 21
429 CRB/TXL COMPLTE RESPONSE 60 3 0 0 0 0 0 0 High grade serous 18/05/2006 09/02/2009 Last seen 20/08/2008 33 27




431 CRB/TXL PARTIAL RESPONSE 70 3 0 0 0 0 0 0 High grade serous 19/07/2000 Last seen 04/08/2009 109 109
432 CARBOPLATIN PROGRESSIVE DISEASE 83 3 0 0 0 0 0 0 Clear cell 24/05/2000 18/12/2000 Died 21/06/2001 7 13
433 CARBOPLATIN NOT EVALUABLE 45 1 0 0 1 0 1 1 Clear cell 22/06/2000 Died 27/06/2006 72
434 CRB/TXL NOT EVALUABLE 72 3 0 0 0 0 0 0 Endometrioid 26/04/2000 Died 01/10/2000 5
435 CRB/TXT NOT EVALUABLE 74 4 0 0 0 0 0 0 High grade serous 11/11/1999 Last seen 26/06/2009 116 116
436 CRB/TXL NOT EVALUABLE 52 2 0 0 0 0 0 0 High grade serous 24/11/1999 19/07/2004 Last seen 04/08/2009 56 116
437 CARBOPLATIN NOT EVALUABLE 56 - 0 0 0 0 0 0 High grade serous 24/11/1999 Died 11/02/2001 15
438 CARBOPLATIN PROGRESSIVE DISEASE 72 3 0 0 0 0 0 0 High grade serous 29/10/1998 21/04/1999 Died 05/10/2000 6 23
439 CARBOPLATIN NOT EVALUABLE 67 3 0 0 0 0 0 0 High grade serous 19/11/1999 15/01/2000 Died 04/11/2000 2 12
440 CRB/TXL PARTIAL RESPONSE 60 3 0 0 0 0 0 0 High grade serous 12/03/1999 10/11/1999 Died 19/03/2000 8 12
441 CRB/TXL NOT EVALUABLE 60 3 0 0 0 0 0 0 High grade serous 09/02/1999 22/02/2000 Died 24/08/2000 12 18
442 CARBOPLATIN NOT EVALUABLE 70 3 0 0 0 0 0 0 High grade serous 24/09/1999 15/01/2001 Died 22/01/2001 16 16
443 CARBOPLATIN NOT EVALUABLE 64 3 0 0 0 0 0 0 Low grade serous 27/08/1999 Died 28/10/2003 50
444 CRB/TXL PARTIAL RESPONSE 44 4 0 1 1 1 3 1 High grade serous 11/06/1999 29/05/2000 Died 28/07/2002 12 38
445 CARBOPLATIN PROGRESSIVE DISEASE 56 1 0 0 0 0 0 0 Clear cell 23/11/2000 18/06/2001 Died 14/10/2002 7 23
446 CRB/TXL PROGRESSIVE DISEASE 54 4 0 0 0 0 0 0 High grade serous 08/02/2000 24/05/2000 Died 09/07/2000 3 5
447 CRB/TXL NOT EVALUABLE 61 2 0 0 0 0 0 0 High grade serous 24/05/2000 Last seen 15/04/2009 107 107
448 CARBOPLATIN NOT EVALUABLE 56 3 0 0 0 0 0 0 High grade serous 08/11/1994 11/07/1996 Died 11/10/1998 20 47
449 CARBOPLATIN PARTIAL RESPONSE 56 4 0 0 0 0 0 0 High grade serous 22/08/1995 14/08/1996 Died 16/02/1997 12 18
450 CISPLATIN NOT EVALUABLE 43 3 0 0 0 0 0 0 High grade serous 18/10/1996 12/11/1997 Died 08/06/1998 13 20
451 CARBOPLATIN NOT EVALUABLE 63 3 0 0 0 0 0 0 High grade serous 06/12/1995 11/04/1997 Died 07/04/1998 16 28
452 CISPLATIN NOT EVALUABLE 51 3 0 0 0 0 0 0 High grade serous/undifferentiated12/01/1996 Died 12/12/2002 83
453 CARBOPLATIN NOT EVALUABLE 71 4 0 0 0 0 0 0 High grade serous 29/12/2003 16/11/2006 Died 26/01/2008 35 49
454 CISPLATIN NOT EVALUABLE 64 3 0 1 1 0 2 1 Endometrioid 04/06/1993 25/08/1994 Died 27/06/1995 15 25
455 CISPLATIN PROGRESSIVE DISEASE 58 2 0 0 0 0 0 0 High grade serous 14/05/1993 22/09/1993 Died 10/11/1993 4 6
456 CISPLATIN COMPLETE RESPONSE 46 3 0 0 0 0 0 0 High grade serous 10/09/1993 Last seen 01/09/2009 192 192
457 CARBOPLATIN PROGRESSIVE DISEASE 46 2 0 0 0 0 0 0 High grade serous 11/11/1997 04/06/1998 Last seen 05/08/2009 7 141
458 CRB/TXL PARTIAL RESPONSE 65 3 0 0 0 0 0 0 High grade serous 08/10/1999 06/05/2004 Died 24/07/2007 55 94
459 CRB/TXT COMPLETE RESPONSE 50 3 0 0 0 0 0 0 High grade serous 21/04/1999 08/03/2002 Died 01/09/2008 35 112
460 CRB/TXL COMPLETE RESPONSE 62 3 0 0 0 0 0 0 High grade serous 31/05/2000 21/05/2001 Died 02/04/2003 12 34
461 CARBOPLATIN NOT EVALUABLE 66 1 0 0 0 0 0 0 High grade serous/undifferentiated14/01/2005 Died 23/10/2008 45
462 CARBOPLATIN NOT EVALUABLE 60 3 0 0 0 0 0 0 High grade serous 18/02/2004 02/02/2005 Died 22/08/2005 12 18
463 CARBOPLATIN NOT EVALUABLE 69 4 0 0 0 0 0 0 High grade serous 20/09/2004 09/06/2005 Died 27/06/2005 9 9
464 CRB/TXL NOT EVALUABLE 55 1 0 1 0 0 1 1 Endometrioid 31/07/2006 Last seen 15/07/2009 36 36
465 CARBOPLATIN NO CHANGE 82 - 0 0 0 0 0 0 High grade serous 05/08/2004 18/04/2005 Died 18/04/2005 8 8
466 CARBOPLATIN NOT EVALUABLE 45 1 0 0 0 0 0 0 Seromucinous 21/06/2005 Last seen 18/02/2009 44 44
467 CARBOPLATIN NOT EVALUABLE 61 4 0 0 0 0 0 0 High grade serous 29/01/2004 16/11/2005 Died 23/02/2007 22 37
468 CARBOPLATIN COMPLETE RESPONSE 71 4 0 0 0 0 0 0 High grade serous 28/09/2005 01/09/2006 Last seen 22/07/2009 11 46
469 CRB/TXL NOT APPLICABLE 53 3 0 0 0 0 0 0 Endometrioid 26/10/2004 26/10/2007 Last seen 11/08/2009 36 58




471 CRB/TXL PARTIAL RESPONSE 56 3 0 0 0 0 0 0 High grade serous 23/12/2002 22/11/2005 Died 17/07/2008 35 67
472 CRB/TXL NOT EVALUABLE 48 4 2 2 2 2 0 0 Low grade serous 03/10/2001 Last seen 25/02/2009 89 89
473 CRB/TXL COMPLETE RESPONSE 67 4 0 0 0 0 0 0 High grade serous 23/08/2000 13/07/2001 Died 02/07/2002 11 22
474 CARBOPLATIN PARTIAL RESPONSE 73 4 0 0 2 0 0 0 High grade serous 08/05/2002 24/11/2003 Died 04/12/2004 19 31
475 CARBOPLATIN NOT EVALUABLE 79 3 0 0 0 0 0 0 High grade serous 17/04/2002 12/03/2003 Died 11/12/2008 11 80
476 CARBOPLATIN NOT EVALUABLE 68 3 0 0 0 0 0 0 High grade serous 07/03/2002 06/02/2003 Died 16/06/2003 11 15
477 CISPLATIN PROGRESSIVE DISEASE 70 3 0 0 0 0 0 0 High grade serous 14/04/2002 10/09/2002 Died 29/09/2002 5 6
478 CARBOPLATIN NOT EVALUABLE 34 1 0 0 0 0 0 0 Endometrioid 27/12/2002 Last seen 14/01/2009 73 73
479 CARBOPLATIN NOT EVALUABLE 37 2 0 0 0 0 0 0 Clear cell 16/10/2002 27/05/2005 Died 04/04/2006 31 42
480 CRB/TXL COMPLETE RESPONSE 61 3 0 1 0 0 1 1 Clear cell 07/08/2003 14/09/2006 Died 17/04/2007 37 44
481 CRB/TXL NOT APPLICABLE 53 1 0 0 0 0 0 0 Clear cell 24/10/2003 Last seen 17/09/2008 59 59
482 CARBOPLATIN PARTIAL RESPONSE 50 4 2 2 1 2 1 1 High grade serous 03/03/1998 14/10/1998 Died 25/04/1999 7 14
483 CISPLATIN PARTIAL RESPONSE 51 4 2 2 2 2 0 0 High grade serous 13/06/2000 Died 23/05/2002 23
484 CARBOPLATIN NOT EVALUABLE 64 1 0 0 0 1 1 1 High grade serous 17/06/1999 13/09/2007 Died 26/01/2008 99 103
485 CISPLATIN NOT EVALUABLE 68 2 0 0 0 0 0 0 Endometrioid 25/11/1998 19/07/1999 Died 09/03/2002 8 39
486 CRB/TXL NOT EVALUABLE 52 3 0 0 0 0 0 0 High grade serous/undifferentiated18/05/2000 30/03/2001 Died 10/06/2001 10 13
487 CRB/TXT NOT EVALUABLE 54 3 0 0 0 0 0 0 Low grade serous 21/12/1999 Last seen 29/07/2009 115 115
488 CRB/TXL NOT EVALUABLE 47 2 0 0 0 0 0 0 High grade serous/undifferentiated16/11/1999 10/02/2009 Last seen 22/07/2009 111 116
490 CRB/TXL NOT APPLICABLE 54 2 0 0 1 1 2 1 Endometrioid 05/07/1999 Last seen 11/03/2009 116 116
491 CARBOPLATIN NO CHANGE 54 4 0 0 0 0 0 0 High grade serous 23/11/1999 25/04/2000 Died 31/08/2000 5 9
492 CARBOPLATIN NOT EVALUABLE 68 2 0 0 0 0 0 0 High grade serous 07/10/1997 14/02/2004 Died 07/03/2004 76 77
493 CARBOPLATIN PARTIAL RESPONSE 50 3 0 0 0 0 0 0 High grade serous 30/04/1996 05/02/1997 Died 10/01/2000 9 44
494 CISPLATIN NOT APPLICABLE 32 2 2 2 2 2 0 0 Undifferentiated 06/10/1995 Last seen 02/09/2009 167 167
495 CARBOPLATIN PROGRESSIVE DISEASE 65 3 2 1 2 2 1 1 High grade serous 18/11/1997 17/02/1998 Died 27/09/1998 3 10
496 CARBOPLATIN NO CHANGE 70 3 2 2 2 2 0 0 High grade serous 06/02/1997 17/03/1998 Died 02/05/1998 13 15
497 CARBOPLATIN NOT EVALUABLE but stopped after 3 cycles due to PD73 3 0 0 0 0 0 0 High grade serous 09/08/1995 Died 20/09/1995
498 CARBOPLATIN NOT EVALUABLE 61 3 0 0 0 0 0 0 High grade serous 11/11/1997 Died 04/01/1998 2
499 CARBOPLATIN NOT APPLICABLE 67 2 0 0 0 0 0 0 Endometrioid 09/01/1996 Last seen-moved away15/12/2003 95 95
500 CARBOPLATIN PROGRESSIVE DISEASE 73 1 0 1 1 0 2 1 Endometrioid 23/05/1997 04/03/1999 Died 14/04/1999 21 23
501 CARBOPLATIN PARTIAL RESPONSE 68 4 0 0 0 0 0 0 High grade serous 08/11/1995 26/07/1996 Died 10/07/1997 9 20
502 CISPLATIN COMPLETE RESPONSE 41 4 0 0 0 0 0 0 High grade serous 06/06/1990 20/08/1991 Died 06/03/1993 14 33
503 CISPLATIN NOT EVALUABLE 65 3 0 0 0 0 0 0 High grade serous 25/03/1991 22/11/1991 Died 21/01/1992 8 10
504 CISPLATIN NOT EVALUABLE 47 3 0 0 0 0 0 0 High grade serous 09/04/1993 24/04/1995 Died 14/03/1997 24 47
505 CISPLATIN NOT EVALUABLE 49 3 0 2 2 2 0 0 High grade serous 25/03/1993 12/05/1994 Died 22/07/1996 14 40
506 CISPLATIN NOT EVALUABLE 68 3 2 2 2 0 0 0 High grade serous 03/11/1993 23/07/1996 Died 15/02/2000 33 75
507 CISPLATIN NOT EVALUABLE 68 3 0 0 0 0 0 0 High grade serous 10/01/1994 12/07/1994 Died 15/01/1995 6 12
508 CARBOPLATIN NOT APPLICABLE 45 1 2 1 1 2 2 1 Clear cell 17/05/1994 Last seen 29/05/2009 181 181
509 CARBOPLATIN NOT EVALUABLE 68 1 0 2 0 0 0 0 Mucinous 19/11/1993 Last seen 04/11/2008 180 180




511 CARBOPLATIN NOT EVALUABLE 71 2 2 2 0 2 0 0 High grade serous 08/08/2002 30/03/2006 Died 18/08/2009 44 84
512 CARBOPLATIN NOT EVALUABLE 73 1 2 0 0 2 0 0 Clear cell 09/09/1999 18/05/2000 Died 09/10/2001 8 25
513 CRB/TXL NOT EVALUABLE 52 3 0 0 2 0 0 0 High grade serous 30/03/2001 05/06/2002 Died 06/07/2004 14 39
515 CRB/TXL NOT EVALUABLE 66 3 0 0 0 0 0 0 High grade serous 30/12/2003 05/05/2005 Died 10/10/2005 16 21
516 CRB/TXL NOT EVALUABLE 69 3 0 0 0 1 1 1 High grade serous 11/12/2001 26/08/2002 Died 27/11/2005 8 48
517 CRB/TXL NOT EVALUABLE 42 3 0 0 0 0 0 0 High grade serous 08/04/2005 Last seen 11/03/2009 47 47
518 CARBOPLATIN NO CHANGE 79 3 0 0 0 0 0 0 High grade serous 18/04/2001 06/03/2002 Died 02/05/2002 11 12
519 CARBOPLATIN NOT EVALUABLE 74 2 0 0 0 0 0 0 High grade serous 17/10/2000 16/11/2001 Died 09/03/2005 13 53
520 CARBOPLATIN NOT EVALUABLE 72 3 0 0 0 0 0 0 High grade serous 10/05/2000 13/06/2001 Died 13/11/2001 13 18
521 CRB/TXL PARTIAL RESPONSE 66 3 0 0 0 0 0 0 High grade serous 26/09/2000 12/12/2001 Died 19/02/2003 15 29
522 CISPLATIN NOT EVALUABLE 37 2 0 0 0 0 0 0 Endometrioid 22/06/1998 Last seen 25/07/2008 121 121
523 CARBOPLATIN NOT EVALUABLE 61 3 0 2 2 0 0 0 High grade serous 21/07/1998 23/08/1998 Died 23/08/1998 1 1
524 CISPLATIN NOT EVALUABLE 47 4 0 0 0 0 0 0 High grade serous 15/10/1995 13/06/1996 Died 07/01/1997 8 15
525 CARBOPLATIN NOT APPLICABLE 74 3 0 0 0 0 0 0 High grade serous 29/06/1995 09/09/1998 Died 28/06/1999 38 48
526 CISPLATIN NOT EVALUABLE 57 3 0 2 0 0 0 0 High grade serous 05/10/1994 14/09/1995 Died 18/09/2001 11 84
257 CISPLATIN NOT APPLICABLE 64 3 0 0 0 0 0 0 High grade serous 06/08/1994 30/11/1995 Died 05/07/1996 16 23
528 CARBOPLATIN NOT APPLICABLE 47 1 0 1 1 0 2 1 Clear cell 07/01/1996 Last seen 06/05/2009 160 160
529 CARBOPLATIN NOT EVALUABLE 66 3 0 0 0 0 0 0 High grade serous 29/07/1997 14/07/1998 Died 03/03/2000 12 31
530 CARBOPLATIN NOT EVALUABLE 68 - 0 0 0 0 0 0 Endometrioid 26/05/1995 19/06/1996 Died 30/08/1997 13 27
531 CARBOPLATIN PARTIAL RESPONSE 71 3 0 0 0 0 0 0 High grade serous 08/09/1997 Died 14/04/1999 19
532 CRB/TXL NOT EVALUABLE 71 2 0 0 0 0 0 0 Endometrioid 23/10/2001 04/02/2005 Died 10/07/2008 39 81
533 CARBOPLATIN PROGRESSIVE DISEASE 48 4 0 0 0 0 0 0 High grade serous 08/08/1995 21/09/1995 Died 16/10/1995 1 2
534 CARBOPLATIN NOT EVALUABLE 38 - 0 0 0 0 0 0 Clear cell 28/04/1999 12/01/2000 Died 15/02/2003 9 46
535 CARBOPLATIN PARTIAL RESPONSE 77 - 0 0 0 0 0 0 High grade serous 14/08/2001 12/11/2002 Died 05/10/2003 15 26
536 CARBOPLATIN NOT APPLICABLE 51 1 0 1 1 1 3 1 Clear cell 10/11/1998 Died 22/11/1999 12
537 CSP/TXT NOT APPLICABLE 52 3 0 0 0 0 0 0 High grade serous 26/09/1996 04/02/1998 Died 02/11/1998 16 25
538 CISPLATIN PROGRESSIVE DISEASE 53 3 0 0 0 0 0 0 High grade serous 03/11/1993 31/03/1994 Died 20/05/1994 5 7





































































F        O 
F 













































Synthesis and SAR of potent EGFR/erbB2 dual 
inhibitors. Bioorganic & Medicinal Chemistry 




















Discovery and in vitro evaluation of potent TrkA 
kinase inhibitors: oxindole and aza-oxindoles. 





















Indazolylamino quinazolines and pyridopyrimidines 
as inhibitors of the EGFr and c-erbB-2. 












    











Aminofurazans as potent inhibitors of AKT kinase. 






































Aminofurazans as potent inhibitors of AKT kinase. 





















Discovery of thiophene inhibitors of polo-like 
kinase. Bioorganic & Medicinal Chemistry Letters 























Discovery of thiophene inhibitors of polo-like 
kinase. Bioorganic & Medicinal Chemistry Letters 
(2009),  19(3), 1018-1021. 























































































































































Discovery of thiophene inhibitors of polo-like 
kinase. Bioorganic & Medicinal Chemistry Letters 































Discovery of thiophene inhibitors of polo-like 
kinase. Bioorganic & Medicinal Chemistry Letters 






























Discovery of thiophene inhibitors of polo-like 
kinase. Bioorganic & Medicinal Chemistry Letters 





























































Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3- 
d]pyrimidines: Potent inhibitors of the IGF-1R 
receptor tyrosine kinase. Bioorganic & Medicinal 









































Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3 
d]pyrimidines: Potent inhibitors of the IGF-1R 
receptor tyrosine kinase. Bioorganic & Medicinal 














































Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3- 
d]pyrimidines: Potent inhibitors of the IGF-1R 
receptor tyrosine kinase. Bioorganic & Medicinal 















































Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3- 
d]pyrimidines: Potent inhibitors of the IGF-1R 
receptor tyrosine kinase. Bioorganic & Medicinal 













































































































N        O 
HN Cl 
O           
























































Optimization of a series of 4,6-bis-anilino-1H- 
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• Both mutational and expression data suggest that MMR deficiency is more common in non-serous ovarian cancer than in serous subtypes. 
• The effect of MMR deficiency on  ovarian cancer chemosensitivity remains unproven but synthetic lethal approaches offer  hope of novel therapies. 
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Mismatch repair deficiency 
Synthetic lethality 
a  b  s  t  r  a  c  t   
 
DNA mismatch repair (MMR) deficiency is associated with increased risk of developing several types of cancer 
and is the most common cause of hereditary ovarian cancer after BRCA1 and BRCA2 mutations. While there has 
been extensive investigation of MMR deficiency in  colorectal cancer, MMR in  ovarian cancer is relatively 
under-investigated. This review summarizes the  mechanism of MMR, the  ways in which MMR deficiency can 
promote carcinogenesis in general and then assesses the available studies regarding MMR deficiency in ovarian 
cancers with specific emphasis on implications for disease incidence and therapy. The incidence of germline 
MMR gene mutations in ovarian cancer is only  2% but other mechanisms of gene inactivation mean that loss of 
expression of one  of the  seven main genes (MSH2,  MSH3, MSH6, MLH1, MLH3, PMS1 and  PMS2)  occurs in up 
to 29% of cases. Both  mutational and expression data suggest that MMR deficiency is more common in non- 
serous ovarian cancer. Some  studies suggest an improved survival for patients with MMR deficiency compared 
to  historical controls but these do  not account for  the preponderance of non-serous tumors. A number of 
in vitro studies have suggested that MMR deficiency is a cause of platinum resistance. To date this has not been 
categorically demonstrated in the clinic. Larger studies that account for stage of presentation and  immunohisto- 
chemical subtype are required to assess the effect of MMR deficiency on survival and chemosensitivity. Investi- 
gation of MMR related synthetic lethality in colorectal cancer has  identified dihydrofolate reductase, DNA 
polymerase β and DNA polymerase γ and PTEN-induced putative kinase 1 as synthetic lethal to certain MMR 
defects by causing accumulation of oxidative DNA damage. These synthetic lethal targets require tested and 
others should be sought within the  context of MMR deficient ovarian cancer in an attempt to provide novel 
therapeutic strategies for these patients.
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Epithelial ovarian cancer is the leading cause of gynecological cancer 
death in the developed world, with a lifetime risk of 1–2% [1]. The most 
common histological subtype is high  grade serous (70%); other sub- 
types include endometrioid (10%), clear cell (5–10%), low grade serous 
(5%), mucinous (3%), and  undifferentiated (1%) [2–7].  Over  60% of 
ovarian cancer patients are  diagnosed with advanced stage disease 
(spread beyond the  pelvis) with an associated five year  survival rate 
of 20–30% [1]. In contrast, for patients with stage I ovarian cancer, the 
five year survival rate is around 90% [1]. 
The most significant risk factor  for ovarian cancer is family  history 
which depends on  the  number of first and  second degree relatives 
with ovarian or breast cancer and  their age at diagnosis [8]. Hereditary 
germline mutations are estimated to account for 10% to 20% of all ovarian 
cancers [9–11].  BRCA1 and  BRCA2 germline mutations are  associated 
with an 11% to 40% risk of developing the disease [12] and  account for 
65–85% of all inherited cases [13–15]. Hereditary non-polyposis colorec- 
tal cancer (HNPCC), which is caused by mutations in genes that are re- 
sponsible for DNA mismatch repair (MMR), is the next most common 
cause  of hereditary ovarian cancer, and  accounts for 10% to 15% of all 
cases  of hereditary ovarian cancer [13,16]. 
Many studies have investigated MMR deficiency in colorectal cancer, 
leading to defined clinical guidelines for detecting HNPCC kindred, iden- 
tification of unique clinical  and  pathological features of these tumors 
and a greater understanding of the molecular pathogenesis of colorectal 
cancer. However, MMR deficiency in ovarian cancer is relatively under- 
investigated. This review summarizes the mechanism of MMR, the ways 
in which MMR deficiency can promote carcinogenesis in general and 
then assesses the available studies regarding MMR deficiency in ovarian 
cancers with specific emphasis on implications for disease incidence 
and  therapy. 
 
 
The mismatch repair system 
 
The MMR system plays  an important role in maintaining genomic 
stability. It recognizes and corrects biosynthetic errors that arise during 
DNA replication [17] as well as mispaired bases that are generated during 
recombination or caused by oxidative DNA damage [18]. MMR therefore 
reduces DNA errors 100–1000 fold, and  prevents them from  becoming 
fixed  mutations during cellular proliferation. 
MMR has  been extensively studied in Escherichia  coli, and  human 
MMR proteins have  been discovered based on  their homology to 
E. coli proteins [17]. Seven  proteins including three MutS-homologs 
(MSH2, MSH3 and  MSH6), and  four  MutL homologs (MLH1, MLH3, 
PMS1 and  PMS2) are involved in human MMR [17,19]. 
DNA mismatch repair consists of three steps: recognition, excision 
and  resynthesis (Fig. 1) [17]. MMR is initiated once  MutS recognizes 
mismatched DNA and  binds to it. The MutS homodimer is formed by 
either MSH2/MSH6 (the MutSα complex) or MSH2/MSH3 (the MutSβ 
complex). The MutSα complex recognizes single  base mismatches and 
short insertion–deletion loops  in the  DNA, while the  MutSβ  complex 
recognizes larger loops  [20]. Subsequently, MutLα (formed by MLH1 
and PMS2) is recruited and it mediates the process from mismatch recog- 
nition by MutS to activation of downstream activities [21]. The endonu- 
clease  function in the  PMS2 subunit is then activated by the mismatch 
and MutS complex and directs strand excision in a proliferating cell nu- 
clear  antigen (PCNA)-, replication factor C (RFC)-, and  ATP-dependent 
process [22]. RFC loads  PCNA onto  the DNA helix and PCNA plays an im- 
portant role in both excision and  DNA repair synthesis [22,23].  Replica- 
tion protein A (RPA) and  Exonuclease 1 (Exo1) are also involved in the 
excision process, and Exo1 has been reported to function in both 3′and 
5′-directed repair events [21,24].  PMS1 and  MLH3 also dimerize with 
MLH1, but their role in DNA repair is less well understood [25]. High- 
fidelity replicative polymerases, Polδ or Polε, and DNA ligase 1 complete 
resynthesis of the strand [24]. 
 
MMR deficiency and cancer development 
 
MMR deficiency leads to microsatellite instability 
 
Defects of any of these MMR genes result in microsatellite instability 
(MSI) [26]. MSI is characterized by accelerated accumulation of single 
nucleotide mutations and  altered length of microsatellite sequences 
[27]. Microsatellites, also known as short tandem repeats (STRs) and 
simple sequence repeats (SSRS) are short, repetitive sequences of DNA 
between one  and  six base  pairs  in length distributed throughout the 
genome [28]. The length of these repeats varies  between individuals, 
but is constant within the cells of an individual, unless they have micro- 
satellite instability. When MMR fails, DNA replication infidelity across 
these tandem repeats coupled with MMR deficiency results in the accu- 
mulation of mutations. 
MSI can significantly affect cellular behavior and is associated with 
multi-step tumorigenesis, as instability at coding microsatellites in 
cancer-related genes can cause  frameshift mutations and  functional 
inactivation of corresponding proteins [29]. To date a number of genes 
involved in DNA repair, apoptosis, signal  transduction, transcriptional 
regulation and  immune surveillance [30] have  been found mutated in 
cancers exhibiting MSI (Fig. 2). Mutated genes that provide selective 
growth advantage to cells lacking  MMR function are considered as the 
driving force during MSI tumorigenesis and  are termed real common 
target genes [29]. 
As a hallmark feature of HNPCC-associated cancers, MSI has  been 
found in 90% of colorectal tumors from individuals with Lynch syndrome, 
and in 10% to 15% of sporadic colorectal tumors [31]. It also occurs in 75% 
of endometrial and up to 100% of ovarian cancers in patients from HNPCC 
families [31]. 
According to the uniform criteria developed by the National Cancer 
Institute (NCI), a panel of five independent genomic sites is recom- 
mended for microsatellite status analysis in colorectal cancer, including 
two mononucleotide repeats (Bat25 and Bat26) and three dinucleotide 
repeats  (D2S123, D5S346,  and  D17S250). Tumors are  termed high- 
frequency MSI (MSI-H) if two or more of the  five loci exhibit variations 
in microsatellite sequence length (e.g. insertion/deletion mutations). If 
only one  of the  microsatellite sequences shows instability, the  tumor 
is termed low frequency MSI (MSI-L). The tumor is classified as micro- 
satellite stable (MSS), if no mutation has  occurred in any  of the five 
markers [27]. 
 
MMR deficiency can also be caused by promoter hypermethylation 
 
As shown in Fig. 2, MMR dysfunction can be caused by both genetic 
and  epigenetic mechanisms. In Lynch syndrome, MMR deficiency is a 
result of germline mutation of one of the 7 MMR genes,  with MLH1 ac- 
counting for most cases.  Somatic inactivation of the  remaining wild- 
type  allele  can be caused by loss of heterozygosity, somatic mutation












Fig. 1. The mismatch repair pathway. The MutS complexes (MSH2/MSH6 or MSH2/MSH3) recognize mismatches in the DNA and the MutLα complex (MLH1/PMS2) is recruited. PCNA is 
loaded onto the DNA strand by RFC. Endonuclease function in the PMS2 subunit is then activated and the protein–protein and protein–DNA interactions are ATP-dependent. RPA and Exo1 
are also  involved in excision. Resynthesis is completed by DNA polymerases (Polδ or Polε) and DNA ligase 1. 
 
or promoter methylation which act as second hits in hereditary cancers 
according to the ‘two-hit’ hypothesis [32]. Hypermethylation of the CpG 
promoter region of MLH1 has been observed in many cases of heredi- 
tary  CRC showing MSI and  has  also  been found in sporadic tumors 
showing MSI-H, including colorectal, endometrial and  ovarian cancers 
[33,34]. 
 
Incidence of MMR deficiency in ovarian cancer 
 
Women with HNPCC have  approximately a 12–15% lifetime risk of 
developing ovarian cancer [35,36].  HNPCC related ovarian cancers 
occur  at a younger age (median 41–49 years) than sporadic ovarian 
cancer (median 60–65 years)[14,37,38]. Pal et al. [38] reported that 
clearly   pathogenic germline MLH1, MSH2  and   MSH6  mutations 
occurred  in only  9/1893 (0.5%) unselected ovarian cancer patients 
(with the majority harboring MSH6 mutations), although a further 28 
patients (1.5%) had  unique pathogenic missense variants. 
To date over  20 studies have  reported the frequency of MSI in a 
number of ovarian cancer series [19] but  only four studies [33,39–41] 
used  the  exact  five NCI markers to detect MSI. Among the four studies, 
one was restricted to clear cell cancer only [39]. The other three studies 
[33,40,41] (which were unselected on the basis of histology) reported 
an MSI frequency between 5 and  13%. It has  now  become clear  that 
assessment of any ovarian cancer disease marker requires to be per- 
formed in a histotype-specific fashion. Although some individual stud- 
ies have  suggested that non-serous histotypes have  a higher incidence 
of MSI than serous ovarian cancers, small  study size and  heterogeneity 
of markers utilized make it impossible to draw this  conclusion at this 
time. Watanabe et al. [42] also reported that cases with MSS in primary 
resected tumors exhibited MSI in the  residual tumors after  cisplatin- 
based chemotherapy raising the  possibility that MSI status can change 
following chemotherapy. 
After 1997, 12 studies used  immunohistochemical (IHC) staining to 
investigate expression of MMR proteins (Table 1). At least one of the six 
MMR genes (MLH1, MSH2, MSH6, PMS2, MSH3 and  PMS1) was tested 
in these studies. The 12 studies had  sample sizes  from  24 to 487 and 
reported the frequency of MMR deficiency (loss of any  protein) to 
range from 2% to 29%. 10 of these studies reported histologic subtypes 
of samples with MMR protein loss (Table 2). Although there is again 
heterogeneity among the small studies, there does appear to be a higher 
incidence of MMR protein loss on immunohistochemical analysis in 
non-serous than serous ovarian cancers. This is consistent with the












Fig. 2. Genetic and epigenetic pathways leading to MSI-H and resulting in tumorigenesis. MMR deficiency can be caused genetically and epigenetically and results in MSI-H which then 
leads to increased accumulation of somatic mutations in a number of genes and drives multi-step tumorigenesis. 
 
findings of Pal et al. [38] who  reported that endometrioid and clear cell 
histological subtypes account for the  majority of ovarian cancer cases 
with germline MMR gene  mutations. 
To date,  seven studies have  investigated MSI status in  ovarian 
cancers lacking  MMR protein expression (Table 1). Results from  six 
studies show that the vast majority of tumors deficient in an MMR pro- 
tein are MSI-H. Three studies [14,43,44] reported that all MMR deficient 
tumors possessed a MSI-high  phenotype. Liu et al. [45] reported that of 
11 out of 74 tumors lacking a MMR protein, one case was MSS, one case 
MSI-L and  the  rest were MSI-H. Cai et al. [39] and  Domanska et al. [37] 
also  reported that two  out of six and  one  out of six MMR deficient 
tumors were MSS respectively. In addition, Liu et al. [45] and  Cai et al. 
[39] reported that six out  of 15 and  two  out  of six MSI-H tumors did 
not  lack expression of MMR proteins respectively. Moreover, Geisler 
et al. [46] reported 21 MSI-H tumors, with hMLH1 mRNA absent in 10 
cases. The remaining 11 MSI-H tumors did not  lack expression of any 
of the six MMR genes. Helleman et al. [47] is the only study that report- 
ed that all seven tumors with MLH1 hyper-methylation had  an MSS 
phenotype and  none of the  75  tumors showed MMR inactivation. 
Watanabe et al. [42] is the  only  study that compared MSI status and 
MMR protein expression before and after cisplatin-based chemotherapy 
and found that 73.3% of cases changed from MSS to MSI-H and also lost 
MLH1 protein expression after  treatment. These  studies suggest that 
MMR protein loss in ovarian cancer is associated with MSI-H. However, 
besides known MMR proteins, other causes of MSI-H may  exist. It has 
been reported that tumors from  Exonuclease 1 (EXO1) families may 
exhibit variable levels  of MSI but EXO1 is not an  HNPCC gene  [26]. 
Furthermore, as some MMR deficient tumors are MSS, there might be 
compensatory mechanisms that maintain stability. Further large  scale 
studies are required to explore this area. 
 
 
Role  of  MMR deficiency in ovarian cancer patient  survival and 
chemotherapy response 
 
Numerous studies have  investigated survival in colorectal cancers 
with MMR deficiency. After reviewing 32 eligible  studies which strati- 
fied  survival in colorectal cancer patients by MSI status, Popat et al. 
[48] confirmed that MSI-H is associated with better survival. Radman 
and Wagner [49] suggested that the genetic instability related to micro- 
satellite instability may  lead  to compromised cancer progression and 
therefore result in improved survival. Compared with colorectal cancer, 













proportion of MMR deficiency in ovarian cancer cases and MSI status of MMR deficient cases. 
 
Reference Year Tested MMR proteins Sample size Loss of any MMR Proportion MSI status (MSI-H/MSI-L) 
[42] 2001 MLH1, MSH2 24 7 29% 2/7 
[45]  (endometrioid only) 2004 MLH1, MSH2 74 11 15% 9/1 
[14] 2006 MLH1, MSH2,  MSH3,  MSH6,  PMS2 128 3 3% 3/0 
[43] 2006 MLH1, MSH2 322 7 2% 7/0 
[37] 2007 MLH1, MSH2,  MSH6,  PMS2 98 6 6% 5/- 
[66] 2008 MSH6 310  11% – 
[41] 2008 MLH1, 52 4 8% – 
  MSH2,  MSH6,  PMS2     
[39]  (clear cell only) 2004 MLH1, MSH2 42 6 14% 4/0 
[44]  (clear cell only) 2005 MLH1, MSH2,  MSH6,  MSH3 24 6 25% 6/0 
[40] 2004 MLH1 54 5 9% – 
[67]  (endometrioid only) 2012 MLH1, MSH2,  MSH6,  PMS2 71 7 10% – 
[68] 2012 MLH1, MSH2,  MSH6 487 62 12.7% – 
A small  number of studies have  investigated the survival of women 
with ovarian cancer due  to MMR defects, and  the  results are inconclu- 
sive. Crijnen et al. [50] compared survival in stage matched HNPCC asso- 
ciated ovarian cancer and sporadic ovarian cancer, and found that there 
was no significant difference between the two groups, with cumulative 
5 year  survival rates being  64.2% and  58.1% respectively. In contrast, 
Scartozzi et al. [51] suggested that loss of MLH1 correlated with im- 
proved survival in advanced ovarian cancer after comparing 19 patients 
with an MLH1 defect (median survival: 55 months) and  15 patients 
with functional MLH1 (median survival: 12 months). Grindedal et al. 
[52] investigated 144 women with HNPCC associated ovarian cancers, 
and  reported that 10 year survival was as high  as 80%. Among the 144 
patients only 18.5% were diagnosed at stage 3 or 4. A probable explana- 
tion for these findings is that because HNPCC-associated ovarian cancers 
are most likely to be non-high grade serous, these tumors are more likely 
to  present with early  stage disease (compared to  matched sporadic 
tumors) and therefore are more likely to be curable by surgery alone. 
Currently, the gold standard treatment of ovarian cancer consists of 
debulking surgery and  platinum-taxane combination chemotherapy 
[6]. However, despite high  initial chemosensitivity (70–80%  response 
rate), with over  50% achieving complete response, the  majority  of 
patients with advanced ovarian cancer will  relapse and  eventually 
develop platinum resistant disease [53]. There  are studies suggesting 
that loss of MMR proteins is associated with drug  resistance in ovarian 
cancer. Strathdee et al. and Zeller et al. [54,55]  reported that methylation 
of the  MLH1 promoter plays  an  important role  in causing cisplatin- 
resistance in ovarian cancer in vitro. Plumb et al. [56], used demethylating 
agent 2′-deoxy-5-azacytidine (DAC) in vivo to treat MMR-deficient, drug- 
resistant ovarian tumor xenografts that are MLH1 deficient due  to pro- 
moter hyper methylation and  found that DAC sensitized the xenografts 
to cisplatin and  carboplatin. Ercoli et al. [57] investigated MSH2 protein 
expression level in 20 epithelial ovarian cancers, and reported that non- 
responding patients had  significantly lower MSH2 levels  compared to 
those of patients who  achieved either complete or partial response to 
cisplatin-based chemotherapy. This study also found that the  amount of 
MSH2 was significantly lower in stage IV patients than that in stage III 
patients. Subsequently, Marcelis et al. [58] reported high  level chemo- 
therapy resistance in two women from  an HNPCC family with germline 
mutations in MSH2. On the other hand, Samimi et al. [59] found that ex- 
pression of both MLH1 and  MSH2 reduced significantly after  platinum- 
based chemotherapy. However, lower expression of MLH1 did not in- 
dicate lack of sensitivity to platinum-based therapy, and  there was 
no association between MSH2 expression and response. Taken together, 
studies on treatment response in ovarian cancers with MMR deficiency 
have  produced inconclusive results. There  are several possible explana- 
tions  for this.  First of all, different methods were used  to determine 
MMR status, including protein expression analysis, mRNA expression 
analysis, promoter hypermethylation assays  and microsatellite instabili- 
ty testing. Secondly, when comparing the  MMR deficient group to the 
MMR proficient group, varying numbers (from 1 to 5) of MMR genes 
were considered. In addition, many studies are limited by small  sample 
size. Moreover, strategies of sampling are also different. Therefore fur- 
ther large  scale studies using  uniform criteria, stage and  treatment are 
required in order to investigate survival and response to chemotherapy. 
As described above  there is a suggestion that MMR deficiency is much 
more frequent in non-serous ovarian cancers. As such  further studies 
investigating the effect of MMR deficiency on sensitivity to conventional 
and novel  anticancer therapies should be performed within an immuno- 
histological subtype-specific context. 
 
Synthetic lethality — targeting MMR deficiency 
 
In recent years, synthetic lethality has been investigated extensively 
as an approach to develop new  targeted cancer therapeutics. Synthetic 
lethality is based on the  premise that loss of function of two  or more 




MMR protein loss  by histologic subtypes. 
 
Reference Year Serous MMR 
loss/total 








Mixed type MMR 
loss/total 
[66] 2001 3/26   1/9  1/8 
[39] 2004  4/42     
[40] 2004  1/18  3/22  1/15 
[45] 2004   12/74    
[44] 2005  6/24     
[14] 2006 0/84 1/22 0/15 1/5  1/1 
[43] 2006 0/168 2/16 1/34 0/7 0/8 3/73 
[67] 2007  0/7 3/15    
[68] 2008 20/230 7/16 4/34 2/6 0/8  
[69] 2012   7/71    
[70] 2012 24/178 6/17 12/52 7/18   
Summary  47/686 27/162 39/295 14/67 0/16 6/97 
  (7%) (17%) (13%%) (21%) (0%) (6%) 
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511 









Fig.  3. MMR deficiency based synthetic lethality. MLH1, MSH2  and MSH6: mismatch 
repair proteins. DHFR:  dihydrofolate reductase. POLβ: DNA polymerase. POLγ: DNA 
polymerase γ. PINK1: PTEN-induced  putative kinase 1. This figure indicates that loss  of 
function of one MMR gene and its corresponding SL molecule result in apoptosis. 
 
whereas inactivation of one  of these genes or pathways (within non 
tumor cells of the  patient) does  not  [60]. This strategy can lead  to a 
high therapeutic index. The classic example is BRCA1 or BRCA2 germline 
defects and poly (ADP-ribose) polymerase (PARP) inhibition. Compared 
with cells which are wild  type  for BRCA1 or BRCA2, BRCA1/2 deficient 
cells are 1000  times more sensitive to PARP inhibitors [61,62]. 
Investigation of  MMR related synthetic lethality has  identified 
dihydrofolate reductase (DHFR), DNA polymerase β (POLβ) and  DNA 
polymerase γ (POLγ),  as  well  as  PTEN-induced putative kinase 1 
(PINK1) as synthetic lethal to certain MMR defects by causing accumula- 
tion  of oxidative DNA damage [63–65]. As shown in Fig. 3, inhibition of 
DHFR is synthetic lethal to MSH2 defect; MSH2 deficiency is also syn- 
thetic lethal with inhibition of POLβ, while MLH1 deficiency is synthetic 
lethal with POLγ; inactivation of PINK1 is synthetic lethal with defects of 
MLH1, MSH2 or MSH6. Currently, methotrexate, a DHFR inhibitor, is 
under clinical  trial to treat advanced bowel cancers with MSH2 defi- 
ciency  [65]. So far, synthetic lethality has  not been investigated in 
MMR defective ovarian cancer patients. Whether these newly identified 
targets also  apply  to  ovarian cancer is unknown. Future studies are 
required to test the  above  synthetic lethal strategies and  looking for 




Women with HNPCC have  an increased lifetime risk of developing 
ovarian cancer. In addition to germline mutation, MMR deficiency can 
also be caused by epigenetic mechanisms. Based on studies on MMR de- 
ficiency in colorectal cancer, various methods such as testing MSI status, 
MMR promoter hypermethylation, MMR protein expression and  MMR 
mRNA expression have  been developed to help  identify defects in 
MMR. However, only  a limited number of studies have  investigated 
MMR deficiency in ovarian cancer. Non-serous histological subtypes 
have  been associated with MMR deficiency. Other important factors 
such  as impact of MMR deficiency on response to chemotherapy and 
survival within a histotype-specific context remain unclear. In addition, 
further studies are required to test synthetic lethal strategies identified 
in the  colorectal cancer setting in ovarian cancer as well as to identify 
new  targets to achieve the goal of targeted therapies for this subset 
of patients. 
 
Conflict of interest statement 




[1]  NCI. National Cancer Institute (NCI),  Cancer Statistics N Cancer Stat Fact  Sheets N 
Cancer of the Ovary. Available from: http://seer.cancer.gov/statfacts/html/ovary. 
html; 2012. 
[2]  Bashashati A, et al. Distinct evolutionary trajectories of primary high‐grade serous 
ovarian  cancers  revealed   through   spatial   mutational   profiling.    J    Pathol 
2013;231(1):21–34. 
[3]  Colombo N, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO 
clinical practice guidelines for diagnosis,  treatment and follow-up.  Ann Oncol 
2010;21(Suppl. 5):v23–30. 
[4]  Conklin CM, Gilks CB. Differential diagnosis and clinical relevance of ovarian carcinoma 
subtypes. Expert Rev Obstet Gynecol 2013;8(1):67–82. 
[5]  Köbel  M, et al. Differences in  tumor type in  low-stage versus high-stage ovarian 
carcinomas. Int J Gynecol Pathol 2010;29(3):203–11. 
[6]  Lalwani N, et al. Histologic, molecular, and cytogenetic features of ovarian cancers: 
implications for diagnosis and treatment. Radiographics 2011;31(3):625–46. 
[7]  Seidman JD, et al. The histologic type and stage distribution of ovarian carcinomas of 
surface epithelial origin. Int J Gynecol Pathol 2004;23(1):41–4. 
[8]  Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic 
factors. Seminars in surgical oncology. Wiley Online Library; 2000. 
[9]  Alsop K, et al. BRCA mutation frequency and patterns of treatment response in BRCA 
mutation—positive women with ovarian cancer: a report from the Australian ovarian 
cancer study group. J Clin Oncol 2012;30(21):2654–63. 
[10]   Risch  HA, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer 
penetrances:  a   kin-cohort  study  in   Ontario,  Canada.  J   Natl   Cancer  Inst 
2006;98(23):1694–706. 
[11]   Schrader KA, et al. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility 
of a histology-based referral strategy. Obstet Gynecol 2012;120(2, Part 1):235–40. 
[12]   Bandera  CA. Advances  in the understanding of  risk factors for  ovarian cancer. 
J Reprod Med 2005;50(6):399–406. 
[13]   Bewtra C, Watson P, Conway T, Read-Hippee C, Lynch HT. Hereditary ovarian cancer: 
a clinicopathological study. Int J Gynecol Pathol 1992;11(3):180. 
[14]   Malander S, et al. The contribution of the hereditary nonpolyposis colorectal cancer 
syndrome to the development of ovarian cancer. Gynecol Oncol 2006;101(2):238–43. 
[15]   Rubin SC, et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene 
mutations in an unselected ovarian cancer population: relationship to family history 
and implications for genetic testing. Am J Obstet Gynecol 1998;178(4):670–7. 
[16]   Lynch HT, Casey MJ, Lynch J, White TE, Godwin AK. Genetics and ovarian carcinoma. 
Semin Oncol 1998;25(3):265–80. 
[17]   Li GM. Mechanisms and functions of DNA mismatch repair. Cell Res 2008;18(1):85–98. 
[18]   Macpherson P, et al. 8-Oxoguanine incorporation into DNA repeats in vitro and mis- 
match recognition by MutSα. Nucleic Acids  Res 2005;33(16):5094–105. 
[19]   Pal T, Permuth‐Wey J, Sellers TA. A review of the clinical relevance of mismatch‐ 
repair deficiency in ovarian cancer. Cancer 2008;113(4):733–42. 
[20]   Genschel J, Littman SJ, Drummond JT, Modrich P. Isolation of MutSbeta from human 
cells   and  comparison of  the  mismatch  repair  specificities of  MutSbeta  and 
MutSalpha. J Biol Chem 1998;273(31):19895–901. 
[21]   Modrich  P.  Mechanisms  in   eukaryotic  mismatch  repair.  J   Biol   Chem  2006; 
281(41):30305–9. 
[22]   Kadyrov FA, Dzantiev L, Constantin N, Modrich P. Endonucleolytic function of MutLα 
in human mismatch repair. Cell 2006;126(2):297–308. 
[23]   Gu L, Hong Y, McCulloch S, Watanabe H, Li GM. ATP-dependent interaction of 
human mismatch repair proteins and dual role of PCNA in mismatch repair. Nucleic 
Acids  Res 1998;26(5):1173–8. 
[24]   Hsieh P, Yamane K. DNA mismatch repair: molecular mechanism, cancer, and ageing. 
Mech Ageing Dev 2008;129(7):391–407. 
[25]   Seifert M, Reichrath J. The role of the human DNA mismatch repair gene hMSH2 in 
DNA repair, cell cycle control and apoptosis: implications for pathogenesis, progres- 
sion and therapy of cancer. J Mol  Histol 2006;37(5):301–7. 
[26]   Abdel-Rahman WM,  Mecklin JP, Peltomäki P. The genetics of HNPCC: application to 
diagnosis and screening. Crit Rev Oncol Hematol 2006;58(3):208–20. 
[27]   Boland CR, et al. A National Cancer Institute Workshop on  Microsatellite Instability 
for cancer detection and familial predisposition: development of  international 
criteria for the determination of microsatellite instability in colorectal cancer. Cancer 
Res 1998;58(22):5248–57. 
[28]   Turnpenny PD, Ellard S. Emery's elements of medical genetics. Churchill Livingstone; 
2011. 
[29]   Woerner SM, et al. Microsatellite instability of selective target genes in  HNPCC- 
associated colon adenomas. Oncogene 2005;24(15):2525–35. 
[30]   Imai K, Yamamoto H. Carcinogenesis and microsatellite instability: the interrelation- 
ship between genetics and epigenetics. Carcinogenesis 2008;29(4):673–80. 
[31]   Shannon C, et al. Incidence of microsatellite instability in synchronous tumors of the 
ovary and endometrium. Clin Cancer Res 2003;9(4):1387–92. 
[32]   Knudson Jr AG. Mutation and cancer: statistical study of retinoblastoma. Proc  Natl 
Acad  Sci U S A 1971;68(4):820–3. 
[33]   Gras E, et al. Microsatellite instability, MLH‐1 promoter hypermethylation, and 
frameshift mutations at coding mononucleotide repeat microsatellites in ovarian 
tumors. Cancer 2001;92(11):2829–36. 
[34]   Wajed SA, Laird  PW,  DeMeester TR. DNA methylation: an  alternative pathway to 
cancer. Ann Surg  2001;234(1):10. 
[35]   Aarnio M, Mecklin JP, Aaltonen LA, Nyström-Lahti M, Järvinen HJ. Life-time risk  of 
different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. 
Int J Cancer 1995;64(6):430–3. 
[36]   Lynch HT, et al. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, 
pathology, and management. Mol  Oncol 2009;3(2):97–137. 
[37]   Domanska K, Malander S, Måsbäck A, Nilbert M. Ovarian cancer at young age: the 
contribution of mismatch‐repair defects in a population‐based series of epithelial 
ovarian cancer before age  40. Int J Gynecol Cancer 2007;17(4):789–93. 
[38]   Pal T, et al. Frequency of mutations in mismatch repair genes in a population-based 
study of women with ovarian cancer. Br J Cancer 2012;107(10):1783–90.
512
512 







[39]   Cai KQ, et al. Microsatellite instability and alteration of the expression of hMLH1 and 
hMSH2 in ovarian clear cell  carcinoma. Hum Pathol 2004;35(5):552–9. 
[40]   Catasús L, et al. Molecular genetic alterations in endometrioid carcinomas of the 
ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite 
instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol 
2004;35(11):1360–8. 
[41]   Jensen KC, et al. Microsatellite instability and mismatch repair protein defects in 
ovarian epithelial neoplasms in  patients 50  years of age  and younger. Am  J Surg 
Pathol 2008;32(7):1029. 
[42]   Watanabe Y, Koi M, Hemmi H, Hoshai H, Noda K. A change in microsatellite instabil- 
ity  caused  by   cisplatin-based chemotherapy  of  ovarian  cancer.  Br  J  Cancer 
2001;85(7):1064. 
[43]   Rosen DG, Cai KQ, Luthra R, Liu J. Immunohistochemical staining of hMLH1 and 
hMSH2 reflects microsatellite instability status in ovarian carcinoma. Mod Pathol 
2006;19(11):1414–20. 
[44]   UEDA H, et al. Microsatellite status and immunohistochemical features of ovarian 
clear-cell carcinoma. Anticancer Res 2005;25(4):2785–8. 
[45]   Liu J, et al. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in 
ovarian endometrioid cancer. Mod Pathol 2004;17(1):75–80. 
[46]   Geisler JP, et al. Mismatch repair gene expression defects contribute to microsatellite 
instability in ovarian carcinoma. Cancer 2003;98(10):2199–206. 
[47]   Helleman J, et al. Mismatch repair and treatment resistance in ovarian cancer. BMC 
Cancer 2006;6(1):201. 
[48]   Popat S, Hubner R, Houlston R. Systematic review of microsatellite instability and 
colorectal cancer prognosis. J Clin Oncol 2005;23(3):609–18. 
[49]   Radman M, Wagner R. Carcinogenesis.  Missing mismatch repair.  Nature 1993; 
366(6457):722. 
[50]   Crijnen TEM, et al. Survival of patients with ovarian cancer due to a mismatch repair 
defect. Fam  Cancer 2005;4(4):301–5. 
[51]   Scartozzi M, et al. Loss of hMLH1 expression correlates with improved survival in 
stage III–IV ovarian cancer patients. Eur J Cancer 2003;39(8):1144–9. 
[52]   Grindedal EM, et al. Survival in women with MMR mutations and ovarian cancer: a 
multicentre study in Lynch syndrome kindreds. J Med Genet 2010;47(2):99–102. 
[53]   Kemp Z, Ledermann J. Update on first-line treatment of advanced ovarian carcinoma. 
Int J Women's Health 2013;5:45–51. 
[54]   Strathdee G, MacKean MJ, Illand M, Brown R. A role for methylation of the hMLH1 
promoter in loss  of hMLH1 expression and drug resistance in ovarian cancer. Onco- 
gene 1999;18(14):2335. 
[55]   Zeller C, et al. Candidate DNA methylation drivers of acquired cisplatin resistance in 
ovarian cancer identified  by  methylome  and  expression profiling. Oncogene 
2012;31(42):4567–76. 
[56]   Plumb JA, Strathdee G, Sludden J, Kaye  SB, Brown R. Reversal of drug resistance in 
human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the 
hMLH1 gene promoter. Cancer Res 2000;60(21):6039–44. 
[57]   Ercoli A, et al. hMSH2 and GTBP expression in advanced stage epithelial ovarian cancer. 
Br J Cancer 1999;80(10):1665. 
[58]   Marcelis CL, van der Putten HW, Tops C, Lutgens LC, Moog U. Chemotherapy resistant 
ovarian cancer in carriers of an hMSH2 mutation? Fam  Cancer 2001;1(2):107–9. 
[59]   Samimi G, et al. Analysis of MLH1 and MSH2 expression in ovarian cancer before and 
after platinum drug-based chemotherapy. Clin Cancer Res 2000;6(4):1415–21. 
[60]   Tucker CL, Fields S. Lethal combinations. Nat Genet 2003;35(3):204–5. 
[61]   Bryant HE, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly 
(ADP-ribose) polymerase. Nature 2005;434(7035):913–7. 
[62]   Farmer H, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic 
strategy. Nature 2005;434(7035):917–21. 
[63]   Martin SA, Hewish M, Sims  D, Lord CJ, Ashworth A. Parallel high-throughput RNA in- 
terference screens identify PINK1 as a potential therapeutic target for the treatment 
of DNA mismatch repair-deficient cancers. Cancer Res 2011;71(5):1836–48. 
[64]   Martin SA, et al.  DNA polymerases as  potential therapeutic targets for  cancers 
deficient in the DNA  mismatch repair proteins MSH2   or MLH1.  Cancer  Cell 
2010;17(3):235–48. 
[65]   Martin SA, et al. Methotrexate induces oxidative DNA damage and is selectively 
lethal to tumour cells  with defects in the DNA mismatch repair gene MSH2.  EMBO 
Mol  Med 2009;1(6‐7):323–37. 
[66]   Zhai QJ, Rosen DG, Lu K, Liu J. Loss of DNA mismatch repair protein hMSH6 in ovar- 
ian cancer is histotype-specific. Int J Clin Exp Pathol 2008;1(6):502–9. 
[67]   Aysal  A, et al. Ovarian endometrioid adenocarcinoma: incidence and clinical signifi- 
cance of the morphologic and immunohistochemical markers of mismatch repair pro- 
tein defects and tumor microsatellite instability. Am J Surg Pathol 2012;36(2):163–72. 
[68]   Coppola D, et al. Uncertainty in the utility of immunohistochemistry in  mis- 
match repair protein expression in epithelial ovarian cancer.  Anticancer  Res 
2012;32(11):4963–9. 
[69]   Strathdee G, et al. Primary ovarian carcinomas display multiple methylator pheno- 
types involving known tumor suppressor genes. Am J Pathol 2001;158(3):1121. 
[70]   Willner J, et al. Alternate molecular genetic pathways in ovarian carcinomas of 
common histological types. Hum Pathol 2007;38(4):607–13. 
